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Abstract 
Transposable elements constitute 45% of the human genome contributing to our 
evolution, creating new exons, structural variation and influencing the regulation of 
transcription. SINE-VNTR-Alus (SVAs) are a hominid specific retrotransposon that 
are still actively retrotransposing in the human genome today. The structure and 
sequence of SVAs, in particular their variable number tandem repeat (VNTR) 
domain, suggest their potential for influencing the regulation of gene expression 
through binding of transcription factors, differential methylation patterns and 
formation of secondary structures along with potential for genetic variation between 
individuals. This project has identified novel regulatory domains and genetic 
variation within elements belonging to a hominid specific group of retrotransposons. 
A global analysis undertaken of their distribution identified their preference for genic 
regions over gene deserts and their insertion into functional regions of the genome 
such as promoters and introns. An in depth analysis of two SVA insertions, one 
upstream of the FUS gene and another upstream of the PARK7 gene, demonstrated 
the ability of SVAs to affect reporter expression in vitro and in vivo. Both of these 
SVAs were identified as polymorphic in their central VNTR regions and the PARK7 
SVA also demonstrated different copy numbers of repeats it its 5’ CCCTCT domain. 
Analysis of the PARK7 SVA insertion and gene in cell lines indicated the SVA is 
not epigenetically silenced, as dogma might suggest to suppress retrotransposition, 
but present in a transcriptionally active region of the genome. There is increasing 
evidence for loss of silencing of retrotransposons including within the human brain 
which would allow for greater influence of potential transcriptional properties 
embedded within SVAs impacting on genomic function. 
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 The regulation of gene expression is a complex process, from the sequence of 
the DNA itself in promoters, enhancers and repressors to the epigenetic 
modifications and the way that DNA is packaged. Genetic variation in the human 
genome between individuals allows for differential modulation of gene expression 
and response to environmental cues, leading to potential phenotypic differences and 
predisposition to disease. The sequencing of the genome of multiple species and 
human individuals has led to a greater understanding of the components of the 
genome and potential sources of genetic variation. The aim of this study is to 
identify novel domains involved in the regulation of gene expression and determine 
whether the genetic variation encompassed within such regions could contribute to 
functional differences between individuals.  
 
1.1 Composition of the human genome 
 The human genome is over 3 billion base pairs in length with less than 2% 
coding for proteins, however the exact number of genes is still unknown (Clamp et 
al. 2007). Much of the human genome is composed of repeated sequences that fall 
into several categories: interspersed repeats derived from transposons, duplicated 
genes, simple sequence repeats, large blocks of duplicated sections of the genome 
and blocks of tandemly repeated sequences at sites such as telomeres (Lander et al. 
2001). The non-coding part of the genome, initially thought of as ‘junk’, at the very 
least harbours important functional domains including promoters, enhancers and 
repressors to control and fine tune the levels of gene expression and non-coding 
RNAs which have structural and regulatory roles.  
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 The greatest degree of conservation across species is within exons, especially 
those of genes with roles in development to maintain key functions of the proteins 
they encode. Evolutionary conserved regions (ECRs) of the human genome (other 
than exons) can indicate domains involved in other functions such as gene 
regulation, as it is hypothesised their sequence has been maintained through 
evolution for a purpose (MacKenzie and Quinn 2004; Visel et al. 2007). Many of 
these ECRs are highly conserved and their ability to affect gene expression has been 
demonstrated in vitro and in vivo (Prabhakar et al. 2006; Bonello et al. 2011; Paredes 
et al. 2011).  Proteins are highly conserved for specific function but it is also the 
amount, tissue specificity and the modulation of gene expression in response to the 
environment that can account for phenotypic differences. Therefore important 
regulatory domains may not only be located in the ECRs but regions containing 
genetic variation that may in part account for the differences between species and 
individuals of the same species. These polymorphic regulatory domains may come in 
different forms ranging from repetitive sequences such as variable number tandem 
repeats (VNTRs) to transposable elements inserted into our genome. Regulatory 
domains may be located within introns or even hundreds of kilobases away from the 
start of transcription (Visel et al. 2009a; Visel et al. 2009b). Identifying potential 
regulatory domains in a vast amount of non-coding DNA can prove difficult, but the 
wealth of data now freely available for the genomes of many species within genome 
browsers can aid this search. Not only can the homology and the sequence of a 
region indicate potential function but the information held in these databases, such as 
the state of chromatin and transcription factor binding across different cell lines, can 
help narrow down these potential functional domains. Much of this data is contained 
within the UCSC genome browser (http://genome.ucsc.edu/index.html), including 
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the encyclopaedia of DNA elements (ENCODE) data. ENCODE is freely available 
data on the functional elements of the human genome which is an international 
collaboration between research groups funded by the National Human Genome 
Research Institute (NHGRI) (http://www.genome.gov/10005107) and is a very 
useful tool in analysing potential functional regions within the genome.  
 
1.2 Genetic variation within the human genome  
 Genetic variation within the genome includes single nucleotide 
polymorphisms (SNPs), copy number variations (CNVs) and VNTRs. SNPs, the 
most common form of genetic variation, are changes at a single nucleotide base and 
must occur at a greater frequency than 1% of the population to be considered 
polymorphic rather than a mutation. SNPs are found throughout the human genome 
with a recent study of 1092 human genomes identifying 38 million SNPs (Abecasis 
et al. 2012). SNPs within coding exons may introduce a change at the amino acid 
level (non synonymous SNPs) and can therefore influence the function of a protein. 
SNPs in non-coding regions may alter features such as transcription factor binding or 
splicing for example. SNPs can be used to map the inheritance of blocks of DNA 
known as haplotypes and the International HapMap project 
(http://hapmap.ncbi.nlm.nih.gov/) was established to create a map of the haplotypes 
in the human genome and common genetic variants across different populations. 
Many multifactorial diseases such as heart disease, cancer, diabetes and neurological 
degenerative diseases have both an environmental and genetic component. Diseases 
that involve neurological degeneration include Multple Sclerosis and Parkinson’s 
Disease but should be differentiated from non-pathological cognitive decline that is 
associated with normal ageing. It is the small differences in the genetics of an 
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individual that may reveal the predisposition of one individual compared to another 
for a specific disorder. Different methodologies have been used to analyse genetic 
variants to identify risk alleles for a specifc disease and include genome wide 
association studies (GWAS) and candidate gene studies. GWAS have used SNPs to 
map susceptibility loci in the human genome correlated with disease (Wagner 2013). 
The SNPs in these identified regions may be directly influencing a genetic 
predisposition to a disease or it could be another element of genetic variation 
inherited in the same haplotype playing a role. Candidate gene studies involve the 
analysis of genes that have been previously linked to a particular disease and have 
contributed greatly to the study of risk variants, however are limited by prior 
knowledge of the disease processes.  
 Another type of genetic variation linked to a predisposition for specific 
disease and a role in gene regulation are VNTRs, which are repeated sequences of 
nucleotides that vary in copy number between individuals. There are 600,000 
candidate VNTRs within the human genome, many located in functional positions 
such as intron-exon splicing junctions or promoters where the repetitive nature of the 
VNTR can provide multiple transcription factor binding sites (Breen et al. 2008; 
Sawaya et al. 2013). The number of alleles of a specific VNTR can vary, for 
example there are two alleles of a VNTR located in the promoter of the serotonin 
transporter gene (SLC6A4) and 9 alleles identified of a VNTR located in the 3’UTR 
of the dopamine transporter gene (SLC6A3) (Haddley et al. 2008).  VNTRs have 
demonstrated the ability to direct gene expression in a tissue and allele specific 
manner in vitro and in vivo (MacKenzie and Quinn 1999b; Roberts et al. 2007; 
Vasiliou et al. 2012) and have been linked to genetic predisposition to disease 
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(Anguelova et al. 2003; Herman et al. 2005; Guindalini et al. 2006; Munafo and 
Johnstone 2008).  
 Two VNTRs located within the SLC6A4, one in the promoter and the other 
in intron 2, have been widely studied for their functional properties in gene 
regulation and association with disease due to the role of the serotonin transporter in 
modulating the levels of serotonin in the synaptic cleft between neurons and 
therefore serotonin signalling. The VNTR located within the promoter of the 
SLC6A4 gene has two alleles consisting of either 14 or 16 copies of a 22-23bp 
repeat (LPR) and the VNTR within intron 2 has three alleles of 9, 10 or 12 copies of 
a 16-17bp repeat (Stin2). A variety of techniques have been employed to analyse the 
transcriptional properties of these VNTRs including chromatin immunoprecipitation 
(ChIP), transient and stable transfections of reporter gene plasmids and generation of 
transgenic mice (MacKenzie and Quinn 1999b; Ali et al. 2010; Vasiliou et al. 2012). 
ChIP was used to identify the binding of specific transcription factors, such as 
CCCTC binding-factor (CTCF), methyl CpG binding protein 2 (MeCP2) and Y box 
binding protein 1 (YB-1), across the two VNTRs with differential binding observed 
across the alleles of the VNTRs in response to challenge indicating expression of 
SLC6A4 could be modulated in an allelic dependant manner in vitro (Vasiliou et al. 
2012). The VNTRs of the SLC6A4 gene demonstrated the ability to differentially 
modulate expression in a reporter gene model in vitro and this expression can be 
modulated by the transcription factor CTCF (Ali et al. 2010). Two of the alleles of 
the Stin2 VNTR (10 and 12) were used to generate transgenic mice where the alleles 
displayed differential regulatory properties in a region of the hindbrain known to 
express the SLC6A4 gene at that time in development (MacKenzie and Quinn 
1999b). Both of these VNTRs have been analysed in a variety of cohorts for 
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associations with neurological and psychiatric diseases such as bi and uni polar 
depression, schizophrenia and migraine, the aim being to identify ‘at risk’ alleles of 
these VNTRs for a specific disorder (Haddley et al. 2012). There have been 
associations found in some cohorts but these have not replicated in others; which 
may be due to ethnic differences, the need to consider more than one genetic variant 
in the pathway to identify stronger links, environmental factors, the parameters used 
to measure specific traits, publication bias or a lack of sufficient size to reach 
statistical significance. The VNTRs of the SLC6A4 are examples of the functional 
properties embedded within VNTRs, including the allelic dependant modulation of 
gene expression in vitro, in vivo and in response to challenge, and identifies methods 
that can be employed to determine the gene regulatory potential within specific loci 
in the genome.  
 Mobile DNA or transposable elements (TEs) are another source of genetic 
variation between species and potentially individuals of the same species if still 
actively transposing. An element called a SINE-VNTR-Alu (SVA) is a hominid 
specific TE (containing a VNTR domain) and it is the potential functional role, the 
genetic variation they contribute to the human genome, and association with disease 
that is to be addressed throughout this project.  
 
1.3 Transposable elements 
  Transposable elements were first identified by Barbara McClintock in 1950 
while studying gene regulation in maize (Mc 1950). There are two classes of TEs: 
class I or retrotransposable elements that move within the genome through a ‘copy 
and paste’ mechanism and class II elements or DNA transposons that move through 
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a ‘cut and paste’ mechanism. Retrotransposable elements are mobilised through a 
RNA intermediate that is reverse transcribed and it is this cDNA ‘copy’ that is 
inserted back into the host genome at a different loci to the source element increasing 
their numbers present in the host genome. DNA transposons encode a transposase 
that removes or ‘cuts’ the transposon from its locus in the host genome and inserts it 
at a different site. The percentage of the genome that consists of TEs differs between 
species as does the type of TEs present (Chenais et al. 2012) with nearly half of the 
human genome consisting of TEs. DNA transposons constitute approximately 3% of 
the human genome and are no longer active (Lander et al. 2001). The 
retrotransposable elements can be further subdivided into two main groups: long 
terminal repeats (LTR) retrotransposons and non-LTR retrotransposons. The non-
LTR retrotransposons contain the only known currently active TEs in the human 
genome and include long interspersed elements (LINEs), short interspersed elements 
(SINEs), SINE-VNTR-Alus (SVAs) and processed pseudogenes (PP). The structure 
of the different types of TEs are shown in Figure 1.1 (Beck et al. 2011).  
 The cell type in which new insertions of TEs occur will determine if they are 
passed onto the next generation (Figure 1.2) (Muotri et al. 2007). New insertions into 
primordial germ cells or very early in development in germ cell progenitors will be 
passed onto following generations. Insertions into other cell types within early 
development will not be heritable but will contribute to somatic mosaicism of the 
individual. A study carried out by Kano et al used transgenic mouse and rat models 
with human and mouse LINE-1 (L1) elements to determine when and where L1 
retrotransposition was occurring in development. It was identified that L1 
retrotransposition occurred more frequently in embryonic development compared to 
within germ cells, estimated at approximately 1 out of 50 to 1 out of 500 somatic 
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cells compared to 1 out of 1000 sperm, resulting in fewer heritable insertions and 
greater somatic mosaicism (Kano et al. 2009).  
 
 
 
 
 
 
 
 
 
Figure 1.1: Structure of the different types of transposable elements in 
mammals. (Beck et al. 2011) 
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Figure 1.2: Consequences of retrotransposition in different cell types.. (Muotri et 
al. 2007)  
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 TEs have often been referred to as parasitic or selfish DNA indicating no 
benefit to the host genome; however in the genome of nearly all living organisms 
TEs of one class or another have been identified. TEs have extensively colonised the 
human genome throughout evolution, even with measures to prevent their 
transposition in place, there are still active elements altering our genome today. TEs 
have had a negative impact through disease causing insertions; however there is 
evidence for their positive contribution to our genomes adaptability during evolution 
through germ line insertions creating new heritable genes and gene regulation 
pathways. The host genome has learnt to tolerate or even co-evolved alongside TEs 
incorporating them into genomic processes; for example Alu elements are involved 
in driving expression of a cluster of miRNA on chromosome 19 via RNA 
polymerase III and new evidence indicating that Alu sequences (found in >5% of 
human UTRs) themselves are targeted by miRNA and could therefore be involved in 
global post transcriptional regulation of gene expression (Muotri et al. 2007). 
 
1.3.1 Retrotransposons 
 Retrotransposons replicate through a RNA intermediate increasing their 
number in the host genome and expanding it. The mechanism through which this 
retrotransposition occurs differs between the types of element but the enzyme 
reverse transcriptase is key to this process, creating a DNA copy of the RNA 
transcribed by the host cell. Autonomous retrotransposons encode for the proteins 
that are required for their own retrotransposition, in contrast non-autonomous 
retrotransposons do not encode proteins and need to ‘hijack’ the proteins coded for 
by the autonomous elements for their retrotransposition. The most successful of 
these elements in the human genome are the non-LTRs. 
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1.3.1.1 Long terminal repeat retrotransposons 
 Long terminal repeats (LTR) are an autonomous retrotransposon named due 
to their characteristic direct repeats at their 5’ and 3’ ends that are around 300-
1000bp long and contain promoter sequences that regulate transcription of the 
element. Human endogenous retroviruses (HERVs) are members of the LTR family 
and constitute 8% of the human genome (Lander et al. 2001) and a full length 
element is approximately 9.5kb in length (Shin et al. 2013). HERVs are previous 
retroviral infections that entered the germ line of the host, became unable to reinfect 
and remained within the host genome (Goodier and Kazazian 2008) and therefore 
HERVs share many characteristics of retroviruses including the proteins they code 
for and their life cycle. HERVs are divided into three classes (I, II, III) by their 
similarities to genera of retroviruses and then further subdivided by a primer binding 
site for a specific tRNA molecule (e.g. HERV-W, HERV-K) when reverse 
transcription is initiated (Griffiths 2001). The genes of the HERV sequence (gag, 
pro, pol and env) encode for proteins with properties such as a protease, reverse 
transcriptase, integrase and also structural proteins, however there are many 
inactivating mutations found within their sequences and these open reading frames 
(ORFs) no longer code for functional proteins (Kim 2012). There are polymorphic 
members of the HERV-K elements in the human population in terms of their absence 
or presence at specific loci, indicating they have been actively retrotransposing since 
the human-chimpanzee divergence (Belshaw et al. 2005; Shin et al. 2013). L1, Alus 
and SVAs are known to be actively retrotransposing today due the identification of 
de novo insertions within specific individuals. There have been no de novo insertions 
of HERVs identified therefore it is uncertain whether these elements are still active 
or have undergone a recent cessation in their retrotransposition capability.  
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1.3.1.2 Non-LTRs retrotransposons  
1.3.1.2.1 Long interspersed elements  
 Long interspersed elements (LINEs) are the only autonomous non-LTR 
retrotransposon in the human genome. The majority of these are LINE-1 (L1) 
elements with approximately 500,000 copies constituting 18% of the human genome 
(Goodier and Kazazian 2008). A full length L1 element is 6kb in size with two ORFs 
(Scott et al. 1987) with both ORF encoded proteins required for retrotransposition 
(Moran et al. 1996). ORF1 encodes for a 40kDa protein (ORF1p) that binds to 
nucleic acids (single stranded preferentially) (Hohjoh and Singer 1997) and ORF2 
encodes for a 150kDa protein (ORF2p) with reverse transcriptase and endonuclease 
functions (Mathias et al. 1991; Feng et al. 1996). The L1 encoded proteins 
demonstrate a cis preference for their encoding RNA over L1 RNA from 
retrotransposition deficient elements and cellular mRNAs, to ensure functioning L1 
RNA is more likely to be inserted into the host genome (Wei et al. 2001). 
Retrotransposition of the L1 elements occurs through a process called target primed 
reverse transcription (TPRT) and this is summarised in Figure 1.3 (Babushok and 
Kazazian 2007). The L1 RNA is transcribed by RNA polymerase II which is 
regulated by a promoter within the 5’UTR of the L1 (Minakami et al. 1992) and then 
exported into the cytoplasm of the cell where translation of the ORF1 and ORF2 
proteins occurs. The ORF1p, ORF2p and L1 RNA form a ribonucleoprotein complex 
(L1 RNP) which is transported back in to the nucleus. The ORF2p with its 
endonuclease activity nicks the bottom strand of the host’s DNA at the consensus 
sequence 5’TTTTAA 3’ at the TA site. This exposes a 3’ hydroxyl group that the 
ORF2p uses as a primer to reverse transcribe the L1 RNA. The ORF2p then nicks 
the top strand of the host DNA and the newly reverse transcribed cDNA of the L1 is 
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integrated into the host genome. The complementary strand of DNA is then 
synthesised. TPRT can result in target site duplications (TSDs), 5’ truncations, 
3’transductions and internal rearrangement and inversions. 
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Figure 1.3: Model of L1 integration reaction. (Babushok and Kazazian 2007) 
  
 
 
 
 
 
 
This text box is where the unabridged thesis included 
the following third party copyrighted material: 
Babushok DV, Kazazian HH, Jr. 2007. Progress in 
understanding the biology of the human 
mutagen LINE-1. Human mutation 28(6): 
527-539. 
Figure 3 
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 More than 99.9% of the L1s in the human genome are no longer active due to 
mutations in their ORFs or rearrangements in their structure such as inversions and 
truncations (Lander et al. 2001). Brouha et al identified 90 L1 elements with intact 
ORFs from the 2001 working draft of the haploid human genome sequence and 
assayed 82 of these elements for their retrotransposition capabilities, they found 40 
of which were active in the cell culture retrotransposition assay. Of these elements 
six were highly active and were responsible for 84% of the retrotransposition 
capability assayed. This led to the prediction that there are 80-100 L1 elements that 
are retrotransposition competent in a given human genome with smaller number of 
‘hot’ elements that are responsible for the majority of retrotransposition in the human 
population (Brouha et al. 2003).  L1 elements have not only expanded the human 
genome through their own proliferation but also mobilise non-autonomous 
retrotransposons including SINEs, SVAs and PPs.  
 
1.3.1.2.2 Short interspersed elements 
 Over 120 families of short interspersed elements (SINEs) have been 
identified in eukaryotic genomes originating from cellular RNA sequences 
transcribed by RNA polymerase III and are on average 150-300bp long (Kramerov 
and Vassetzky 2011). The most successful SINE to populate the human genome is 
the primate specific Alu element with more than 1 million copies (Lander et al. 
2001) and many different subfamilies that have been actively expanding our genome 
for the past 65 million years (Batzer and Deininger 2002). These elements were 
named Alu due the presence of the AluI restriction enzyme site in their sequence 
(Houck et al. 1979). Alus are 300bp long and their sequence originates from a 
processed 7SL RNA gene (Ullu and Tschudi 1984). Alus contain an internal RNA 
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polymerase III promoter to regulate their transcription and are retrotransposed by the 
L1 encoded proteins (Batzer and Deininger 2002).  
 
1.3.1.2.3 Processed pseudogenes 
 Processed pseudogenes (PP) or retropseudogenes are RNAs that have been 
reverse transcribed and inserted back into the genome by L1 retrotransposition 
machinery (Pavlicek et al. 2006), they do not contain introns and have a 3’ poly A 
tail (Ding et al. 2006). There are an estimated 11,000 PPs in the human genome 
(Beck et al. 2011). PPs are mostly transcriptionally silent as the sequence of the gene 
retrotransposed does not include promoter and regulatory sequences, however there 
is evidence of some PPs being transcribed with one study estimating this number at 
4-6% (Harrison et al. 2005). PPs are no longer under selective pressure and the vast 
majority accumulate mutations and do not code for proteins. There are examples of 
PPs that have maintained their protein coding ability and are transcribed and 
translated into a functional protein and these are called retrogenes (Ding et al. 2006) 
with an estimated 120 of these retrogenes in the human genome (Vinckenbosch et al. 
2006). 
 
1.3.1.2.4 SINE-VNTR-Alus 
SINE-VNTR-Alus (SVAs) are the youngest of the retrotransposable elements 
in the human genome and are hominid specific. They are the most recent to be 
identified and least widely studied but will be the focus of this thesis.  
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Historically SVAs were originally identified as a sequence derived from part 
of the envelope (env) gene and a 3’LTR from the HERV-K10 endogenous retrovirus 
with a poly A-tail and a GC-rich tandem repeat directly upstream and were named 
SINE-R elements (Ono et al. 1987; Zhu et al. 1992). The env gene of a HERV codes 
for envelope surface and transmembrane proteins of the retrovirus. It was later 
shown that in the C2 gene, the GC-rich tandem repeat of the SINE-R element was a 
VNTR. This composite element was termed a SINE-VNTR-Alu (SVA) when further 
analysis of its components revealed the Alu-like sequences adjacent to the VNTR 
(Shen et al. 1994). Thus typically SVAs consist of a hexamer repeat (CCCTCT), an 
Alu-like sequence, a GC-rich VNTR, a SINE and a poly A-tail, however a 
proportion of the SVAs contain two central GC-rich VNTRs as opposed to one 
(Figure 1.1). SVAs vary in length from 700-4000bp with 63% of SVA insertions in 
the human genome full length: containing all five domains of a canonical element 
(Wang et al. 2005). A precursor of the VNTR domain found within the SVAs is 
present within the rhesus macaque genome, many of these precursor elements are 
also present in the human genome suggesting they were retrotransposing prior to the 
divergence of the old world monkeys and the hominoids (Han et al. 2007). The 
precursor sequence was termed SVA2 and contains a GC-rich VNTR, a unique 3’ 
sequence and a poly A tail with 40 copies identified in the rhesus macaque genome 
(Hancks and Kazazian 2010).  
SVAs are divided into subtypes (A-F) by the SINE region and their age 
estimated at 13.56 million years (Myrs) old for the oldest subtype (A) and 3.18Myrs 
old for the youngest subtype (F) (Wang et al. 2005). A seventh subtype has been 
identified that contains a 5’ transduction of the sequence from the first exon of the 
MAST2 gene and associated CpG island and has been referred to as either CpG-
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SVA, MAST2 SVA or SVA F1 (Bantysh and Buzdin 2009; Damert et al. 2009; 
Hancks et al. 2009). The sequence of the MAST2 loci that has been incorporated into 
the F1 structure has been shown to act as a positive regulator of transcription in a 
reporter gene construct when transfected into human germ cells and is thought to 
have contributed to the success of the subtype in its retrotransposition (Zabolotneva 
et al. 2012). The percentage of SVAs for each of the subtypes in the human genome 
is shown in figure 1.4. Subtype D is by far the largest consisting of 44% of all SVAs 
with the most recent F1s the smallest group at 3%. Subtypes E, F and F1 are human 
specific as are some members of SVA subtype D with a total of 864 SVA insertions 
since the human-chimpanzee divergence ~6 million years ago (Mills et al. 2006). 
After the human-chimpanzee divergence the SVAs continued to expand within the 
chimpanzee genome as well as the human creating chimpanzee specific insertions 
including a subtype unique to chimpanzees called SVA PtA (Wang et al. 2005).  
Actively retrotransposing elements cause inter-individual variation between 
humans with elements being polymorphic for their absence or presence, SVAs 
included. This has been analysed for a group of human specific SVAs which 
estimated that 37.5 % of SVA Es and 27.6% of SVA Fs were polymorphic for their 
presence in the genome (Wang et al. 2005) and the average human is estimated to 
have 56 SVA absence/presence polymorphisms (Bennett et al. 2004). The frequency 
of this presence or absence of specific SVAs located in HLA genes has been shown 
to be variable between groups with different ethnic origins (Kulski et al. 2010).  
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Figure 1.4: The proportion of each SVA subtype in the Hg19 according to 
UCSC. The SVA subtypes A-F are defined by their SINE region and SVA F1 is 
subtype F with addition of sequence from the exon 1 of the MAST2 gene. 
 
 The site of SVA insertions show the hallmarks of LINE-1 mediated 
retrotransposition such as insertion at a consensus L1 endonuclease recognition motif 
(5’TTTTAA 3’), poly A-tails, inversions and rearrangements, target site 
duplications, truncations and transductions (Hancks and Kazazian 2010). The 
mobilisation by the L1 protein machinery was validated by two separate studies 
(Hancks et al. 2011; Raiz et al. 2012) and their retrotransposition rate is estimated at 
1 in every 916 births (Xing et al. 2009). To demonstrate the methods employed to 
analyse the ability of SVAs to retrotranspose the cell line model used by Hancks et al 
will be outlined. A ‘passenger’ plasmid was generated containing the sequence of the 
SVA to be tested for its retrotransposition capability marked with a neomycin 
retrotransposition indicator cassette. The cassette contains a SV40 promoter and 
neomycin resistance gene (neo) on the opposite strand to the SVA (antisense). The 
SVA A 
8% 
SVA B 
17% 
SVA C 
10% 
SVA D 
44% 
SVA E 
5% 
SVA F 
13% 
SVA F1 
3% 
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neo gene contains an intron on the sense strand interrupting the gene. Therefore the 
neo gene will only confer resistance to the host cell once it has undergone 
transcription, splicing, reverse transcription and integration into the genome and the 
ORF is restored. This cassette can be used to show if retrotransposition of the SVA 
has occurred in the cell line by selecting for cells with the resistance gene and the 
retrotransposition frequency can be calculated. The passenger plasmid is co-
transfected into the cell line (in this study HeLa cells) with a ‘driver’ plasmid which 
is a highly active unmarked L1 element. The driver plasmid can be modified, for 
example to introduce mutations in the ORFs to determine the requirements for SVA 
retrotransposition in greater detail.  In the studies by Hancks et al and Raiz et al, 
SVAs from subtypes D, E and F1 were shown to be retrotransposition competent in 
multiple cell lines but at differing frequencies with the ORF2p essential for 
retrotransposition but the requirement of ORF1p was variable. The retrotransposition 
capability of the SVA D tested by Hancks et al was ORFp1 independent whereas the 
SVA F1 required ORFp1. L1 retrotransposition requires both of its ORF encoded 
proteins but Alus, like SVAs mobilised in trans by the L1 machinery, do not require 
the ORFp1 (Dewannieux et al. 2003). The L1 encoded proteins show a cis 
preference for their encoded RNA therefore some non-autonomous elements may 
have evolved to require only ORFp2 in an attempt to increase their success.  
 The regulation of transcription of the SVA mRNA is yet to be fully defined 
unlike the regulation of L1 and Alu elements. A recent study to determine the nature 
of SVA retrotransposition revealed that no individual domain of an SVA is 
fundamental for this to occur, but each domain differentially affected the rate at 
which retrotransposition can take place in the human osteosarcoma cell line (U2OS) 
(Hancks et al. 2012). Removal of the CCCTCT repeat or the central VNTR reduced 
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the retrotransposition activity of the SVA by 75% and 79% respectively however the 
retrotransposition activity of the CCCTCT repeat and Alu-like sequence alone was 
nearly double that of the whole SVA. All domains of the SVA are dispensable to a 
certain degree and retrotransposition of the sequence will still occur in the cell line 
model used by Hancks et al (outlined above). The CCCTCT repeat and the Alu-like 
sequence of a SVA F were shown to have some promoter activity when cloned into a 
promoter-less vector and transfected in to the Tera-1 cell line (Zabolotneva et al. 
2012). This study also showed that the acquisition of the sequence of the MAST2 
CpG island enhanced the transcriptional activity of the F1 subtype showing that the 
incorporation of an external regulatory sequence contributed to the success of this 
recent SVA subtype. 
 SVAs can influence the genomic location of their insertion through 
mechanisms such as alternative splicing, exon shuffling, formation of secondary 
structure, recombination events and generation of differentially methylated regions 
(Hancks and Kazazian 2010). 
 
1.3.2 The impact of transposable elements on the human genome  
 Transposable elements, despite long being thought of as ‘junk’ DNA, have 
influenced the human genome during its evolution through mechanisms such as 
insertional mutagenesis, recombination events, exonisation and modulation of gene 
expression (Muotri et al. 2007; Goodier and Kazazian 2008). Several classes of TEs 
are actively retrotransposing creating human specific traits within our genome and 
even between human individuals, whether harmful or beneficial, these differences 
can impact on our phenotype. There is a vast array of literature focused on the L1 
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and Alu retrotransposable elements and their impact on the human genome as they 
have been the most widely studied. The focus of this thesis is the SVA 
retrotransposons and therefore will be discussed here in greater detail. 
 Insertions of the actively retrotransposing non-LTRs into coding or intronic 
regions affecting transcriptional regulation and processing of genes have been 
associated with diseases, including haemophilia, Duchenne muscular dystrophy, 
cystic fibrosis and several cancers (Hancks and Kazazian 2012; Kaer and Speek 
2013). To date 8 SVA insertions have been associated with disease (Hancks and 
Kazazian 2012; Kaer and Speek 2013) through a variety of mechanisms including 
exon skipping and decreased mRNA production. Table 1.1 adapted from Hancks and 
Kazazian 2012 summarises the disease causing insertions that are outlined in detail 
in the following paragraphs.  
 The first human disease identified to be caused by a SVA insertion was 
Fukuyama-type congenital muscular dystrophy (FCMD), which is one of the most 
common autosomal recessive diseases in Japan (0.7-1.2 per 10,000 births). A SVA 
insertion in the 3’UTR of the fukutin gene is found in 87% of individuals with 
FCMD and is rarely found outside of the Japanese population (Kobayashi et al. 
1998; Watanabe et al. 2005). The insertion of the SVA causes abnormal splicing 
creating a new splice site removing the original stop codon and creating an 
additional exon coded for by the sequence of the SVA. The protein therefore lacks 
38 amino acids located at the C-terminal of the normal fukutin protein and contains 
an additional 129 amino acids encoded by the SVA causing mislocalisation of the 
protein in mammalian cells (Taniguchi-Ikeda et al. 2011). The authors were able to 
prevent the pathogenic exon trapping of the SVA in cells from FCMD patients and 
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model mice using antisense oligonucleotides returning normal protein levels to 
approximately 40%.  
 Abnormal mRNA levels caused by a SVA insertion, in this case within an 
intron of the TAF1 gene, were linked to X-linked dystonia-parkinsonism (XDP). 
This resulted in a tissue specific reduction of mRNA of the RNA polymerase II, 
TATA box binding protein (TBP)-associated factor, 250kDa (TAF1) gene in the 
caudate nucleus of the patient’s brain and was linked with hypermethylation of the 
SVA within the same region (Makino et al. 2007). In addition to the reduction of 
TAF1 mRNA there was also a decrease in the expression of the dopamine receptor 
D2 gene in the caudate nucleus. The insertion of a SVA either into intron 1 of the 
LDLRAP1 gene or into exon 3 of the PNPLA2 gene cause autosomal recessive 
hypercholesterolemia (ARH) and neutral lipid storage disease with subclinical 
myopathy (NLSDM) respectively, through a decrease in mRNA production with 
levels undetectable in the assays performed (Wilund et al. 2002; Akman et al. 2010). 
Further analysis revealed abnormally spliced transcripts of these genes that were 
then predicted to be subjected to nonsense mediated mRNA decay (NMD) 
(Taniguchi-Ikeda et al. 2011). In hereditary eliptocytosis and pyropoikiolcytosis (HE 
and HPP) the insertion of a SVA into exon 5 of the α-spectrin gene resulted in the 
skipping of this exon and production of a truncated dysfunctional protein (Hassoun 
et al. 1994). A case of Lynch Syndrome, an autosomal dominant predisposition to 
cancer, was linked to the production of a mutant transcript which was degraded by 
NMD caused by an intronic SVA insertion into the PMS2 gene (van der Klift et al. 
2012). The authors discuss the difficulties encountered when identifying large 
heterozygous insertions in genomic DNA due to the preferential amplification of the 
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wild type allele. These technical difficulties are likely to be masking the actual 
number of this type of disease causing insertion in autosomal dominant disorders.  
 A detailed study of seven patients with X-linked agammaglobulinemia 
(XLA) and large scale genomic alterations in the BTK gene identified one patient 
with an insertion of a fragment of a SVA in exon 9 of the BKT gene causing 
skipping of that exon (Rohrer et al. 1999). A further study by Conley et al identified 
another XLA patient with an Alu insertion at the same site as the previously 
mentioned SVA insertion indicating this site is vulnerable to retrotransposons 
insertions (Conley et al. 2005). Finally an identical SVA insertion accompanied by a 
14kb deletion including the entire HLA-A gene has been linked to leukaemia in three  
Japanese families (Takasu et al. 2007). Although these three families appear to be 
unrelated they originate from the same area of Japan suggesting this SVA insertion 
event may have occurred in a single ancestral individual. The authors compare this 
SVA insertion and 14kb deletion to the insertion of a L1 element accompanied by a 
46kb deletion in the PDHX gene resulting in pyruvate dehydrogenase complex 
deficiency (Mine et al. 2007), suggesting a similar mechanism is occurring in both of 
these insertions.  
35 
 
 
 
 
 
 
 
 
 
 
Table 1.1: The eight SVA insertions that have been associated with disease. Information taken from (Hancks and Kazazian 2012) and cited 
articles in the table. Diseases: FCMD - Fukuyama-type congenital muscular dystrophy, XDP - X-linked dystonia-parkinsonism, ARH - 
Autosomal Recessive Hypercholesterolemia,  XLA – X-linked agammaglobulinemia, HE – hereditary eliptocytosis, HPP – hereditary 
pyropoikiolcytosis, NLSDM – neutral lipid storage disease with subclinical myopathy.  
Disease Gene 
SVA 
Subtype 
Size 
(kb) 
Loci of 
insertion 
Affect of Insertion Reference 
FCMD FKTN E 3 3’UTR 
Alternative 
splicing/exon 
trapping 
Kobayashi et al 1998 
Wantanbe et al 2005 
Taniguchi-Ikeda et al 2011 
XDP TAF-1 F 2.6 Intron 
Tissue specific 
mRNA reduction 
Makino et al 2007 
ARH LDRAP1 E 2.6 Intron Alternative splicing 
Wilund et al 2002 
Taniguchi-Ikeda et al 2011 
NLSDM PNPLA2 E 1.8 Exon Alternative splicing 
Akman et al 2010 
Taniguchi-Ikeda et al 2011 
HE and HPP SPTA1 E 0.63 Exon Exon skipping Hassoun et al 1994 
Lynch 
Syndrome 
PMS2 F 2.2 Intron Alternative splicing van der Klift et al 2012 
XLA BTK - 0.25 Exon Exon skipping 
Rohrer et al 1999 
Conley et al 2005 
Leukaemia HLA-A F1 2 - 14kb deletion Takasu et al 2007 
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 Instances of both germ line and somatic insertions of non-LTRs into known 
cancer related genes have been associated with several types of cancer including 
breast, ovarian, colon and leukaemia (Chenais 2013). TEs are linked to the 
development of cancer however the environment of the cancer cells can lead to the 
activation of these elements and may contribute to the progression of the disease 
through their mutagenic properties. It has been demonstrated that retrotransposons, 
in particular the primate specific elements, undergo a loss of methylation in the 
tumour compared to normal tissue (Szpakowski et al. 2009). This loss of epigenetic 
silencing of retrotransposons could enable their retrotransposition or open up their 
regulatory properties impacting on the structure of the genome and gene 
transcription of the tumour cells. Analysis of somatic retrotransposition in five types 
of cancer revealed 194 somatic insertions preferentially into genes that are 
commonly mutated in the tumour (Lee et al. 2012a). The expression of L1 and 
HERV transcripts have been identified in both breast and ovarian cancers 
(Bratthauer et al. 1994; Wang-Johanning et al. 2001; Menendez et al. 2004; Wang-
Johanning et al. 2007) and high levels of RNA of retrotransposons have also been 
detected in tumour microvesicles which could potentially contribute to further 
genomic instability if delivered to other cells (Balaj et al. 2011). 
 The human specific NANOGP8 processed pseudogene that originated from 
the retrotransposition of the parent gene NANOG, a transcription factor involved in 
maintaining pluripotency, inserted into the SINE region of a SVA A already present 
within in the human genome and demonstrated oncogenic properties (Fairbanks et al. 
2012). Experimental evidence has yet to link the regulation of NANOGP8 
expression to its site of insertion into the SVA A but the authors hypothesise the 
regulatory properties of the SVA, in particular the LTR of the SINE, may play a role 
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in the tissue specific expression of this tumourigenic processed pseudogene. 
NANOGP8 was transcribed in several cancer lines including human osteosarcoma 
(OS732), human hepatoma (HepG2) and human breast adenocarcinoma (MCF-7) 
and all cancer tissues tested (uterine, breast and urinary bladder) and protein 
expression was confirmed in the OS732 cell line (Zhang et al. 2006) . 
 Somatic retrotransposition has been identified in cancer cells and linked to 
the tumourigenic process; however there is growing evidence for somatic 
retrotransposition occurring in neuronal and replicative senescent cells. L1 
retrotransposition has been shown to be possible in non-dividing human somatic 
cells, neural progenitor cells and neuronal cells in vitro and in vivo (Muotri et al. 
2005; Kubo et al. 2006; Coufal et al. 2009). It was also demonstrated that L1 
retrotransposition occurs in the adult human brain (Coufal et al. 2009; Evrony et al. 
2012). A high-throughput analysis of somatic retrotransposition identified 7743 L1, 
13692 Alu and 1350 SVA putative somatic insertions across the brains of three 
individuals with these insertions occurring at a higher frequency in protein coding 
genes expressed in the brain (Baillie et al. 2011). Replicative senescent cells have 
also shown global epigenetic changes of more open chromatin of retrotransposons, in 
particular the evolutionary recent retrotransposable elements, and associated increase 
in the presence of their RNA and retrotransposition (De Cecco et al. 2013). This 
process of somatic mosaicism through retrotransposition could introduce genetic 
variability between individual cells. Depending on the site of insertion the affect of 
this process could be 1) neutral, 2) positive as may provide novel and increased 
variation in transcriptional control for the cell or could be 3) detrimental through 
mutation and contribute to the aging process and even neurological disease.  
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 Mutations although considered negative in many cases of disease have been a 
source of genetic variation throughout the evolution of a species and allow the 
development of new traits and adaptations to changing environments. TEs provide a 
mechanism for generating genetic variation within a genome adding to the potential 
adaptability and evolution of the species they are present in (Kazazian 2004; 
Cordaux and Batzer 2009; Kim et al. 2012). There are 47 genes identified in the 
human genome that are derived from the sequence of TEs (Lander et al. 2001). For 
example the syncytin gene is derived from the env gene of a HERV-W and is 
involved in human placental morphogenesis (Mi et al. 2000). 
 Chimpanzees are the closest living related species to humans and since the 
publication of the human and chimpanzee reference genomes comparisons of the 
TEs content of the two have been studied. Since the divergence of humans and 
chimpanzees there have been an additional 10719 insertions of TEs; 7786 in humans 
and 2933 in chimpanzees showing there has been a higher rate of transposition in 
humans than chimpanzees (Mills et al. 2006). Of these insertions 2642 in humans 
and 990 in chimpanzees were within genes defined as 3kb upstream and 0.5kb 
downstream of RefSeq genes. These differences in transposon insertions could have 
in some part influenced speciation and differences in gene expression between the 
two species. For SVAs there was an additional 864 insertions in the human genome 
and 396 in the chimpanzee genome. An analysis of the human and chimpanzee 
genomes revealed that 46537bp had been deleted from the human genome through 
the processes of SVA insertion mediated deletions and SVA recombination 
associated deletions (Lee et al. 2012b). A study looking at regions that were highly 
conserved between chimpanzees and other mammals but deleted in humans revealed 
tissue specific regulatory domains had been included in these deletions and were 
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hypothesis to be responsible for the loss or gain of traits contributing to the evolution 
of humans (McLean et al. 2011).   
 Transduction events during retrotransposition can result in flanking sequence 
of a SVA being transcribed and retrotransposed along with the SVA duplicating 
sections of the genome and integration at a different locus; 10% of SVA insertions 
have transduced sequence at their 3’ end (Wang et al. 2005). 5’ transduction occurs 
when an upstream promoter may be used to transcribe the SVA mRNA; the process 
that created the subtype F1. 3’ transductions occur when the RNA polymerase II 
bypasses the weak polyadenylation signal of the SVA and uses another 
polyadenylation signal downstream of the SVA. These processes provide 
mechanisms for creation of new exons or even duplication of genes. Approximately 
53kb of genomic sequence has been duplicated by 143 different SVA mediated 
transduction events including the duplication of the entire solute carrier family 35, 
member G5 (SLC35G5/AMAC) gene three times with at least two of the SVA 
transduced genes expressed in humans (Xing et al. 2006). Gene duplication is an 
important mechanism in the evolution of a species and the generation of new genes. 
The second gene is no longer under selective pressures to maintain its current 
function and can therefore undergo mutation with the potential development of a 
protein with a new function. The genome can evolve with less risk as the function of 
genes already present can be maintained.   
 TEs are a source of regulatory elements providing promoters (sense and 
antisense), binding sites for transcription factors, donor and acceptor splice sites and 
polyadenylation signals that could affect gene expression (Rebollo et al. 2012). 
Retrotransposons play an important role in the transcriptome of mammalian cells 
with retrotransposons located at the 5’ of protein coding regions functioning as 
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alternative promoters and that retrotransposon derived transcriptional start sites 
(TSS) are generally tissue specific and associate with gene dense regions (Faulkner 
et al. 2009).  
 SVAs although they have no characterised promoter, would provide due to 
their repetitive nature, multiple sites for methylation, transcription factor binding and 
the formation of secondary DNA structures such as G-quadruplex (G4 see below) 
that could influence gene transcription. SVAs contain large domains of repetitive 
DNA (VNTRs) similar in copy number and size of individual repeats, that have been 
found to direct differential tissue specific and stimulus inducible gene expression in 
many genes and the copy number of those repeats have been correlated to disease 
predisposition as discussed previously in section 1.2. Due to the young age of the 
SVAs they still share many similarities even across subtypes therefore they could 
respond to similar stimuli throughout the genome to give a concerted response to the 
environment. SVAs can also cause alternative splicing and exon skipping resulting 
in differential transcripts of a gene as documented by disease causing insertions 
(Hancks and Kazazian 2012; Kaer and Speek 2013). The poly A-tail present at the 3’ 
end of a canonical SVA insertion if located on the same strand as a gene could affect 
the transcriptional machinery causing pausing or termination of transcription. The 
SINE region of the SVA contains LTR sequences from the HERV-K10 which are 
known to contain regulatory domains and have been hypothesised to be involved in 
the expression of the human specific processed pseudogene NANOGP8 and the 
duplicated AMAC genes (Xing et al. 2006; Fairbanks et al. 2012). 
 The sequence of SVAs is highly GC rich, approximately 60%, with the 
central VNTR having a GC content of above 70% (Wang et al. 2005) and contain 
many potential sites of methylation, CG dinucleotides or CpGs. CpGs can be 
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modified by the addition of a methyl group covalently to one of the carbons within 
the cytosine nucleotide. The number of CpGs located within the human genome is 
under represented, one fifth of the expected number, due to the spontaneous 
deanimation of the methylcytosine to thymine (Lander et al. 2001). Throughout the 
human genome there are regions of high CpG content relative to the rest of the 
genome and these are called CpG islands (Gardiner-Garden and Frommer 1987). 
CpG islands are located generally at the 5’ and 3’ ends of genes and are associated 
with promoters in particular with the promoters of genes that are widely expressed 
(Gardiner-Garden and Frommer 1987; Larsen et al. 1992). CpG islands are involved 
in gene regulation, genomic imprinting and X-chromosome inactivation with 
hypermethylation of CpG islands associated with stable repression of transcription 
(Bird 2002; Reik 2007). TEs, including SVAs, are targeted for methylation to 
prevent their retrotransposition and potential detrimental effects associated with their 
insertions. SVAs could therefore potentially act as CpG islands at the site of their 
insertion influencing the neighbouring genomic locus, which could include the 
repression of expression of nearby genes. SVAs share characteristics that define CpG 
islands which have been outlined for a handful of these elements in chapter 5.4.6 of 
this thesis.  
 The nature of the sequence contained within SVAs also shows the potential 
for formation of secondary structures such as cruciforms and G4 DNA (Hancks and 
Kazazian 2010). Cruciform formation requires perfect or imperfect inverted repeats 
of 6 or more bases, like those seen in the central VNTR of the SVAs, and are 
involved in processes such as DNA replication and gene regulation (Brazda et al. 
2011).   
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 G4 DNA is a secondary structure formed in guanine-rich sequences and is 
abundant in promoter regions (Huppert and Balasubramanian 2007; Zhao et al. 
2007). G4 structures are hypothesised to interfere with replication of DNA and a host 
of regulatory functions including gene expression, genome stability and telomerase 
activity (Fletcher et al. 1998; Huppert and Balasubramanian 2005; De and Michor 
2011; Clark et al. 2012). Sequences with potential to form G4 are located in the 
promoters of several genes such as c-MYC and their ability to decrease transcription 
has been demonstrated (Siddiqui-Jain et al. 2002; Cogoi and Xodo 2006; Membrino 
et al. 2011). The proto-oncogene c-MYC has been shown to be regulated by G4 
formation in the nuclease hypersensitivity region III1 (NHE III1) located -142 to -
115bp upstream of its promoter1 which regulates up to 90% of the c-MYC 
transcription (Gonzalez and Hurley 2010). Figure 1.5 depicts the model proposed for 
the regulation of c-MYC via transcription factors bound and G4 formation to 
demonstrate how this type of secondary structure is involved in transcription. The 
expression of c-MYC is activated when the factors Sp1 or hnRNPK and CNBP are 
bound to the promoter region. Sp1 binding sites are frequently found in regions 
where sequences with G4 potential are located due the G-rich nature of Sp1 binding 
motifs. The other factors, hnRNPK and CNBP, are single stranded DNA binding 
proteins that will bind preferentially to the pyridimine and purine strands 
respectively. When these factors are not bound, G4 DNA and i-motifs (a type of 
secondary structure that forms in c-rich regions) are able to form and the expression 
of c-MYC is repressed. The nature of the sequence of SVAs provides the potential 
for the formation of G4 DNA which could be involved in the regulation of nearby 
genes in a similar process as outlined for the c-MYC gene. The CCCTCT hexamer 
repeat of the SVA has G4 potential on the opposite strand which is similar to the 
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equence found in the NHE III1 of the c-MYC gene. The potential of SVAs to form 
G4 DNA is analysed in detail in chapter 5.4.5 and the sequence within SVA that 
have the potential to form G4 DNA is shown in Figure 4.2B and 6.8.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Model of transcriptional regulation at the NHE III1 of the c-MYC 
gene. (Gonzalez and Hurley 2010) 
 
 
 
 
This text box is where the unabridged thesis included 
the following third party copyrighted material: 
Gonzalez V, Hurley LH. 2010. The c-MYC NHE 
III(1): function and regulation. Annual review 
of pharmacology and toxicology 50: 111-129. 
Figure 3 
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1.4 General aims  
 The properties of SVAs, in particular the repetitive nature of their sequence, 
and their potential influence on the regulation of gene expression is the focus of this 
thesis. The relatively small number of these elements enables a global analysis of 
their distribution in relation to genomic features of interest including genes and 
regulatory domains. The VNTR domains of these elements provide additional 
genetic variation, and therefore potential functional variation between individuals. 
The structure and functional properties of specific SVA elements will be analysed in 
an attempt to understand how these elements may be influencing the human genome 
and the link they may pose with disease predisposition. 
 
 
 
 
 
 
 
 
 
 
 
45 
 
 
 
 
 
 
 
 
Chapter 2 
Materials and Methods 
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2.1 Materials 
2.1.1 Commonly used solutions 
TBE buffer 5X - Tris Base 108g, Boric acid 55g, EDTA 5.84g, distilled water up to 
2L. 
LB Broth - 25g/L in distilled water (Fluka Analytical).  
LB Agar - 40g/L in distilled water (Fluka Analytical). 
 NZY
+
 Broth – 10g of NZ amine, 5g yeast extract and 5g NaCL up to 1L of 
deionised water and pH adjusted to 7.5 using NaOH. The solution was autoclaved 
and then following filter sterilisation, supplements were added prior to use: 12.5ml 
of 1M MgCl2, 12.5ml of MgSO4 and 10ml of 2M glucose.  
 
2.1.2 Solutions used in Chromatin Immunoprecipitation  
Cell lysis buffer – 50mM Hepes-KOH pH7.5, 140mM NaCl, 1mM EDTA, 10% 
glycerol, 0.5% NP-40, 0.25% Triton X-100. 
Nuclear lysis buffer – 10mM Tris-HCl, pH8.0, 200mM NaCl, 1mM EDTA, 0.5mM 
EGTA. 
ChIP dilution/sonication buffer – 16.7mM Tris–HCl, pH 8.1, 167mM NaCl, 1.1% 
Triton X-100, 0.01% SDS, 1.2mM EDTA. 
Low salt wash buffer – 20mM Tris–HCl, pH 8.1, 150mM NaCl, 0.1% SDS, 1% 
Triton X-100, 2mM EDTA. 
High salt wash buffer – 20mM Tris–HCl, pH 8.1, 500mM NaCl, 0.1% SDS, 1% 
Triton X-100, 2mM EDTA. 
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LiCl wash buffer - 10mM Tris–HCl, pH 8.1, 250mM LiCl, 1% Igepal, 1% sodium 
deoxycholate and 1mM EDTA. 
TE buffer – 10mM Tris–HCl, pH 8.0, 1 mM EDTA. 
Elution buffer - 50mM Tris–HCl pH 8, 1mM EDTA, 1% SDS, 50mM NaHCO3. 
  
2.1.3 Sources of cell lines 
SK-N-AS – human neuroblastoma cell line, CRL-2137 from the European 
Collection of Cell Culture (ECACC). 
MCF-7 – human breast adenocarcinoma cell line which was provided to the lab by 
collaborators: Prof Rudland and Prof Palmeri. 
JAr - human placental choriocarcinoma cell line, HTB 144 from the ECACC. 
 
2.1.4 Cell culture media 
2.1.4.1 Complete media for SK-N-AS cell line 
Dulbecco’s Modified Eagles medium with 4500mg glucose/L (Sigma D5796) 
supplemented with 1% (v/v) non essential amino acid solution (Sigma), 100 units per 
ml of penicillin and 0.1mg/ml of streptomycin and 10% (v/v) foetal bovine serum 
(Sigma). 
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2.1.4.2 Complete media for MCF-7 cell line 
Dulbecco’s Modified Eagles medium with 4500mg glucose/L (Sigma D5796) 
supplemented with 100 units per ml of penicillin and 0.1mg/ml of streptomycin and 
10% (v/v) foetal bovine serum (Sigma). 
 
2.1.4.3 Complete stripped media for MCF-7 cell line  
Dulbecco’s Modified Eagles medium with 4500mg glucose/L and  phenol red free 
(Sigma D1145) supplemented with 100 units per ml of penicillin and 0.1mg/ml of 
streptomycin, L-Glutamine final concentration 2mM (Sigma) and 5% (v/v) charcoal 
stripped foetal bovine serum (Sigma). 
 
2.1.4.4 Freezing media 
90% foetal bovine serum (Sigma), 10% DMSO (Sigma). 
 
2.2 Methods 
2.2.1 Bioinformatic and in silico analysis of SVA distribution and structure 
 Several genome browsers and software available freely on the internet were 
used in the analysis of the global distribution of SVAs. These are listed below with 
the version used: 
UCSC genome browser Hg19 (http://genome.ucsc.edu/index.html) 
Galaxy (http://galaxyproject.org/) 
NCBI HuRefChr37.3 (http://www.ncbi.nlm.nih.gov/) 
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Quadparser (G-quadruplex prediction software) (Wong et al. 2010) 
For detailed methods using these programs see methods section of chapter 4 
(sections 4.3.1-7). 
 
2.2.2 Cell culture 
2.2.2.1 Culturing of SK-N-AS and MCF-7 cell lines 
 SK-N-AS cells (human neuroblastoma cell line) were grown in media 
outlined in 2.1.4.1 and MCF-7 cells (human breast adenocarcinoma cell line) were 
grown in media outlined in 2.1.4.2 both in T175 flasks and when 70-80% confluent 
they were passaged into new T175 flasks. To passage cells the media was removed 
from the flask and the cells were washed with 10ml sterile PBS. 5ml of 1x trypsin 
(Sigma) was added, washed over the cell and then removed. The flask was placed in 
the incubator at 37
o
C for 3 minutes until the cells began to detach from the surface. 
The cells were washed away from the surface of the flask using 10mls of appropriate 
media and 1-2mls (approximately 1-2.4 million cells depending on cell type) of 
which was then placed in a new T175 flask with 40mls of media for that cell line. 
 The cell lines were tested for mycoplasm every six months using MycoAlert 
Mycoplasma Detection kit (Lonza) to prevent infection. 
 
2.2.2.2 Cell counts with a haemocytometer 
To determine the number of cells per ml of media a cell count was completed 
using a haemocytometer. A T175 flask of cells at approximately 70% confluency 
was passaged as in methods 2.2.2.1 up to when the cells were washed down with 
50 
 
10mls of media. Prior to use the haemocytometer and coverslip were washed with 
ethanol. On the centre of the counting surface of the haemocytometer there are 25 
squares (5x5) bounded by three parallel lines each containing 25 smaller squares 
(5x5). The coverslip was placed onto the counting surface of the haemocytometer 
and 20µl of the media containing the cells was introduced under the coverslip. The 
counting surface was visualised under a light microscope on the 10x objective and 
the number of cells within the 25 larger squares bounded by three parallel lines were 
counted. Any cells on the top or left hand borders of the 25 squares were included in 
the count where as cells on the bottom or right hand borders were excluded. This 
area corresponds to 0.1mm
3
 therefore the number of cells was multiplied by 10
4
 
(10000) to give the number of cells in 1cm
3 
which is the equivalent of 1ml. This 
gave the number of cells per ml of media.  
 
2.2.2.3 Freezing cells for storage in liquid nitrogen 
 For long term storage of cell lines the cells were frozen in freezing media 
(2.1.4.4) in liquid nitrogen. The cells were grown in T175 flasks until 70-80% 
confluent and then passaged as in 2.2.2.1 but the cells were washed from the surface 
of the flask using 10mls of freezing media (2.1.3.4).The freezing media containing 
cells were split across cryovials with 1.8mls in each. The cryovials were then placed 
into a Mr Frosty with isopropanol at -80
0
C for 24 hours. The cryovials were then 
transferred to liquid nitrogen. 
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2.2.3 Analysis of endogenous gene expression 
2.2.3.1 Extraction of total RNA from cultured cells 
Total RNA was extracted using TRIzol reagent (Invitrogen). SK-N-AS and 
MCF-7 cells were plated out into 6 well plates (450,000 and 400,000 cells per well 
respectively) and left for 24hrs. The media from each well was removed and 1ml of 
TRIzol was added per 10cm
2
 and pipetted up and down to lyse the cells. 1ml of the 
lysed cells was added to a microcentrifuge tube and incubated for 5 minutes at room 
temperature. 0.2ml of chloroform (per 1ml of TRIzol reagent) was added to each 
sample, shaken by hand for 15 seconds and then incubated at room temperature for 
2-3 minutes. The samples were then centrifuged at 12,000 g for 15 minutes at 4
o
C. 
After centrifugation the mixture had separated into three layers: a colourless aqueous 
upper layer containing the RNA, a middle interphase layer and a lower red organic 
layer containing the DNA and protein. The upper colourless layer was carefully 
removed and transferred to a new microcentrifuge tube (approximately 500µl). 0.5ml 
of 100% molecular grade isopropanol (per 1ml of TRIzol reagent) was added to each 
sample and incubated for 10 minutes at room temperature and then centrifuged at 
12,000 g for 10 minutes at 4
o
C.  
The supernatant was removed leaving behind the pellet of RNA. This was 
then washed with 1ml of 75% ethanol (per 1ml of TRIzol reagent used in initial 
step). Once the ethanol had been added to the pellet it was vortexed and centrifuged 
at 7500 g for 5 minutes at 4
o
C. The supernatant was removed and the pellet was air 
dried for 5 to 10 minutes. The pellet was resuspended in 20µl of nuclease free water 
and heated on a heat block at 55
o
C for 10-15 minutes. RNA was quantified using a 
Nanodrop 8000. The Nanodrop was set to measuring RNA and calibrated with 
nuclease free water (the dilutant the RNA was resuspended in) and then 1.5µl of 
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each sample was loaded on the pedestal. The amount of UV light absorbed at 260nm 
by nucleic acids is dependent on their concentration. The Nanodrop measures the 
optical density of the RNA and then calculates its concentration (an OD260nm of 1 
equals an RNA concentration of 40µg/ml). The Nanodrop was also used to assess the 
quality of the RNA by looking at the 260/280 and 260/230 ratios where expected 
values of high quality RNA are ~2.0 and 2.0-2.2 respectively.  The RNA was then 
stored at -80
o
C.  
 
2.2.3.2 First strand synthesis of cDNA from total RNA 
 cDNA was synthesised from the total RNA extracted in 2.2.3.1 using the 
GoScript Reverse Transcription System (Promega) following the recommended 
protocol from the manufacturer that can convert up to 5µg of RNA in each reaction. 
The same amount of RNA was used in the reverse transcriptase reaction for each 
sample. The following components were combined into a PCR tube: 
RNA (up to 5µg)                              Xµl 
Random Primers (0.5µg/reaction)     1µl 
Nuclease free water                          Yµl 
Final volume 5µl 
  
The mixture was denatured at 70
o
C for 5 minutes to and then cooled on ice. The 
following reverse transcription mix was added to the RNA, random primers and 
nuclease free water reaction so total volume was 20 µl: 
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Component                              Volume Final Concentration 
Nuclease free water (to a final volume of 15µl)                     Xµl  
GoScript 5X reaction buffer                                                  4µl 1X 
MgCl2 (25mM)                                                                      4µl 5mM 
PCR nucleotide mix (10mM of each dNTP)                          1µl     0.5mM 
Recombinant RNasin Rinonuclease inhibitor 
(40U/µl)       
0.5µl 1U/µl         
GoScript Reverse Transcriptase                                           1µl  
  
The combined reaction mixes were incubated at 25
o
C for 5 minutes for the primers 
to anneal and then incubated at 42
o
C for 60 minutes (extension step). The reverse 
transcriptase is inactivated by heating the reaction to 70
o
C for 15 minutes. The 
cDNA was then stored at -20
o
C. 
 
2.2.3.3 Amplification of cDNA for detection of mRNA expression  
2.2.3.3.1 Primer design 
 Primers were designed using Primer3 (http://frodo.wi.mit.edu/). The primers 
were designed in separate exons to distinguish product from any amplicons arising 
from contaminating gDNA acting as template. Firstly the complete gDNA of the 
gene of interest was taken from UCSC genome browser (Hg19) and the introns 
deleted. This sequence was then used with the Primer3 software. The potential 
primers were inserted into the In-silico PCR tool of the UCSC genome browser to 
ensure they were specific to the area of interest and were no other potential PCR 
products. Primers were synthesised by Eurofins (MWG primers).  
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2.2.3.3.2 Polymerase chain reaction 
 GoTaq Flexi DNA Polymerase (Promega) was used in Polymerase chain 
reaction (PCR) for the amplification of cDNA targets in analysis of gene expression 
using the cDNA generated in 2.2.3.2 as template. 
GoTaq Flexi DNA Polymerase master mix (per reaction) 
Component                              Volume Final Concentration 
5X Green GoTaq Flexi buffer                             5µl 1X 
MgCl2 (25mM)                                                                      4µl 4mM 
PCR nucleotide mix (10mM of each dNTP)                          1µl     0.4mM 
Upstream Primer (20µM)                                  0.5µl 0.4µM       
Downstream Primer (20µM)                             0.5µl 0.4µM       
GoTaq DNA polymerase (5u/µl)                      0.25µl                                 0.05U/µl                    
Nuclease free water                                            Xµl  
cDNA template                                                  Yµl  
Final Volume                                                     25µl  
     
The PCR was performed in a thermocycler: QB-96 (Quanta Biotech) or peqSTAR 
2X (peqlab). For the cycle conditions for each primer set used see Table A1 in the 
appendix. The annealing temperature of each primer set was optimised using a 
gradient PCR. The amount of cDNA template used again varied between primer sets 
depending on the abundance of the target for amplification.  
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2.2.3.4 Agarose gel Electrophoresis 
 PCR products were analysed using agarose gel electrophoresis, which allows 
the separation of DNA fragments by mass as they migrate through the agarose gel 
with the application of an electric field. The appropriate amount of agarose (Bioline) 
was dissolved in 0.5X TBE with the addition of a nucleic acid stain intercalating of 
either 1µl of GelRed per 10ml (Biotium 10000X) or 0.5µl per 10ml of ethidium 
bromide (Sigma 10mg/ml). The percentage of the gel used was determined by the 
size of the fragments to be run on the gel. The gel was poured into the appropriate 
sized casting tray and combs inserted to set at room temperature.  The gels were 
placed into horizontal gel tanks with 0.5X TBE and if ethidium bromide was used as 
nucleic acid stain 5µl of ethidium bromide was added for every 1L of buffer. The 
samples were loaded into the wells of the gel. If no loading dye was already present 
in the samples (GoTaq Flexi buffer contains dye) loading dye (Promega 6X) was 
added at 1µl per 5µl of sample. For sizing of the fragments on the gel a DNA ladder, 
either 100bp (Promega) or 1kb (Promega) depending on the size of the fragments 
expected, was loaded in at least one of the wells. The voltage (standard is 5V/cm) 
and time for which the gel was run was dependant on the percentage of the gel and 
fragment size. The DNA was then visualised using a UV transillumintor (BioDoc-it 
Imaging System) and an image was captured.   
 
2.2.4 Methods for cloning 
2.2.4.1 Primer design for amplification of targets for cloning  
The genomic sequence of the locus to be cloned was obtained from UCSC 
genome browser (Hg19) with flanking sequence. Primer3 (http://frodo.wi.mit.edu/) 
56 
 
was used to design the primers with the specific sequence required in the PCR 
product indicated using brackets to ensure the primers would be located in the flank 
of the target sequence. Primers containing restriction sites for directional ‘sticky end’ 
cloning were designed with approximately 15bp of sequence specific to the region to 
be amplified, the restriction enzyme site sequence at the 5’end of the primer and then 
six random bases 5’ of the restriction enzyme site sequence to increase efficiency of 
digestion. All primers designed were screened using in-silico PCR tool from UCSC 
genome browser to ensure they produced one specific product. Templates used were 
gDNA from Jar cell line (source of cell lines 2.1.3 and gDNA extraction method 
2.2.7) and gDNA from the CEU HapMap cohort (Utah residents with Northern and 
Western European ancestry from the CEPH collection) which is commercially 
available DNA and was provided by our collaborator Gerome Breen.  
 
2.2.4.2 Amplification of fragments for cloning using PCR 
 The proof reading enzyme KOD Hot Start Polymerase (Novagen) that 
produces blunt ended products was used to amplify the appropriate fragments for 
cloning.  
KOD Hot Start master mix (per reaction): 
Component                              Volume Final Concentration 
10X buffer for KOD Hot start polymerase          5µl 1X 
MgSO4 (25mM)                                                   3µl 1.5mM 
dNTPs (2mM of each)                                                                  5µl       0.2mM of each dNTP 
Upstream Primer (10µM)                                  1.5µl 0.3µM       
Downstream Primer (10µM)                             1.5µl 0.3µM       
57 
 
KOD hot start DNA polymerase (5u/µl)            1µl                                 0.02U/µl                    
Nuclease free water                                            Xµl  
gDNA template                                                  Yµl  
Final Volume                                                     50µl  
 
The products were analysed by agarose gel electrophoresis (2.2.3.4). For details of 
each primer set and methods used for the different fragments to be cloned see 2.2.5.1 
and 2.2.5.2 and Table A1 in the appendix. 
 
2.2.4.3 Restriction enzyme digests 
 Restriction enzyme digests were used either to create specific nucleic acid 
overhangs for ligation or as a diagnosis tool for determining the presence and/or 
orientation of inserts. For restriction enzymes from Promega the following reaction 
components was used: 
Nuclease free water                         Xµl 
10X Buffer                                          2µl 
Acetylated BSA (10µg/µl)              0.2µl 
DNA (1µg)                                      Yµl 
Restriction Enzyme (10u/ µl)         0.5µl 
Final volume                                  20µl 
 
The buffer recommended for each enzyme’s optimum activity was used. The 
digestion was incubated for 1-4 hours at the appropriate temperature for the enzyme 
activity and run on an agarose gel to visualise the fragment size (2.2.3.4). 
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 Restriction enzymes used from New England Biolabs were used with the 
following components: 
Nuclease free water                         Xµl 
10X Buffer                                          5µl 
BSA (10mg/ml)                              0.5µl 
DNA (1µg)                                      Yµl 
Restriction Enzyme (10u/µl)         0.5µl 
Final volume                                  50µl 
 
The digestion was then incubated at the appropriate temperature for 1-4 hours and 
run on an agarose gel to visualise the fragment size (2.2.3.4). 
 
2.2.4.4 Extraction of DNA fragments from agarose gels 
 DNA fragments run on an agarose gel from either a PCR or restriction 
enzyme digestion were extracted using the QIAquick Gel Extraction Kit (Qiagen) 
and the manufacturers guidelines provided with the kit were followed. The gel 
extraction kit can be used for purification of dsDNA fragments from 70bp-10kb 
removing primers, nucleotides, enzymes, salts, agarose and other impurities for use 
in downstream applications such as ligation with the appropriate vector. Briefly the 
fragment of DNA of interest is cut from the agarose gel, which is completely 
dissolved in the appropriate buffer, purified using a column system and wash buffers 
and recovered from the column using an elution buffer. The eluate is then used as 
required in downstream applications or stored at -20
o
C. 
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2.2.4.5 Ligation of DNA fragments into pCR-Blunt intermediate vector 
 For cloning of PCR fragments into an intermediate vector the Zero Blunt 
PCR Cloning Kit (Invitrogen) was used. The amount of PCR product required was 
calculated using the following equation: 
Xng insert = (10 x Ybp PCR product) X (25ng linearised pCR-Blunt)/3500bp pCR-
Blunt 
3 ratios from 10:1 to 100:1 of insert:vector were used in the following ligation 
reaction: 
pCR-Blunt (25ng)                               1µl 
Blunt PCR product                      1 to 5µl 
10X Ligation Buffer (with ATP)        1µl 
Sterile water                                      Xµl 
T4 DNA Ligase (4 units/µl)               1µl 
Final volume                                  10µl 
 
The ligation reaction was incubated at 16
o
C for 1 hour and then used in the 
transformation of chemically competent cells 2.2.4.7.1 or stored at -20
o
C. 
 
2.2.4.6 Ligation of DNA fragments into reporter gene pGL3 vectors 
 The cloning of inserts into pGL3 vectors was completed using vector and 
insert with complementary overhangs generated after restriction enzyme digest. The 
ligations were generally carried out at a molar ratio of vector to insert of 1:3. The 
amount of insert required was calculated using the following equation: 
60 
 
Insert(ng) = Vector (ng) X size of insert(kb)/size of vector(kb) 
Vector DNA                                     Xµl 
Insert DNA                                       Yµl 
10X Ligation Buffer  1µl 
Nuclease free water Zµl 
T4 DNA Ligase  0.1-1units 
Final volume                                  10µl 
 
The ligation reaction was incubated at room temperature for 3 hours and then used in 
the transformation of chemically competent cells 2.2.4.7.1 or 2.2.4.7.2 or stored at -
20
o
C. 
 
2.2.4.7 Transformation of chemically competent cells 
2.2.4.7.1 Transformation of DH5α competent E.coli  
 Chemically competent DH5α E.coli (Invitrogen) were defrosted on wet ice 
and divided into 50µl aliquots in 1.5ml microcentrifuge tubes, any aliquots not 
required were snap frozen in an ethanol dry ice bath and placed at -80
o
C for storage.  
5 µl of each ligation mixture from 2.2.4.5 or 2.2.4.6 was added to 50µl of competent 
DH5α cells, tapped gently to mix and then incubated on ice for 30mins. The 
transformation mixture was then heat shocked at 37
o
C for 20 seconds and placed on 
ice for 2 minutes. 950µl of pre-warmed LB broth (2.1.1) was added to the 
transformation mixture and placed in a shaking incubator at an angle to allow for 
increased gaseous exchange as an aerobe at 37
o
C and 225rpm for 1hr. 200µl of the 
transformation mixture was spread onto LBagar plates that have been warmed in the 
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incubator previously and contained appropriate amount of specific antibiotic 
(75µg/ml ampicillin or 25µg/ml kanamyacin). The plates were then incubated at 
37
o
C overnight. The remainder of the transformation mixture was stored at 4
o
C for 
future use if required.   
 
2.2.4.7.2 Transformation of XL10-Gold Ultracompetant cells 
 A 14ml round bottom BD Falcon polypropylene tube was chilled on ice per 
transformation reaction and NZY
+
 broth (2.1.1) was warmed to 42
o
C. 100µl aliquots 
of XL-10 Gold ultracompetant cells were then thawed on ice and once defrosted 
added to the round bottom falcon tubes. 4µl of β-mercaptoethanol was added to the 
cells, swirled and then incubated on ice for 10 minutes with the cells being swirled 
every two minutes. 2µl of ligation mixture was added to the cells and then incubated 
on ice for 30 minutes. The cells were then heated pulsed for 30 seconds at 42
o
C in a 
water bath and incubated on ice for 2 minutes. 900µl of pre-warmed NZY
+
 was 
added to the cells and placed in a shaking incubator at 225rpm and 37
o
C for one 
hour. 200µl of the transformation mixture was spread onto agar plates containing 
75µg/ml of ampicillin that had been pre-warmed. These were incubated overnight at 
37
o
C. 
 
2.2.4.8 Miniprep: preparation and purification of plasmid DNA with low yield  
 For extraction of low yield plasmid DNA from transformed bacteria QIAprep 
spin Miniprep Kit (Qiagen) was used and the manufacturer’s guidelines followed. 
These types of extractions were used to screen colonies grown from the 
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transformation of chemically competent bacteria with ligation reactions for 
determining if an insert of the correct size/orientation is present. Colonies were 
picked from the agar plates on which the transformation mixture was spread 
(2.2.4.7.1 and 2.2.4.7.2) and grown in 5ml of LB broth with the appropriate 
antibiotic overnight to expand the numbers of bacteria containing the plasmid of 
interest. This culture media could then be used to create a bacterial pellet to extract 
the plasmid using the miniprep kit. Briefly the miniprep kit system involves the lysis 
of the bacteria to release the plasmid and subsequent neutralisation of this reaction. 
The cellular debris is removed and the plasmid DNA is purified using a column 
system and then eluted. The plasmid was then used in downstream applications such 
as restriction enzymes digests or stored at -20
o
C.  
 Glycerol stocks of transformed bacteria were made for long term storage. 
1.4ml of the overnight culture was transferred to a microcentrifuge tube and pelleted 
by centrifugation at 8000rpm for 3 minutes at room temperature. The supernatant 
was removed and the pellet resuspended in 0.5ml of sterile 15% glycerol (v/v in LB 
broth) and transferred to a cryovial. This was then immediately frozen at -80
o
C. 
 
2.2.4.9 Maxiprep: preparation and purification of plasmid DNA with high yield  
 A Plasmid Maxi Kit (Qiagen) was used to purify high yields of plasmid DNA 
from transformed bacteria following the manufacturer’s guidelines. This type of 
plasmid extraction was used to produce a high yield of plasmid DNA with a greater 
purity than that of a miniprep for use in downstream applications such as in vitro 
reporter gene assays. A small scraping of the glycerol stock was grown in 3ml of LB 
broth with the appropriate antibiotic for 6-8hrs of which 200µl was then cultured in 
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100ml of LB broth with the appropriate antibiotic to generate a sufficient quantity of 
bacteria for extraction of the plasmid. Briefly the bacteria was pelleted and 
resuspended for lysis. Once the cellular lysis had occurred to release the plasmid the 
reaction was neutralised and the cellular debris was removed. The plasmid was 
purified through column by gravity flow, washed and eluted. Isopropanol was used 
to precipitate the DNA from the eluate. Once the DNA was pelleted it was washed 
with 70% ethanol to remove excess salt. The ethanol is removed and the pellet is air 
dried before being resuspended in 300-500µl of EB buffer. The plasmid DNA was 
quantified using a Nanodrop 8000 and then stored at -20
o
C. 
 
2.2.4.10 Sequencing 
 Samples such as plasmids with inserts cloned in and PCR products were sent 
for sequencing to either Dundee DNA Sequencing and Service or Source Bioscience 
Life Sciences. The samples and primers were supplied as required by the companies. 
 
2.2.5 Generation of reporter gene constructs 
2.2.5.1 Cloning of PCR products of different fragments and alleles of the 
PARK7 SVA into an intermediate vector 
 The fragments of interest of the PARK7 SVA and its alleles were amplified 
using KOD hot start polymerase (2.2.4.2) and ligated into the multiple cloning site of 
pCR-Blunt intermediate vector (2.2.4.5).  
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  The ligation reactions were transformed into chemically competent DH5α 
E.coli (2.2.4.7.1). During the transformation process of the plasmid containing the 
whole SVA it is postulated that a recombination event occurred resulting in a 
truncated insert comprised of the 5’ end of the SVA and a small portion of the SINE 
region. This was used as a template in order to amplify a fragment of the SVA 
containing the hexamer repeat, alu-like sequence and the first 10 repeats of the 
tandem repeat that otherwise would have not been possible due to the repetitive 
nature of the sequence. The plasmids that appeared to contain the correct insert were 
sequenced (2.2.4.10). Methods used in this process are described in detail in section 
2.2.4 and table 2.1 summaries the information for each construct generated. 
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Name 
Primers for amplification of 
insert  
Template for PCR 
Restriction enzyme used to 
determine orientation of insert 
Orientation of insert 
Whole SVA I 
For 5’ggctttttgataacccctga 3’ 
Rev 5’tttcggatcacaggcatgagc 3’ 
gDNA JAr Bgl1 Rev 
SVAΔSINE  I 
For 5’ggctttttgataacccctga 3’ 
Rev 5’ ccgcctttctattccacaaa 3’ 
gDNA JAr Bgl1 For 
TR/VNTR I 
For 5’ctcagtgctcaatggtgcc 3’ 
Rev 5’ ccgcctttctattccacaaa 3’ 
Whole SVA amplicon PFIfI For 
Truncated SVA I 
For 5’ggctttttgataacccctga 3’ 
Rev 5’gacggggcggttgcc 3’ 
Truncation of whole SVA 
plasmid in pCR blunt 
Bgl1 For 
Allele 1 I 
For 5’ggctttttgataacccctga 3’ 
Rev 5’gcaaggcttagcttggacag 3’ 
gDNA of an individual from 
the  CEU HapMap 
Bgl1 For 
Allele 2 I 
For 5’ggctttttgataacccctga 3’ 
Rev 5’gcaaggcttagcttggacag 3’ 
gDNA of an individual from 
the CEU HapMap 
Bgl1 For 
Allele 3 I 
For 5’ggctttttgataacccctga 3’ 
Rev 5’gcaaggcttagcttggacag 3’ 
gDNA of an individual from 
the CEU HapMap 
Bgl1  For 
Allele 4 I 
For 5’ggctttttgataacccctga 3’ 
Rev 5’gcaaggcttagcttggacag 3’ 
gDNA of an individual from 
the CEU HapMap 
Bgl1 For 
  
Table 2.1: Plasmids generated using fragments cloned into the intermediate vector pCR-Blunt. This table contains information on the 
generation of intermediate vectors containing various fragments of the PARK7 SVA and its alleles for use in downstream cloning or required for 
sequencing. For fragment sizes of PCR products see Table A1 of the Appendix.  
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2.2.5.2 Cloning of PCR products of different fragments and alleles of the 
PARK7 SVA into reporter gene vectors 
 The pCR-Blunt intermediate vectors containing the correct fragments 
(determined by sequencing) of the PARK7 SVA: whole SVA I, SVAΔSINE I, 
TR/VNTR I and truncated SVA I were used to clone the fragments into pGL3P in 
the forward and reverse orientation. The whole SVA I was also used to clone the 
SVA into the pGL3B vector in the forward and reverse orientation. The intermediate 
vectors containing the different alleles of the PARK7 SVA were used as template to 
amplify a shorter fragment removing the 3’ flanking sequence. A larger fragment of 
the alleles of the PARK7 SVA was required to amplify all four alleles from gDNA 
therefore when being cloned into a reporter gene vector the additional 3’ flanking 
region needed to be removed. These fragments of the different alleles with minimal 
flanking sequence were cloned into the pGL3P vector using restriction enzymes sites 
introduced by the PCR primers. All the ligation reactions except that of allele 3 were 
transformed into DH5α E.coli (2.2.4.6.1), however due to problems encountered, the 
ligation of allele 3 into pGL3P was transformed into XL-10 ultracompetant cells 
(2.2.4.7.2). The plasmids that appeared to contain the correct insert were sequenced 
(2.2.4.10). All the methods used in the cloning process are described in section 2.2.4 
and table 2.2 summaries the information for each construct generated. 
For sufficient quantity and purity for downstream applications the reporter 
gene constructs were extracted from the transformed DH5α E.coli or XL-Gold 
ultracompetant cells using a maxiprep kit (2.2.4.9). 
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Table 2.2: The reporter gene constructs generated for use in in vitro luciferase assays. This table shows information regarding the 
backbones used and the origin of the inserts for generating reporter gene constructs containing different sized fragments of the PARK7 SVA and 
its different alleles. 
Name Vector Orientation 
RE sites of 
insertion 
RE used to 
digest 
intermediate 
plasmid 
Template for 
digest or 
amplification 
Primers for amplification 
Digest to 
detect 
presence of 
insert 
Whole SVA pGL3P For NheI BglII BamHI XbaI Whole SVA I - Acc65I NcoI 
Whole SVA pGL3P Rev Acc65I XhoI Acc65I XhoI Whole SVA I - Acc65I XhoI 
SVAΔSINE pGL3P For Acc65I XhoI Acc65I XhoI SVAΔSINE  I - Acc65I XhoI 
SVAΔSINE pGL3P Rev NheI BglII BamHI XbaI SVAΔSINE  I - Acc65I NcoI 
TR/VNTR pGL3P For Acc65I XhoI Acc65I XhoI TR/VNTR I - Acc65I XhoI 
TR/VNTR pGL3P Rev NheI BglII BamHI XbaI TR/VNTR I - Acc65I NcoI 
Truncated 
SVA 
pGL3P For Acc65I XhoI Acc65I XhoI 
Truncated 
SVA I 
- Acc65I XhoI 
Truncated 
SVA 
pGL3P Rev NheI BglII BamHI XbaI 
Truncated 
SVA I 
- Acc65I NcoI 
Whole SVA pGL3B For NheI BglII BamHI XbaI Whole SVA I - Acc65I NcoI 
Whole SVA pGL3B Rev Acc65I XhoI Acc65I XhoI Whole SVA I - Acc65I XhoI 
Allele 1 pGL3P For Acc65I XhoI - Allele 1 I 
For 5’tgtaggtaccggctttttgataaccc3’ 
Rev 5’gtaactcgagtttcggatcacaggc3’ 
Acc65I XhoI 
Allele 2 pGL3P For Acc65I XhoI - Allele 2 I 
For 5’tgtaggtaccggctttttgataaccc3’ 
Rev 5’gtaactcgagtttcggatcacaggc3’ 
Acc65I XhoI 
Allele 3 pGL3P For Acc65I XhoI - Allele 3 I 
For 5’tgtaggtaccggctttttgataaccc3’ 
Rev 5’gtaactcgagtttcggatcacaggc3’ 
Acc65I XhoI 
Allele 4 pGL3P For Acc65I XhoI - Allele 4 I 
For 5’tgtaggtaccggctttttgataaccc3’ 
Rev 5’gtaactcgagtttcggatcacaggc3’ 
Acc65I XhoI 
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2.2.6 Analysis of reporter gene expression  
2.2.6.1 Transient transfection of reporter gene constructs into SK-N-AS and 
MCF-7 cell lines  
 Turbofect (Thermo Scientific) was used to transfect SK-N-AS and MCF-7 
cell lines following the manufacturer’s guidelines. The cells were counted (2.2.2.2) 
and were then plated into 24 well plates at the following concentrations 24 hours 
prior to transfection: SK-N-AS 120,000 cells per well and MCF-7 100,000 cells per 
well with 1ml of media.  For each transfection/well 1µg of the test reporter gene 
plasmid, 10ng of the internal control and 2µl of Turbofect were combined in a total 
volume of 100µl of serum free media, vortexed and then incubated for 20 minutes at 
room temperature. 100µl of the transfection mixture (1/10 of the volume of media) 
was added per well and after 4 hours the media was changed to remove the 
transfection mixture reducing cell death.  
 
2.2.6.2 Cell lysis 
 48 hours after the cells had been transfected with the reporter gene constructs 
the cells were lysed in preparation for the Dual Luciferase Reporter Assay 
(Promega). Prior to the addition of the passive lysis buffer (PLB) the media was 
removed and the cells washed with PBS. 100µl of 1X PLB was added to each well 
and the 24 well plates were placed on a rocking platform for 15 minutes. 20µl of the 
cell lysate was transferred to an opaque 96 well plate in preparation for the luciferase 
assay.  
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2.2.6.3 Measuring levels of reporter gene using Dual Luciferase Assay 
 The appropriate amount of luciferase assay reagent II (LARII) and Stop and 
Glo reagent was prepared for the number of measurements required and allowed to 
reach room temperature. The opaque 96 well plate containing the cell lysate was 
placed into a Glomax 96 Microplate Luminometer (Promega). The luminometer has 
two injectors and therefore can automatically dispense both the LARII and the Stop 
and Glo one after the other at programmed intervals. The injectors were flushed with 
distilled water, 70% ethanol, distilled water and then air to thoroughly clean them. 
The injectors are then primed with the reagents (LARII in injector 1 and Stop and 
Glo in injector 2) before the promega dual luciferase program is run, which measures 
the bioluminescence from the reaction catalysed by the firefly and renilla luciferase 
enzymes. The LARII is added first to measure the bioluminescence produced by the 
reaction catalysed by the firefly luciferase protein and then the Stop and Glo 
quenches this reaction and is used to measure the bioluminescence from the reaction 
catalysed by the renilla luciferase protein.  
 Using the measurements from the activity of the two reporter gene constructs 
that were co-transfected the activity of the constructs across the different wells can 
be accurately compared as the internal control reduces experimental variability 
caused by differences in transfection efficiencies.  
 
2.2.7 Extraction of gDNA from cell lines 
 Genomic DNA was extracted from the cell lines available in the lab using the 
QIAamp DNA mini kit (Qiagen) following the manufacturer’s guidelines. The cells 
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were trypsinised from a confluent T175 flask and counted. The recommended 
number of cells (5x10
6
) were transferred to a 1.5ml microcentrifuge tube and 
centrifuged for 5 minutes at 300g. The supernatant was removed and the cell pellet 
resuspended in 200µl of PBS. For the extraction from the MCF-7 cell line a range of 
the number of cells was used due to their reported unusual karyotype. The samples 
were lysed using enzymes and then passed through a column where the DNA binds 
to the membrane. The impurities were removed with wash steps and then the gDNA 
is eluted. The quantity and quality of the gDNA was analysed using a Nanodrop 
8000 and then stored at -20
o
C. 
 
2.2.8 Genotyping of SVAs  
 Several SVAs were amplified throughout this project and the methods are 
outlined in the methods sections of the relevant results chapters (3.3.2, 5.3.5, 6.3.5, 
6.3.8-10). 
 
2.2.9 Chromatin Immunoprecipitation (ChIP) 
2.2.9.1 Harvesting the cell pellet 
 SK-N-AS and MCF-7 cells were grown in T175 flasks under basal conditions 
and when they reached 70-80% confluency were harvested for ChIP. The number of 
cells required to provide enough chromatin for ChIP is specific to each cell line. 
There are approximately 12 million SK-N-AS cells in a T175 flask which provides 
sufficient chromatin for ~10 immunoprecipitations using 10µg and a T175 flask of 
71 
 
MCF-7 cells contains approximately 15 million cells and would provide sufficient 
chromatin for ~15 immunoprecipitations using 10µg. 
 To crosslink the proteins to the DNA the cells were fixed with 1% 
formaldehyde (v/v) and incubated at room temperature for 8-10 minutes occasionally 
swirling the mixture. The reaction was quenched by added glycine to a final 
concentration of 0.125M and incubated for 5 minutes at room temperature. Each 
flask of cells was then washed twice with 10mls of ice cold PBS supplemented with 
10µl of 200X protease inhibitor cocktail (PIC) (Calbiochem) and 100µl of 0.1M of 
phenylmethanesulfonyl fluoride (PMSF) (Sigma). 5ml of PBS supplemented with 
10µl of 0.1M PMSF was added to each flask and the cells were scraped from the 
surface of the flask using a cell scraper and collected into a 15ml falcon tube. The 
cells were pelleted by centrifugation at 1500rpm for 10 minutes at 4
o
C and the 
supernatant was removed using an aspirator. The cell pellet can be frozen at this 
stage of the protocol at -80
o
C.  
  
2.2.9.2 Cell and nuclear lysis 
 The pellet was taken directly from 2.2.9.1 and resuspended in 5ml of cell 
lysis buffer with the addition of 5µl of 200X PIC and incubated for 10 minutes at 
4
o
C on a rotating wheel. The mixture was centrifuged at 3500rpm for 5 minutes at 
4
o
C and then the supernatant was removed. The pellet was resuspended in 5ml of 
nuclear lysis buffer with the addition of 5µl of 200X PIC and incubated for 10 
minutes at 4
o
C on a rotating wheel. The mixture was centrifuged at 3500rpm for 5 
minutes at 4
o
C and then the supernatant was removed and the pellet resuspended in 
1.5ml of sonication buffer.  
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2.2.9.3 Sonication of chromatin 
 It is recommended to sonicate fresh chromatin that has not been stored at -
80
o
C as this can affect the shearing process as frozen cell pellets or frozen chromatin 
are more stable. The Biorupter (Diagenode) was used to sonicate the chromatin from 
step 2.2.9.2. The chromatin extracted fresh from the SK-N-AS cells was sheared 
using 30 rounds of 30s on and 30s off on the high setting.  The chromatin extracted 
fresh from the MCF-7 cells was sheared initially using 40 rounds of 30s on and 30s 
off on the high setting. The sheared chromatin from the MCF-7 cells when analysed 
(2.2.9.4) had not been sheared enough. Therefore the chromatin from the MCF-7 cell 
line, that had then been frozen, was sonicated again for another 40 rounds of 30s on 
and 30s off on the high setting. 
 
2.2.9.4 Estimating the quantity and fragment size of sheared DNA 
 50µl of sheared chromatin was removed and used to estimate the quantity 
and fragment size of the DNA. 50µl of nuclease free water was added to the sheared 
chromatin along with 6µl of 5M NaCl and 2µl of RNase one (Promega). The mixture 
was vortexed and then incubated at 37
o
C for 30 minutes. 2µl of proteinase K at 
20mg/ml (Sigma) was added to the RNase digested mixture, vortexed and then 
incubated at 65
o
C for 2 hours to reverse the cross links. The DNA was then purified 
using the MiniElute reaction cleanup kit (Qiagen) following the manufacturer’s 
guidelines. The DNA is eluted from the purifying columns in a volume of 10µl and 
then quantified using a Nanodrop 8000. The remaining DNA was run on a 1% 
agarose gel (2.2.3.4) with both a 100bp and 1kb ladder to determine the size of the 
fragments of sheared DNA. 
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2.2.9.5 Immunoprecipitation of cross-linked protein–DNA interactions 
 Antibodies for specific histone marks and transcription factors of interest 
were used in the immmunoprecipitation of the protein-DNA complexes to determine 
the factors bound to the DNA when the cells were harvested. 100µl of the sheared 
chromatin was removed for use as the positive control in the PCR analysis. 10µg of 
sheared chromatin was transferred to a new microcentrifuge tube for each 
immunoprecipitation to be carried out and made up to 250µl using dilution buffer. 
The primary antibody was added to the sheared chromatin and incubated on a 
rotating wheel at 4
o
C overnight. One tube of sheared chromatin had no primary 
antibody added to act as a control for non-specific of binding of DNA to the 
dynabeads. The details of the antibodies and the amount used in displayed in Table 
A2 in the appendix.  
 50µl of magnetic dynabeads (Invitrogen 30mg/ml) were transferred to a 
1.5ml microcentrifuge tube per immunoprecipitation and washed with 1ml of 
dilution buffer twice. The second wash was for 2 hours on a rotating wheel at 4
o
C. 
The beads were then captured using a magnetic rack and the supernatant removed. 
The beads were resuspended using 50µl of the antibody chromatin mix and then 
added to the rest of the chromatin antibody mix and incubated on a rotating wheel at 
4
o
C for 1 hour. The Dynabead and protein-DNA complexes were captured using a 
magnetic rack and the supernatant removed. The Dynabeads with the bound DNA 
were washed to remove non-specific DNA and protein bound to the beads. The 
washes were performed on a rotating wheel at 4
o
C for 3-5 minutes each with 1ml of 
the following buffers: low salt wash buffer, high salt wash buffer, LiCl wash buffer 
and TE buffer.  
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2.2.9.6 Elution of DNA and reversal of cross links 
 To elute the immune complex from the beads the bead-immune complex was 
captured using the magnetic rack and 100ul of elution buffer with a final 
concentration of 50µg/ml of proteinase K was added. This was mixed at 62
o
C for 2 
hours to release the protein bound DNA and reverse the cross links. The Dynabeads 
were then captured and the supernatant removed and transferred to a new tube and 
incubated at 95
o
C for 10 minutes to denature the protein and inactivate the proteinase 
K. The DNA was then cleaned up using the MiniElute enzyme reaction cleanup kit 
(2.2.9.4), quantified using a Nanodrop 8000 and stored at -20
o
C. 
  
2.2.9.7 Analysis of precipitated DNA using polymerase chain reaction 
 The regions of interest, the PARK7 gene promoters and 5’ of the SVA, were 
amplified using GoTaq flexi polymerase (2.2.3.4.2) and the conditions for each 
primer set are listed in Table A1 of the appendix. 5ng of precipitated DNA was used 
as template for the PCR. A primer set for a gene desert as a negative control for the 
ChIP assay and the sequence and conditions of the primer set are shown in Table A1 
of the appendix. The PCR products were run on 1.2% agarose gels for analysis 
(2.2.3.4).  
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Chapter 3 
A SVA retrotransposon upstream of the FUS gene 
can function as a regulatory domain and its 
implications in ALS 
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3.1 Introduction 
 VNTRs have been shown by the lab and others to be important in regulating 
gene expression and have been associated with disease (section 1.2). One of the 
projects in the lab at this time was analysing the potential regulatory domains of the 
fused in sarcoma (FUS) gene important for its association as a candidate gene for 
amyotrophic lateral sclerosis (ALS). Therefore analysis of the FUS gene locus was 
undertaken to determine areas with potential regulatory function and genetic 
variation.  
 FUS is found on chromosome 16p11.2 and is a RNA/DNA binding protein 
involved in the regulation of RNA processing (Verma 2011). Mutations within the 
exons of the FUS gene identified it as a causative gene in some cases of ALS; a fatal 
disease caused by the degeneration of motor neurons in the brain and spinal cord 
with death occurring 3-5 years after the onset of symptoms. The incidence of ALS 
each year in Europe is 2.7 per 100,000 people over the age of 18 occurring more 
frequently in males than females at a ratio of 1.3:1 (Logroscino et al. 2010) with a 
lifetime prevelance of 1 in 400 (Al-Chalabi et al. 2010). Familial ALS (FALS) 
accounts for approximately 5% of all cases of ALS with the rest showing no family 
history and are considered sporadic (SALS) (Byrne et al. 2011). The heritability of 
ALS was estimated at 40-45% when the concordance within ALS patients and their 
parents was analysed inlcuding familial and sporadic forms of the disease and a twin 
study estimated the heritability of SALS at 61% (Al-Chalabi et al. 2010; Wingo et al. 
2011).There have been many studies into the causes of ALS with the identification 
of 50-60% of genetic mutations in known causative genes of FALS cases and 11% 
of SALS (Lattante et al. 2012), however there is much still unknown about this 
disease. The number of ALS cases attributed to mutations in the FUS gene is small; 
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FUS mutations are present but rare in SALS at around 1% (Corrado et al. 2010; Chio 
et al. 2011; Lai et al. 2011; Sproviero et al. 2012) and found in only 3-5% of FALS 
(Kwiatkowski et al. 2009; Vance et al. 2009). Cytoplasmic FUS positive inclusions 
have been identified in the neurons of individuals with FALS caused by FUS 
mutations (Kwiatkowski et al. 2009; Vance et al. 2009) but have also been found in 
the spinal anterior horn neurons of SALS patients without FUS mutations, and in 
non-superoxide dismutase 1 (SOD1) familial ALS (Deng et al. 2010).  
 The identification of causative genes for a specific disease, in this case FUS 
and ALS, can provide insight into pathways involved in the development and 
progression of the disease and potential regions for genetic associations of common 
variants within a population. FUS is ubiquitously expressed but the regulation of the 
gene, in particular in response to challenge, may be an important factor in the 
initiation or progression of disease processes. Although it is difficult to accurately 
predict the regulatory domains for a particular gene it has been demonstrated that 
important domains for gene regulation can occur in both ECRs and VNTRs as 
discussed in chapter 1 (sections 1.1 and 1.2).  The searches for potential areas 
involved in transcriptional regulation can be aided by the utilisation of the ENCODE 
data searching for the presence of potential transcription factor binding sites, active 
histones or DNase 1 hypersensitivity clusters (Doolittle 2013; Kavanagh et al. 
2013a) and genome browsers such as UCSC (http://genome.ucsc.edu/index.html). 
The locus of the FUS gene was analysed using the UCSC genome browser for 
repetitive regions that may act as regulatory domains, respond to environmental cues 
and be polymorphic as seen for several of these types of elements throughout the 
genome. Within 10kb of the TSS of the FUS gene a large repetitive region was 
identified, which was part of a composite retrotransposable element called a SVA 
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(SVAs are discussed in detail in sections 1.3.1.2.4 and 1.3.2), Figure 3.1. The 
potential regulatory properties and association with ALS of this primate specific 
retrotransposon was addressed.  
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3.2 Aims 
 Identify potential novel regulatory and polymorphic domains of the FUS 
gene. 
 Further analysis of the genetic variation of this SVA element identified in 
commercial gDNA (personal communication from Thomas Wilm) in a CEU 
HapMap cohort. 
 Assess the genetic variants of the FUS SVA in SALS and matched control 
cohort to analyse any potential associations of the SVA alleles with disease.  
 Determine if there is a tagging SNP for the FUS SVA variants to assist in the 
analysis of much larger disease cohorts. 
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3.3 Methods 
3.3.1 Bioinformatic analysis of the FUS gene locus 
 The FUS gene locus was analysed using the UCSC genome browser 
(http://genome.ucsc.edu/index.html) to determine repetitive sequences in the region 
that could potentially act as regulatory domains. 
 
3.3.2 Genotyping the TR/VNTR of the FUS SVA 
3.3.2.1 Genotyping the TR/VNTR of the FUS SVA in a CEU HapMap cohort 
 The TR/VNTR of the SVA upstream of the FUS gene was amplified in the 
CEU HapMap cohort (Utah residents with Northern and Western European ancestry 
from the CEPH collection) using 1ng of genomic DNA as template (for primers and 
cycling conditions see Table A1 in Appendix). Go Taq Flexi Polymerase (Promega) 
was used under standard conditions with the addition of betaine (Sigma) at a final 
concentration of 1M. For details of the composition of the master mix for Go Taq 
Flexi Polymerase see 2.2.3.3.2. The products were run on a 1.2% agarose gel 
(2.2.3.4). To determine if the FUS SVA locus is in Hardy-Weinberg equilibrium 
(HWE) in the CEU HapMap population the allele frequencies (Figure 3.3A) were 
used in conjuction with the following equation p
2
+2pq+q
2
=1 to calculate the 
expected genotypes for this particular locus. The expected values were compared to 
the observed values using the Chi squared test to determine if the two sets of values 
were significantly different to each other. If the expected and the observed values are 
not significantly different to each other (p>0.05) the locus can be said to be in HWE.  
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3.3.2.2 Genotyping the TR/VNTR of the FUS SVA in a SALS and matched 
controls cohort 
 The PCR for genotyping the TR/VNTR of the FUS SVA in the SALS and 
control samples was completed at the laboratory in the MRC Social Genetic and 
Developmental Psychiatry Research Centre at the Institute of Psychiatry due to the 
location of the samples, therefore the protocol differed to previous method in 3.3.2.1. 
The same primers as in 3.3.2.1 were used but the SALS and matched control samples 
were amplified using Taq Polymerase with the FailSafe 2XD buffer (Cambio) 
following their recommended protocol with 5ng of gDNA as template. The PCR 
products were run on a 1.2% agarose gel (2.2.3.4). The SALS and controls matched 
for ethnicity and age were obtained from King's College London MND DNA Bank 
All participants gave ethically approved written consent to participate in the study, 
which was approved by the South London and Maudsley Ethics Committee 
(reference 222/02). HWE analaysis was carried out for the SALS and control 
cohorts, see 3.3.2.1 for further details. 
 
3.3.3 Statistical analysis of the genotype data from the SALS and matched 
controls 
 The statistical significance of the results from this study were analysed using 
CLUMP (Sham and Curtis 1995). The CLUMP program was developed as a tool to 
analyse case-control studies of genetic variants to determine if an allele occurs more 
frequently in one group or the other. 
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3.3.4 Identification of a tagging SNP for the FUS SVA alleles 
 The genotyping results of the individuals of the CEU HapMap cohort could 
be used in conjunction with publicly available SNP data to identify a tagging SNP 
for the two variants of the FUS SVA. The genotype for the FUS SVA was 
determined for the individuals within the CEU HapMap cohort as in method section 
3.3.2 and the alleles were named long and short. The long and short genotype of the 
individuals had to be converted to ‘SNPs’ so they could be uploaded into the 
Haploview software (downloaded from the Broad Institute web page 
http://www.broadinstitute.org/scientific-community/science/programs/medical-and-
population-genetics/haploview/downloads) for analysis. Two ‘SNPs’ were generated 
one for each allele. FUS SVA SNP 1 corresponded to the long allele and FUS SVA 
SNP 2 corresponded to the short allele. These ‘SNPs’ were given genotypes based 
on the genotype of the individual, see below: 
FUS SVA SNP 1                                                     FUS SVA SNP 2  
AA=if no long allele present                                 AA=if no short allele present  
AC=if one long allele present                               AC=if one short allele present 
CC=if two long alleles present                              CC=if two short alleles present 
This system would therefore distinguish a single allele of the SVA present in a 
halplotype block using the genotype of the two ‘SNPs’ that were created; AC=short 
allele and CA-=long allele.  
 Genotype data of the known SNPs 200kb either side of the FUS SVA for the 
CEU HapMap individuals was downloaded from the International HapMap database 
(http://hapmap.ncbi.nlm.nih.gov/) using release 28. This was copied into an excel 
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spreadsheet and the ‘SNPs’ generated for the FUS SVA genotypes were inserted at 
the loci corresponding to the actual FUS SVA. The SNP genotypes were then 
converted from ACGT to numbers as follows 1=A, 2=C, 3=G and 4=T. This data 
was then used to generate two files: a ped file containing the ID of the individuals 
and the SNP genotypes and an info file containing the names/rs numbers for the 
SNPs and their chromosomal loci. These two files were uploaded to the software 
Haploview where the ped file was used as the data file and the info file as the locus 
information file. Once uploaded the ‘Run Tagger’ option was selected with the r2 
threshold set to >0.8 for software to identify SNPs in linkage disequilibrium with 
each other. This generated a list of SNPs that are tagging other SNPs and haplotype 
blocks to demonstrate how the region of the genome is inherited. The lists of SNPs 
in linkage disequilibrium with each other were then searched for the SNPs 
corresponding to the SVA alleles to determine if the SVA is being tagged and 
inherited in a set haplotype. 
 
84 
 
3.4 Results 
3.4.1 A SVA D is located upstream of the FUS gene  
 The UCSC genome browser was used to analsye the FUS gene locus. The 
UCSC genome browser provides a vast array of data and is an extremely useful tool 
when analysing the genome for potential functional elements. It includes information 
such as the structure of genes, the location of CpG islands, repetitive regions of 
DNA, areas of active chromatin and the binding of transcriptions factors to name but 
a small number of the types of data accessible through this browser.  
 Analysis of the loci of the FUS gene identified a large GC–rich repetitive 
region (boxed in red in Figure 3.1A) within 10kb upstream of the FUS gene TSS. 
The repeat was flanked by DNase 1 hypersensitivity clusters and transcription factor 
binding sites according to the ENCODE data indicating this region may be active. 
Similar repeats were searched for using the Blat tool on the UCSC genome and the 
results contained many homologous regions. 
 The repetitive region was actually part of a larger composite element called a 
SVA (boxed in blue in Figure 3.1B). This SVA is a member of the subtype D and is 
found in humans and chimpanzees only. The structure of this SVA is shown in 
Figure 3.2A; it differs to the canonical SVA structure as it does not contain a 
CCCTCT hexamer repeat at the 5’ end and a poly A-tail after the SINE. The central 
repetitive region consisits of a tandem repeat (TR) and a VNTR with two alleles 
(named long and short) which were identified and discussed in sections 3.4.2 and 
3.4.4. The sequence of the TR/VNTR of the SVA is shown in Figure 3.2B. The extra 
repeat present in the long allele of the SVA is underlined. Many SVAs contain the 
potential for G-quadruplex (G4) which is a type of secondary structure and the 
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sequence responsible for this potential is in italics. The function of G4 DNA and 
how this is predicted is dicussed in chapter 1 section 1.3.2 and chapter 4 section 
4.4.5 in detail. The SVA present in the chimpanzee genome in the UCSC genome 
browser (Chimp Feb. 2011) has a much larger central VNTR (873bp) compared to 
that of the human (447bp) and the sequence of the chimpanzee VNTR is shown in 
Figure 3.2C. The polymorphic nature of the chimpanzee VNTR has not been 
analysed as chimpanzee gDNA was unavailable therefore it is not known whether 
this SVA is variable in the chimpanzee as well as the human.  
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Figure 3.1: Image from UCSC genome browser of the region upstream of the 
FUS gene. In the UCSC genome browser the names of the tracks on display are 
found on the left hand side of the image with the scale and chromosomal loci located 
at the top. The tracks to be displayed in the browser are chosen by the user, in this 
case from the top of both images A and B the tracks are: UCSC genes, simple 
repeats, DNase clusters, H3K27Ac histone mark (often found near regulatory 
elements), repeat masker, ESTs (expressed sequence tags), transcription factor 
binding and the bottom track in image B shows the mammalian conservation and 
homology shared with specific species across this region. 
A – This screen shot shows the different transcripts of the FUS gene at the top right 
hand side with DNase hypersensitivity clusters and peaks of active chromatin at the 
TSS of the gene. The different types of repetitive elements such as LINEs, SINEs 
and LTRs found in the region are shown by the repeat masker track. There is a large 
region of repetitive DNA boxed in red within 10kb of the start of the FUS gene 
identified by the simple repeat track.  
B – This is a zoomed in screen shot of the large repetitive region upstream of the 
FUS gene. The region of repetitive DNA identified in 3.1A is part of a larger 
composite element called a SVA boxed in blue. This particular SVA is only found in 
humans and chimpanzees shown by the conservation track at the bottom of the 
image and has DNase hypersensitivity clusters either side. 
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Figure 3.2: Structure and sequence of the SVA located upstream of the FUS 
gene.  
A - A schematic showing the components contributing to the structure of the SVA D 
located upstream of the FUS gene. It contains an Alu-like sequence, a TR, VNTR 
and a SINE. This particular SVA is missing the CCCTCT hexamer repeat seen at the 
5’ end of a canonical SVA.  
B - Sequence of the central repetitive region of the human SVA upstream of the FUS 
gene. There are 7 copies of a 37-40bp repeat in the TR and 3-4 copies of a 37-50bp 
repeat within the VNTR (for identification of the two alleles named long and short 
see section 3.4.2). The repeat underlined is the additional copy found in the long 
allele and is absent in the short allele of the SVA (sequence in UCSC corresponds to 
long allele). The sequence in italics within this repeat has G4 potential predicted by 
the Quadparser software; therefore a small percentage of the SVA long allele (1.8%) 
has G4 potential whereas the less common short allele does not. G4 is discussed in 
further detail in chapter 4.  
C – The sequence of the central VNTR of the SVA upstream of the FUS gene in the 
chimpanzee. The VNTR of this SVA is much larger than compared to the human. 
The variability in the number of repeats of this VNTR has not been analysed 
therefore this has not been divided into a TR and VNTR as in the human.  
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3.4.2 Two alleles of the FUS SVA are present in a CEU HapMap cohort 
 During the cloning of the FUS SVA for use in a reporter gene construct 
(3.4.3) from commercial gDNA (Promega) two alleles of this SVA were identified 
(personal communication from Thomas Wilm). The frequency of the genetic 
variation within this region was then analysed further in the CEU HapMap cohort 
(Utah residents with Northern and Western European ancestry from the CEPH 
collection). The primer set used for genotyping targeted the central TR/VNTR. There 
were also two alleles identified within this cohort with PCR products 665bp in length 
for the long allele and 615bp for the short allele, which are shown in the example gel 
image in Figure 3.3A. The long allele is the most common and the frequencies of the 
different genotypes in the 86 individuals are as follows; LL-41.9%, LS-45.3% and 
SS-12.8% (Figure 3.3B). The frequency of on the long and short alleles, 64.5% and 
35.5% respectively, in the CEU HapMap cohort are shown in Figure 3.3C. Analysis 
revealed that FUS SVA locus is in HWE within this population (p=0.99). The 
conditions for the amplification of SVAs require optimisation, sometimes proving to 
be a difficult region of DNA to amplify, and the conditions can vary between each 
element as discussed further in chapter 6. 
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Figure 3.3: Genotype and allele frequencies of samples from the CEU HapMap 
cohort for the SVA upstream of the FUS gene. A - An example image of the PCR 
products of the alleles of the TR/VNTR of the FUS SVA (L=665bp and S=615bp). 
The TR/VNTR of the SVA was amplified by PCR and the product run on a 1.2% 
agarose gel to allow sufficient separation of the alleles and calls were made on the 
genotype for that individual. B - The table shows the frequency of the genotype for 
the CEU HapMap cohort. (LL=homozygous long, LS= heterozygous long and short, 
SS=homozygous short). C – The table shows the allele frequencies of the long and 
short alleles of the FUS SVA in the CEU HapMap cohort. The locus is in HWE: 
p=0.99. 
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3.4.3 The FUS SVA and the VNTR within its structure can act as a regulatory 
domain in vitro and in vivo 
 Functional anaylsis of the SVA, its central VNTR component and genetic 
variants (long and short alleles) was undertaken in the lab by Thomas Wilm and 
Kejhal Khursheed. This data has been compiled into a manuscript titled ‘An 
evaluation of a SVA retrotransposon in the FUS promoter as a transcriptional 
regulator and its association to ALS’ along with data generated on the genetic 
variants in a SALS cohort discussed in section 3.4.4 of this chapter. The data of the 
in vitro and in vivo experiments has been summarised here to show the functional 
properties of the SVA.  
Reporter gene constructs were cloned into the pGL3P vector including both 
variants of the SVA (L-SVA and S-SVA), and the isolated central TR/VNTR (L-
TR/VNTR and S-TR/VNTR). The activity of the constructs was measured in the 
human neuroblastoma cell line SK-N-AS (Figure 3.4B). Significant differences were 
observed in the levels of reporter gene expression supported by the complete SVA or 
the TR/VNTR compared to the minimal SV40 promoter of the pGL3P vector alone 
(S-SVA P<0.05, L-SVA P<0.05, S-TR/VNTR P<0.001 and L-TR/VNTR P<0.05). 
Both alleles of the complete SVA repressed reporter gene expression while both 
alleles of the TR/VNTR were activators in this cell line, demonstrating that the SVA 
may contain multiple and distinct regulatory domains, one of which is a dominant 
repressor in SK-N-AS cells. When comparing the two different length TR/VNTR 
constructs no significant difference to the amount of reporter gene activity observed 
was noted, however there was a small but significant difference in the levels of 
reporter gene expression when these variants were contained within the complete 
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SVA sequence (P<0.05). In both the SVA and TR/VNTR constructs it was the long 
variant that showed lower activity when compared to the short. 
The SVA and TR/VNTR (long allele) domains as used above in the SK-N-
AS cell line were inserted into a reporter gene vector that had been developed 
previously in the lab to visualise activity via hrGFP in the chick embryo model.  
Briefly the reporter vector phrGFP contained the proximal human FUS promoter –
160 of the major transcriptional start site to +84 upstream of hrGFP, the L-
TR/VNTR and L-SVA sequences were inserted immediately upstream of the 
promoter sequence.   
The test plasmid was injected into the neural tube and then transfected into 
the cells by electroporation. The reporter gene construct was co-injected with an 
internal control, the tomato reporter plasmid directed by the chick β-actin promoter; 
the latter acts as an internal control for cells which were successfully transfected. In 
this manner the activity and tissue specificity of the L-SVA and L-TR/VNTR 
reporter could be addressed and the internal control indicated the efficiency of the 
transfection. The series of FUS reporter gene constructs were injected into the 
developing embryo at embryonic stage 14HH and monitored at stage 22HH. The 
proximal FUS promoter alone did not support sufficient reporter gene expression to 
be observed in this assay (Figure 3.A panel B). Both the L-SVA and L-TR/VNTR 
reporter gene constructs supported expression; which was readily observed in the 
neural tube of the chick embryo (Figure 3.A panel E and H respectively). The 
activation properties of the L-TR/VNTR was consistent in the cell line model and the 
chick embryo model, however the complete L-SVA showed the repressive qualities 
in the cell line but acted as an activator in the chick embryo model enhancing 
expression over that of the minimal FUS promoter.  
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Figure 3.4: The FUS SVA and VNTR act as a functional regulatory domain in 
vitro and in vivo. This image has been compiled from data produced from two other 
members of the lab (TPW and KK) and is present within the manuscript (Savage et 
al) which has been submitted for publication. 
 A - Chick embryos were electroporated with either a FUS proximal promoter GFP 
(ppGFP) reporter construct (Panels A-C), L-SVA ppGFP-reporter (Panels D-F) or L-
TR/VNTR ppGFP-reporter (Panels G-I) at stage 14HH and GFP expression analysed 
48 hours later (stage 22HH). Expression could not be detected in the neural tube 
from the FUS proximal promoter sequences alone (panel B), however when either 
the L-SVA (panel E) or L-TR/VNTR (panel H) sequences were included, GFP 
reporter gene expression could readily be seen. Panels A, D & G show the 
corresponding brightfield images. Panels C,F &I show the identical fields taken with 
a red filter to demonstrate the extent of successful electroporation of the neural tube 
using a control tomato marker expression plasmid.  Scale bar in B is 2mm and in E 
& H is 1mm.  
B – Reporter gene constructs containing each allele of the FUS SVA and TR/VNTR 
(long and short) were transfected into the neuroblastoma cell line, SK-N-AS. The 
fold values of each construct compared to pGL3P normalised to the internal control 
(pMLuc-2) to account for differences in transfection efficiency are displayed. One 
tailed t-test was used to measure the significance of fold activity of the FUS SVA 
and TR/VNTR over the minimal promoter of the pGL3P vector *P<0.05, 
***P<0.001, and to compare the activity of the alleles of the SVA and the TR/VNTR 
to each other # P<0.05 N=7. 
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3.4.4 The FUS SVA does not show association with SALS 
 The genetic variation of the FUS SVA was analysed in a cohort of 241 
individuals with SALS and a cohort of 228 matched controls to determine if there 
was an association of a specific variant of the SVA with SALS. The same primer set 
was used as in the genotyping of the CEU HapMap cohort and an example gel image 
of the PCR fragments in the SALS and controls cohort in shown in Figure 3.5A. The 
sequence of the two alleles of the TR/VNTR of the FUS SVA was confirmed by the 
sequencing of both an L and S allele after gel purification (2.2.4.4 and 2.2.5.10). 
This demonstrated that the L allele corresponded to the sequence found in the UCSC 
browser for the TR/VNTR of this SVA element. The following genotype frequencies 
were observed in the SALS cohort 45.6% LL, 39% LS and 15.4% SS and 46.9% LL, 
42.1% LS and 11.0% SS in the matched controls (Figure 3.5B). In addition the allele 
frequencies for these cohorts are shown in Figure 3.5C. The genotype frequencies of 
the two cohorts were analysed for significant differences using CLUMP (Sham and 
Curtis 1995). Although there was a small difference of 4.4% between the frequencies 
of SS individuals in the SALS cohort compared to the matched controls these were 
found not to be significant when analysed. This small difference may be a false 
positive as the SS frequency in the CEU HapMap cohort is 12.8% (Figure 3.3B) 
which is in between the two values. The p-values from the T1 and T4 tests from the 
CLUMP analysis were P=0.36 and P=0.33 respectively (Sham and Curtis 1995).  
 HWE anlaysis was carried out for the FUS SVA locus in the SALS and 
control cohorts with both showing to be in HWE, p=0.09 and p=0.88 respectively. 
However there is a notable difference in the p values of the two cohorts; the SALS 
cohort had a much lower p value close to being statistically significant indicating 
there is a trend towards the FUS SVA locus being out of HWE within this group. 
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This locus was also shown to be in HWE in the CEU HapMap cohort with a p value 
of 0.99, indicating that out of the three populations the genotype frequencies in the 
SALS cohort showed the greatest difference to the expected based on allele 
frequency.  
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Figure 3.5: Genotype and allele frequencies of SVA located upstream of the 
FUS gene in Sporadic ALS and matched control cohort A - Example image of 
the two alleles of the TR/VNTR of the FUS SVA run on a 1.2% agarose gel after 
amplification using PCR. The genotype of each individual was determined. One of 
each allele was gel extracted and sequenced and corresponded to the previously 
sequenced and cloned alleles. (L=665bp and S=615bp) B - Table showing the 
percentage of each genotype in the SALS patients (241 individuals) and the matched 
controls (228 individuals). C – Table showing the allele frequencies for the FUS 
SVA in the SALS and control cohorts. The FUS locus is in HWE in both the SALS 
and control cohorts, p=0.09 and p=0.88 repectively.  
 
         
97 
 
3.4.5 Multiple tagging SNPs identified for the FUS SVA alleles including 
rs11864632 
 Although the analysis of the SVA by PCR analysis of the VNTR 
polymorphism did not show significant statistical association with the SALS cohort I 
could only address a limited population using this method. I therefore set out to 
identify tagging SNPs so that such SNPs could be addressed in not only larger 
cohorts of SALS but other conditions in which FUS is implicated. Tagging SNPs 
were identified for the alleles of FUS SVA using the genotype data generated for the 
individuals of the CEU HapMap cohort (3.3.2 and 3.4.2) and the freely avaiable SNP 
genotype data for this cohort in the International HapMap database. The screen shot 
in Figure 3.6A shows the SNPs tagged or in linkage disequilibrium with the SNP 
rs11864632 which includes the SNPs created to represent the alleles of the FUS 
SVA. The haplotype block (3) in which the SNPs representing the alleles of the SVA 
are inherited is shown in figure 3.6B which includes rs11864632 along with 20 other 
SNPs. A genotype of C at rs11864632 is inherited along with the short allele of the 
FUS SVA (represented at SNP 147 and 148 with a genotype of AC) and a G at 
rs11864632 is inherited with the long allele of the FUS SVA (represented at SNP 
147 and 148 with a genotype of CA). This was validated by addressing the genotype 
of SNP rs11864632 for each individual in the HapMap that had been genotyped for 
the FUS SVA and checking they correlated as predicted by the haploview analysis.  
 The 20 other SNPs that were tagged by rs11864632 with an r
2
>0.8, 18 of 
which were inherited in haplotype block 3 and 2 in haplotype block 4, were analysed 
for the correlation of their genotype with the genotype of the FUS SVA. Seven also 
showed the ability to predict the genotype of the FUS SVA as accurately as 
rs11864632 (100%) with rest being able to predict >90% of the time within the 
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HapMap individuls genotyped for the FUS SVA. Therefore several SNPs have been 
shown to be in strong linkage disequilibrium with the alleles of the FUS SVA and 
could be used as tagging SNPs. This would remove the requirement for the labour 
intensive PCR and gel electrophoresis method for genotyping the FUS SVA as the 
SNP genotype could be used to determine alleles of the SVA present. This will 
constitute future experiments in this area and extrapolated to other appropriate SVAs 
to determine if they represent a genetic risk based on polymorphism present for 
particular disease as discussed in chaper 6. 
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Figure 3.6: rs11864632 identified as a tagging SNP for the SVA upstream of the 
FUS gene. A – Screen shot of the haploview software results from running the 
tagger analysis. The SNP rs11864632 is highlighted in the top left box is tagging the 
SNPs in the bottom left box including the SNPs corresponding to the FUS SVA 
alleles.  B – Haplotype block of the region containing the FUS SVA and its tagging 
SNP. Genotypes of the SNPs are shown. 82 represents the tagging SNP rs11864632 
with this loci either containing a G or C. 147 represents the long allele of the FUS 
SVA and 148 represents the short allele of the FUS SVA (AC=short allele, CA=long 
allele). A genotype of C at the rs11864632 SNP tags for the short allele of the FUS 
SVA and a G tags for the long allele. (r
2
>=0.8)  
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3.5 Discussion 
Mutations within the FUS gene and the levels at which it is expressed have 
been associated with diseases of the central nervous system such as ALS and 
Frontotemporal lobar degeneration (FTLD) (Neumann et al. 2009; Mackenzie et al. 
2010; Mitchell et al. 2013), however little is known about the parameters regulating 
FUS gene expression. The FUS gene locus was analysed for potential regulatory and 
polymorphic domains and a candidate was identified in a SVA retrotransposon 10kb 
upstream of the TSS of the gene (Figure 3.1). SVAs are highly CG-rich and are 
assumed to be silenced within the genome through mechanisms such as methylation 
in an attempt to stop their retrotransposition. However there is evidence for this 
methylation to be lost over retrotransposons in cancer, for somatic retrotransposition 
in the aging brain and for transposable elements to become active in replicatively 
senescent cells (Szpakowski et al. 2009; Baillie et al. 2011; De Cecco et al. 2013). 
The activity of the SVAs may be variable depending on their environment and 
corresponding epigenetic structure.   
Retroviruses, exogenous and endogenous, have been linked with ALS 
(Alfahad and Nath 2013). There was an increased prevalence of reverse 
transcriptase, a key enzyme in the retrovirus life cycle converting RNA to DNA, 
observed in the serum of patients with SALS (Andrews et al. 2000; Steele et al. 
2005). In the second study (Steele et al. 2005) the elevated reverse transcriptase 
levels were interpreted as indicative of involvement of an endogenous retrovirus 
rather than an exogenous retrovirus as blood relatives also had elevated levels 
whereas spouses were the same as controls. Another study also implicated the role of 
retrotransposons in ALS as HERV-K transcripts and reverse transcriptase protein in 
autopsy brain tissue of patients with ALS was detected along with the abberant 
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expression of TDP-43  (Douville et al. 2011). The cellular environment that led to 
this increased expression of HERV-K transcripts and reverse transcriptase may be a 
global change that could influence the expression or activity of other 
retrotransposons in the genome including the SVAs. Alteration of epigenetic factors 
may modulate any transcriptional properties embedded within the SVA affecting the 
regulation of the FUS gene and this may be dependant on the genetic variation at this 
locus.  
The SVA upstream of the FUS gene is polymorphic in the second of its 
central  repetitive domains with two alleles identified in the population named long 
and short (for structure and sequence see figure 3.2). The frequency of these two 
alleles was analysed in a CEU HapMap cohort with the long allele most common in 
the population; LL-41.9%, LS-45.3% and SS-12.8% (Figure 3.3). The demonstration 
of polymorphic variation in this region in a VNTR domain, a class of domain that 
has extensively been shown to act as a risk factor in a number of diseases suggested 
that the region could support differential gene expression under appropriate 
environmental cues.  
The potential for the SVA to act as a transcriptional regulator was tested in a 
reporter gene construct by other members of the research group (Thomas Wilm and 
Kejhal Kursheed) and is summarised in figure 3.4 from a submitted manuscript 
(Savage et al). The regulatory properties of both alleles, when part of the complete 
SVA and when alone as the TR/VNTR, were tested in the neuroblastoma cell line 
SK-N-AS (Figure 3.4A). It is interesting that while both the L & S TR/VNTR 
regions were enhancers the L & S SVA acted as a repressor in the SK-N-AS cell 
line. This would suggest that in addition to the activator region in the TR/VNTR the 
SVA contains a strong silencer element, flanking this central TR/VNTR region, 
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which is functional in the SK-N-AS neuroblastoma cell line. There was no 
significant difference between the activities of the two alleles of the TR/VNTR when 
tested alone but there was a small but significant difference between the two alleles 
when tested as part of the complete SVA (P<0.05). To further validate the regulatory 
properties of this domain the long allele of the complete SVA and of the TR/VNTR 
domain were tested in the neural tube of the chick embryo. This region contains 
motor neurons which are the appropriate cell type to test a domain that might be 
involved in ALS; however FUS is a ubiquitously expressed protein. The expression 
of the FUS mRNA and protein was confirmed in the chick embryo at stage E5 
(Kejhal Khursheed personal communication). As in the cell line model the 
TR/VNTR acted as an activator but in this model the SVA also demonstrated 
activator properties. This would be consistent with previous definitions of VNTRs 
from the both the serotonin and the dopamine transporters having cell line specific 
properties in reporter gene constructs (Michelhaugh et al. 2001; Haddley et al. 2008; 
Paredes et al. 2012) and that of the serotonin transporter having tissue specific 
properties in a transgenic mouse model (MacKenzie and Quinn 1999a). The data 
also validates again the fact that primate-specific domains such as the serotonin 
transporter VNTR and now the FUS SVA can function in other species. This has 
been previously proposed as a mechanism in evolution to generate different 
transcriptome profiles that would involve the promoters or regulatory domains of a 
gene altering to take advantage of the transcription factor complement in a cell to 
expand or lay extra complexity upon the gene’s regulation.    
Genotypic analysis of the TR/VNTR of the SVA was analysed in a SALS 
and control cohort provided by collaborators at King’s College London. There were 
two alleles identified in this cohort (Figure 3.5A) that had also been observed in the 
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CEU HapMap cohort. The frequency of LL, LS and SS was found not to be 
significantly different in the sporadic cases compared to the matched controls, 
although minor differences could be seen between the frequency of individuals with 
a SS genotype in SALS and controls (15.4% vs 11.0%) when analysed using 
CLUMP (Sham and Curtis 1995). A much larger cohort will be required to validate 
such variation as an association in the SALS cohort.  
A major problem performing genotyping analysis with large domains such as 
the SVA or the TR/VNTR domain is its time consuming and labour intensive 
involving PCR and its subsequent analysis through gel electrophoresis. Therefore the 
genotyping data for the CEU HapMap cohort from Figure 3.3 was used to identify a 
tagging SNP for the alleles of the FUS SVA. Several SNPs were shown to be in 
linkage disequilibrium with the FUS SVA (Figure 3.6), which may enable much 
larger cohorts to be analysed for variation of the FUS SVA. Large numbers of SNPs 
can be analysed at once and there are many genome wide association studies carried 
out determining the genotypes of SNP across the human genome. This data could be 
utilised along with the FUS SVA tagging SNP to enlarge the numbers for the SALS 
cohort already generated or within different cohorts. 
In summary this chapter has demonstrated a novel primate tissue specific 
regulator that could play a role in FUS regulation in the form of a SVA located 10kb 
upstream of the FUS gene. This regulation could be modified by a number of 
environmental challenges including the changes correlated with the increased reverse 
transcriptase activity seen in the serum of ALS patients that could affect the 
epigenetic structure of the FUS locus in a manner analogous to epigenetic changes in 
cancer observed over retrotransposons. There was no association of the FUS SVA 
genotype with the SALS cohort analysed, however the identification of a tagging 
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SNP for this domain may make it easier to increase the numbers of this cohort and 
analyse the SVA variation within other disease cohorts.  
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Chapter 4 
Global analysis of the distribution and structure of 
SVAs within the human genome 
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4.1 Introduction 
 The analysis of the SVA upstream of the FUS gene (chapter 3) has identified 
an element that has the ability to affect gene expression in a reporter gene model in 
vitro and in vivo and is polymorphic for the number of repeats in its central VNTR. 
Other SVAs throughout the human genome may also share these functional 
properties of the FUS SVA so the location of these elements is important for 
identifying the potential impact of SVAs on the genome on a global scale. There 
were 2762 SVAs identified in the human genome by Wang et al, so providing a 
manageable number in this retrotransposon family to analyse in a global approach to 
determine the distribution of the SVAs across the human genome. 
 The distribution of Alus has been associated with increased GC content 
whereas L1 elements are predominantly found in AT-rich regions (Medstrand et al. 
2002). Analysis of the distribution of SVAs by Wang et al determined they were 
associated with regions of higher GC content but not with genes despite the SVAs 
preference for gene dense chromosomes (Wang et al. 2005). However the analysis of 
somatic retrotransposon insertions in the brain by Baillie et al revealed that these 
insertions were prevalent in actively transcribed genes and therefore more likely in 
regions of active chromatin (Baillie et al. 2011). This would correlate with the 
hypothesis that retrotransposons insert into active regions of chromatin due to its 
more open and accessible state for the insertions to occur. Therefore I expanded 
upon the analysis by Wang et al to determine if the SVA insertions do correlate with 
specific features of the genome, if the distribution varies between subtypes and how 
this could affect their influence on the human genome. 
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 The nature of the sequence of SVAs also provides the potential to influence 
gene expression through multiple mechanisms such as differential methylation or G4 
formation. Therefore a global in silico analysis of the potential of SVAs to form G4 
DNA was undertaken to determine the extent to which SVAs may contribute to G4 
within the genome and if amount of G4 potential was equal across the different 
subtypes. A handful of elements were also analysed for their potential to share 
characteristics of CpG islands. 
 This global analysis will hopefully provide greater insight into the pattern of 
insertions of the SVAs within the human genome and their potential functional 
impact. 
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4.2 Aims 
 To determine if the site of insertion of SVA elements across the genome is 
random or correlated with features of the genome using the UCSC genome 
browser.  
 To analyse the prevalence of SVAs key regions of the genome such as 
introns and promoters and their orientation in relation to the nearest gene. 
 To analyse the potential of the SVA sequence using an in silico approach to 
form a type of secondary structure called G4.  
 To calculate the potential of SVAs by subtype to act as CpG islands.  
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4.3 Methods 
4.3.1 Manual annotation of SVA coordinates from UCSC SVA track and 
creation of a new SVA track for use in analysis 
A list of coordinates was generated for all SVAs identified in the Hg19 from 
the repeat masker track of UCSC genome browser 
(http://genome.ucsc.edu/index.html). To download information from the tracks 
available in the UCSC genome browser the table browser needs to be accessed either 
through the homepage of the browser or the ‘tools’ menu. The table browser can be 
used to gather summary/statistics of each track, for example the number of LINE 
elements in the repeat masker track and the number of bases they contribute to the 
whole genome etc, or it can be used to extract data. The data from each track can be 
extracted as sequence data or chromosomal loci and can be viewed instantly or sent 
directly to the Galaxy software for further analysis. The following example of 
extracting the chromosomal loci of SVA elements from the repeat masker track will 
be used to illustrate the method employed and Figure 4.1 shows a screen shot of the 
table browser during this process. The correct species and version of the genome are 
selected along with the track of interest. In this instance the group ‘variation and 
repeats’ and the track ‘repeat masker’. The filter button was then used to ask for the 
repeat of choice which was the SVAs. The SVAs are split into subtypes A-F so the 
data had to be extracted by subtype. The elements in the repeat masker track were 
filtered by the ‘repName’ option for each subtype in turn for example SVA_A. The 
output format of the data was chosen as ‘BED-browser extensible data’ and then the 
‘get output’ button was pressed. There is then the option of creating one record per 
item or adding flanking regions to each item. The ‘whole gene’ option is chosen as 
this will create one record per SVA without additional flanking regions and the ‘get 
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BED’ button is used. The chromosomal loci of your chosen items, in this case SVA 
for each subtype, will be listed. 
 
Figure 4.1: Screen shot of the table browser available on UCSC used to extract 
track data. The parameters were set to the required species and the repeat masker 
track selected. The filter was then used to select for SVAs by subtype. The data was 
collected in the BED format and retrieved by selecting the get output button. The 
data can also be exported to Galaxy which is freely available software on the internet 
that can be used to analyse the relationship between data sets or create new 
chromosomal coordinates surrounding the regions of interest. The summary/statistics 
button also allows for information such as the numbers of items in the selected track. 
 
Many of these SVAs on the repeat masker track were fragmented and 
sometimes did not include the CCCTCT hexamer repeat at the 5’end (this 
component was often classified as a separate simple repeat). The seventh subtype F1 
was also not present in the UCSC genome browser as the members of this group 
were included in the subtype F. Therefore a new list of SVA coordinates was to be 
created to be uploaded to UCSC as a custom track for use in analysis and this 
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process is summarised in Figure 4.2 and the following paragraphs. Firstly with the 
aid of the interrupted repeat masker track in UCSC that recombined some of the 
SVAs that were fragmented into two or more pieces the coordinates were manually 
altered so there was one set of coordinates per SVA in Microsoft Excel. Secondly to 
include the CCCTCT repeat and poly A tails that are part of a canonical SVA but 
sometimes not contained within the coordinates of the SVA by the UCSC browser 
the 100bp upstream and downstream of the SVA coordinates (created in Galaxy 
http://galaxyproject.org/) were intersected with the simple repeat track from UCSC. 
This generated a list of all the simple repeats upstream and downstream of an SVA 
with their coordinates and their sequences. These coordinates of the simple repeats 
containing the CCCTCT like repeats or the poly A-tails of the SVA were merged 
with the coordinates of the SVAs. Finally to define which of the SVA Fs classified 
by UCSC were actually subtype F1 the Blat tool from UCSC was used to search for 
all sequences in the human genome sharing homology to the sequence of exon1 of 
the MAST2 gene (subtype F1 was generated when a 5’ transduction integrated 
sequence from the MAST2 gene with an SVA F). Any results that were upstream of 
an SVA F were used to generate the loci of the subtype F1.  
This list of SVA loci was uploaded to UCSC genome browser as a custom 
track called ‘annotated SVAs’ for use in the analysis and included 2676 elements. To 
upload the track the table browser was opened in UCSC and then the add custom 
track was chosen. The species and the version of the genome were set to human and 
version Hg19 that the track will be uploaded to. The chromosomal position 
(coordinates) and the subtype of the SVA of all the elements identified in the manual 
annotation process were pasted into the box on the page to create the new track, for 
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example: chr1  30819215 30819861 SVA_A. The submit button is pressed to create 
the new track; this can then be accessed and viewed like any other UCSC track. 
 
 
Figure 4.2: Flow diagram describing the steps taken to generate the annotated 
SVA track for use in analysis of their distribution. To accurately analyse the 
distribution of the SVAs across the human genome a new track had to be generated 
as many of the SVAs were fragmented in the UCSC genome browser, some did not 
contain their CCCTCT repeat and poly A tails in the coordinates and the subtype F1 
was not present.  
 
4.3.2 Analysis of SVA distribution across human chromosomes and their 
correlation with gene density 
Information on chromosome size and the number of genes present was 
collected from the NCBI website for HuRefChr37.3 (http://www.ncbi.nlm.nih.gov/). 
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The size of each chromosome was used to generate the number of SVAs expected 
for that particular chromosome and was plotted against the number of observed 
SVAs. The percentage of each SVA subtype present in the whole genome and the 
number of actual SVAs on each chromosome was used to calculate the expected 
number of each subtype for each chromosome. The Chi squared statistical test was 
used to determine if the distributions of SVAs and the subtypes across chromosomes 
were significantly different to that of the expected distribution.  
The gene density (number of genes per million bases) and the SVA density 
(number of SVAs per million bases) were calculated for each chromosome and the 
two values plotted against each other on a scatter graph. The correlation coefficient 
for the relationship between the two sets of data was calculated and this was repeated 
for each subtype individually. 
 
4.3.3 Analysis of SVA distribution within genes, intergenic regions and gene 
deserts 
To analyse the distribution of SVAs further the genome was separated into 
three broad categories genes, intergenic regions and gene deserts. Gene deserts were 
defined as regions between genes which were over 250kb away from the start or end 
of a known gene, intergenic as regions between genes that are less than 250kb from 
the start or end of a known gene and genes were determined by the UCSC gene track 
from the UCSC genome browser. The regions were defined in this manner to assess 
if the retrotransposons had preferentially inserted into regions devoid of genes (gene 
deserts) or regions of the genome that could include active chromatin where genes 
and intergenic regions potentially containing regulatory domains (up to 250kb from 
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TSS) are located (Visel et al. 2009b; Shanley et al. 2010). The custom track 
‘annotated SVAs’ was intersected with tracks for the three categories in the table 
browser of UCSC and the number of SVAs in these three regions was recorded. The 
three lists were analysed for any overlap (i.e. SVAs that spanned a border between 
two categories) and a decision was made as to which category the SVA should be 
assigned to. The number of observed SVAs in genes, intergenic regions and gene 
deserts was compared to the expected for the size of those regions. This analysis was 
also completed for three other retrotransposons: SINEs, LINEs and LTRs. The 
SVAs’ distribution was also broken down into subtypes and compared to their 
proportional distribution across the whole genome.  
 
4.3.4 Analysis of SVA distribution in defined regions up to 20kb up and 
downstream of genes 
To assess the prevalence of SVA insertions within close proximity of genes 
and if they had been selected against in these regions the number of SVAs within set 
distances upstream of genes was determined. Galaxy software was used to generate 
coordinates of 1kb, 10kb and 20kb upstream of genes. These were uploaded back 
into UCSC and the table browser was used to analyse the number of SVAs in these 
regions. These numbers were compared to the expected number of SVAs determined 
by the size of these regions if the insertion was random. The same analysis was 
carried out for three other classes of retrotransposons (LTRs, LINEs and SINEs) and 
for each class the fold difference of the observed number of elements in these set 
regions of the genome to the expected was calculated. The distribution of the SVAs 
was broken down into subtypes for each of these set regions of the genome and 
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compared to their proportional distribution across the whole genome. The same 
method was followed to analyse the presence of retrotransposons in the regions 1kb, 
10kb and 20kb downstream of genes.   
 
4.3.5 Analysis of orientation of SVAs in relation to their nearest gene  
 The strand of DNA the genes that had been previously indentified to contain 
a SVA within an exon or intron, 10kb upstream and 10kb downstream (4.3.3 and 
4.3.4) was compared to the strand of DNA the SVA was located on. The coordinates 
of the SVAs and the strand of DNA they are located on (- or +) were downloaded 
from the table browser in UCSC as were the coordinates and the strand of DNA for 
the genes containing a SVA within their sequence or their 10kb flank. These were 
aligned manually in Microsoft Excel and whether the SVA and gene were on the 
same or opposite strand was recorded. The percentage of genes and SVAs on the 
same strand of DNA was calculated. 
 
4.3.6 Prediction of sequences of SVAs that could form G-quadruplex DNA  
The ‘annotated SVAs’ track (see 3.3.1) was used along with a track provided 
by a colleague (Mr Paul Myers) that contained all the sequences in the human 
genome that would potentially form G4 as predicted by Quadparser software 
(http://www.quadruplex.org/). This software uses a predictive algorithm that 
identifies potential G4 sequences on either strand of DNA and uses the following 
formula G3+N1–7G3+N1–7G3+N1–7G3+ (Wong et al. 2010). The process of quantifying 
the amount of G4 potential in each SVA domain and other repetitive elements of the 
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genome is summarised in Figure 4.3. The SVA and the G4 prediction track were 
intersected to provide the number of bases within the SVAs that have the potential to 
form G4 DNA. This number was calculated as a proportion of the total amount of G4 
DNA predicted sequences in the genome. This was also done for several other 
elements which were either repetitive or mobile structures with the human genome; 
including simple repeats, microsatellites, LTRs, LINEs, SINEs and DNA 
transposons for comparison to the data for the SVAs. The fold difference of the 
proportion of these elements that are contributing to potential G4 DNA formation to 
their proportion of the whole genome was calculated and plotted on a bar graph.   
To determine the amount of G4 DNA that could be formed separately by the 
CCCTCT hexamer repeat and the VNTRs of each SVA subtype two new tracks in 
UCSC were created; one containing the loci of the CCCTCT hexamer repeat alone 
and the other containing the loci of the VNTRs alone. This was achieved by 
intersecting the ‘annotated SVAs’ track with the Simple Repeat track of UCSC. This 
generated a list of all simple repeats within the SVAs, which was then merged in 
Galaxy so any overlapping repeats became one. This list contained the CCCTCT 
hexamer repeats, the VNTRs and the poly A-tails of the SVAs so the genomic 
sequence of all the loci were extracted. The sequence of all the repeats was used to 
delete the loci containing the poly A tails and then the remaining coordinates could 
be separated into two separate lists; one for the hexamer repeats and one for the 
VNTRs. The two new lists of coordinates were uploaded back to UCSC to create 
new tracks for the hexamer repeats and the VNTRs of the SVAs. This was 
intersected with the track containing all the sequences in the genome that could form 
G4 DNA and the number of bases of the hexamer repeat and the VNTRs that 
overlapped for each subtype was recorded. 
117 
 
The number of bases that could form G4 from the CCCTCT and the VNTRs 
for each subtype was converted to a proportion of the total number bases of each 
subtype and was plotted on a bar graph. Any G4 DNA of the SVAs that could not be 
attributed to the CCCTCT element of the VNTR was called ‘other’. 
The tracks of the hexamer repeats and the VNTRs of the SVAs were used to 
calculate the average size of each subtypes’ hexamer repeat and VNTR. To 
determine if the differences in the amount of G4 formed by the hexamer repeats and 
the VNTRs of the subtypes was due to size or sequence a comparison across the 
subtypes of the their hexamer repeat and VNTR size and the percentage that they 
could form G4 was carried out. 
Figure 4.3: A flow diagram demonstrating the process of identifying the amount 
of G4 potential with specific elements within the human genome. The amount of 
G4 in certain elements of the genome was determined using tracks within UCSC 
browser and a track containing the coordinates of the regions of the genome with G4 
potential based on the equation from Quadparser. Two new tracks were generated of 
the coordinates of the CCCTCT repeat and the GC-rich VNTR of the SVAs to 
determine which domains of the SVA contribute to their G4 potential. 
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4.3.7 Potential of the sequences of the SVA subtypes to provide CpG islands 
across the human genome 
 The UCSC genome browser contains a track predicting CpG islands across 
the genome using the following criteria for a region to be considered a CpG island: a 
GC content of 50% or more, length greater than 200bp and a ratio greater than 0.6 of 
observed number of CG dinucleotides to the expected number on the basis of the 
number of Gs and Cs. This ratio is calculated using the following formula: Obs/Exp 
CpG = Number of CpG * length of sequence / (Number of C * Number of G) 
(Gardiner-Garden and Frommer 1987). The above criteria were used to analyse 
SVAs and their central VNTR domain for their potential as CpG islands. The 
sequence of the SVAs was extracted from the ‘annotated SVAs’ track on UCSC 
genome browser for each subtype. This was a preliminary analysis of a handful of 
SVAs therefore 3 SVAs from each subtype were chosen at random, but it was 
confirmed they contained all the domains of a canonical SVA, and analysed for their 
ability to meet the criteria listed. 
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4.4 Results 
4.4.1 Distribution of SVAs is not correlated to chromosome size but to their 
gene density  
A previous study carried out by Wang et al had shown that the distribution of 
SVAs across chromosomes was significantly different to the predicted distribution, 
which would assume a random insertion model so the number of insertions was 
directly proportional to chromosome size (Wang et al. 2005). However I decided to 
replicate that study as to see if the data generated in my study was comparable to the 
published data to validate the methods in use (4.3.1). This analysis also showed that 
the expected and the actual distributions were significantly different if the expected 
number of SVA insertions for each chromosome was based on its size (X
2
=220.0, 
df=23, P<0.001) (Figure 4.1A). Chromosome 1, 17, 19 and 20 showed a much 
higher number of SVAs than predicted for their size and this was noted that they are 
some of the most gene dense chromosomes (in particular 17 and 19).  Conversely the 
chromosomes with lower than expected SVAs (13, 21 and Y) have much lower gene 
densities.  
In addition to this the distribution of the SVAs by subtype across 
chromosomes was analysed to determine if the subtypes followed the general trend 
of all SVAs being located in greater numbers on gene dense chromosomes or if the 
subtypes had inserted differently to each other. The predicted number of each SVA 
subtype was calculated for each chromosome based on the actual number of SVAs 
on each chromosome and the percentage of each subtype across the whole genome. 
This demonstrated that subtype A’s distribution was significantly different to the 
predicted (P<0.05) (Figure 4.1B). All the other subtypes were distributed as 
predicted by the actual number of SVAs identified on each chromosome. SVA As 
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appear to have the opposite chromosomal distribution to the general distribution of 
all SVAs; being found in general in larger numbers on the chromosomes with lower 
gene densities.  
 
 
Figure 4.1: Chromosomal distribution of SVAs is significantly different to the 
predicted. A - The number of SVAs expected on each chromosome based on their 
size compared to the observed. Chi squared test showed that the actual chromosomal 
distribution of the SVAs was significantly different to the predicted. (X
2
=220.0, 
df=23, P<0.001) B – The table shows the results of the chi squared test for each SVA 
subtypes’ predicted distribution compared to the actual with subtype A only showing 
a significant difference. 
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The hypothesis would therefore be that the SVA distribution (except subtype 
A) was related to the distribution of genes, which was investigated by comparing the 
SVA density to the gene density of each chromosome (Figure 4.2A). This showed a 
positive correlation (r=0.74) for the relationship of chromosomal SVA density and 
gene density calculated using bootstrap confidence of 95% to remove outliers. This 
correlation was tested for each individual SVA subtype (A-F1) and the positive 
correlation with gene density was maintained for all subtypes except A, which 
showed a negative correlation with gene density (Figure 4.2C). 
 
 
Figure 4.2: SVA density across chromosomes is correlated with their gene 
density. A – The SVA density is positively correlated with the gene density across 
human chromosomes. The correlation coefficient (0.74) was calculated using 
bootstrap confidence interval of 95% to remove outliers. B – This table shows the 
raw data used to create figure 4.2A to highlight which chromosomes are contributing 
to each point on the graph. C – The table shows the correlation coefficient of each 
SVA subtype density with the gene density of each chromosome. All subtypes show 
a positive correlation to varying degrees except SVA As, which have a negative 
correlation with gene density across chromosomes. 
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4.4.2 SVAs show a reduced presence in gene deserts with deviation in the 
subtype distribution from the expected in these regions compared to genic 
regions 
Figures 4.1 and 4.2 showed a correlation of SVA insertions with gene dense 
regions of the genome. To dissect the distribution of SVAs further, the genome was 
divided into the three following regions: genes, intergenic and gene deserts defined 
in 4.3.1 and the difference in the expected and the observed distributions was 
calculated. The distribution of three other classes of retrotransposon (LTRs, LINEs 
and SINEs) were also analysed for comparison to that of the SVAs. The distribution 
of the different classes of retrotransposons shared some similarities, in particular a 
lower number than expected were found in gene deserts and all classes showed a 
significant difference in their actual distribution to the expected across the three 
regions analysed, Figure 4.3A (SVAs X
2
=339.5, df=2, P<0.001, SINEs X
2
=170647, 
df=2, P<0.001, LINEs X
2
=44320, df=2, P<0.001, LTRs X
2
=77018, df=2, P<0.001).  
The distribution of SVAs was further analysed by subtype within the 
previously defined regions: genes, intergenic and gene deserts, Figure 4.3B. The 
SVA subtypes showed a significant difference in their distribution within gene 
deserts compared to the whole genome (Gene deserts X
2
=13.91, df=6, P<0.05) but 
not within genes and intergenic regions (Genes X
2
=0.71, df=6, P=0.99, Intergenic 
X
2
=0.47, df=6, P=0.99). Subtypes D, E and F1 were underrepresented in gene 
deserts whereas subtype B in particular was found in higher numbers. 
 
 
 
123 
 
 
 
Figure 4.3: There are fewer than expected SVAs within gene deserts compared 
to genic regions. A – The number of observed retrotransposons in defined regions of 
the genome compared to the expected due to the size of the regions. Each class of 
retrotransposons are found in lower numbers in gene deserts most notably SVAs. For 
each class of retrotransposon the actual distribution was significantly different to the 
expected when analysed with the Chi squared test (Chi squared test carried out using 
raw data). (SVAs X
2
=339.5, df=2, P<0.001), (SINEs X
2
=170647, df=2, P<0.001), 
(LINEs X
2
=44320, df=2, P<0.001), (LTRs X
2
=77018, df=2, P<0.001). B – The 
distribution of SVAs within genes, intergenic regions and gene deserts was broken 
down by subtype and compared to their distribution across the whole genome. The 
subtype distribution in gene deserts showed a significant difference with B and F 
being more prevalent and D, E and F1s being underrepresented. (Genes X
2
=0.71, 
df=6, P=0.99), (Intergenic X
2
=0.47, df=6, P=0.99), (Gene deserts X
2
=13.91, df=6, 
P<0.05). 
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4.4.3 The retrotransposons, SVAs and SINEs, show an increased presence in 
regions directly upstream and downstream of genes 
 The analysis of the presence of retrotransposons within regions directly 
upstream of the TSS of genes (within 20kb) was undertaken to assess the potential of 
these elements to influence gene expression. Retrotransposons contain characteristics 
such as internal promoters, CG rich sequences therefore potential sites of 
methylation and repetitive regions providing multiple sequence specific transcription 
binding sites. These are properties that could influence the loci of the site of their 
insertion and therefore may be selected against in areas such as promoters where 
they could interfere with the regulation of gene expression. The number of expected 
elements of the retrotransposon classes (SVAs, SINEs, LINEs and LTRs) in defined 
regions upstream of the start of the 5’UTR/TSS of genes (1kb, 10kb and 20kb) were 
compared to the observed (Figure 4.4A). SVAs and SINEs were significantly 
overrepresented throughout the 20 kilobases upstream of TSS of genes (SVAs 
X
2
=221.9, df=2, P<0.001 and SINEs X
2
=138825, df=2, P<0.001). LINEs and LTRs 
also show a significant difference in their distribution with fewer present in the first 
kilobase upstream of the TSS than expected but with less deviation in the 10 and 20 
kilobase regions (LINEs X
2
=2343, df=2, P<0.001 and LTRs X
2
=2057, df=2, 
P<0.001). The same analysis was completed for defined regions (1kb, 10kb and 
20kb) downstream of the 3’UTR of genes for comparison to the upstream data 
(Figure 4.4B). The SVAs and SINEs were also overrepresented throughout the 20kb 
downstream of genes and to a greater extent in the first kilobase of that region 
(SVAs X
2
=227.6, df=2, P<0.001 and SINEs X
2
=89097, df=2, P<0.001). The LINEs 
and LTRs showed a more similar distribution compared to the expected across the 20 
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kilobases downstream of genes, however it was still significantly different (LINEs 
X
2
=695.2, df=2, P<0.001 and LTRs X
2
=741.0, df=2, P<0.001). 
 The SVA distribution in these two regions was analysed further to determine 
if the percentage of each subtype present differed to that across the whole genome 
(Figure 4.5). The subtype distribution was not significantly different except within 
the first kilobase upstream of the start of transcription; subtypes A, B and E were 
found in lower numbers than expected and there were a greater number of subtypes 
C and D. 
 
Figure 4.4: The number of SVAs and SINEs is greater than expected in regions 
upstream and downstream of genes. A- The fold difference of the number of 
retrotransposons within 1kb, 10kb and 20kb of the 5’UTR of genes compared to the 
expected. The distribution of the expected of the four classes of retrotransposon were 
all significantly different from the observed using the Chi squared test (Chi squared 
test carried out using raw data).  (SVAs X
2
=221.9, df=2, P<0.001), (SINEs 
X
2
=138825, df=2, P<0.001), (LINEs X
2
=2343, df=2, P<0.001), (LTRs X
2
=2057, 
df=2, P<0.001). B- The fold difference of the number of retrotransposons within 
1kb, 10kb and 20kb of the 3’UTR of genes compared to the expected. The 
distribution of the expected of the four classes of retrotransposon were all 
significantly different from the observed using the Chi squared test (Chi squared test 
carried out using raw data).  (SVAs X
2
=227.6, df=2, P<0.001), (SINEs X
2
=89097, 
df=2, P<0.001), (LINEs X
2
=695.2, df=2, P<0.001), (LTRs X
2
=741.0, df=2, P<0.001) 
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Figure 4.5: The distribution of SVA subtypes within the regions upstream and 
downstream of the whole gene. A- The distribution of the SVA subtypes across the 
whole genome compared to the distribution in 1kb, 10kb and 20kb directly upstream 
of the 5’UTR of genes. There is a significant difference in the distribution of the 
subtypes within the first kilobase compared to the whole genome. (1kb X
2
=16.30, 
df=6, p<0.05), (10kb X
2
=2.97, df=6, p=0.81), (20kb X
2
=1.30, df=6, p=0.97). B- The 
distribution of the SVA subtypes across the whole genome compared to the 
distribution in 1kb, 10kb and 20kb directly downstream of the 3’UTR of genes. 
There no significant difference in the subtype’s distribution within regions 
downstream of genes (1kb X
2
=4.31, df=6, p=0.63), (10kb X
2
=1.63, df=6, p=0.95), 
(20kb X
2
=0.71, df=6, p=0.99). 
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4.4.4 SVA insertions are found on the opposite strand more frequently when 
exonic or intronic but there is not a preference for relative orientation when 
inserted upstream or downstream of the gene 
 When analysing the distribution of SVAs across the human genome a list of 
genes that had a SVA within an intron, exon or their 10kb flank was generated and 
this was used to compare the orientation of the SVA to the gene to determine if 
SVAs preferentially inserted in a particular orientation relative to the nearest gene. 
The SVAs within the genes’ 10kb flank showed close to a 50/50 relationship to 
whether they were on the same strand or opposite as each other; showing there was 
not a preference for the orientation for the SVA insertion within these regions (Table 
4.1). Of the SVAs that had inserted into introns or exons only 26.1% of them were 
on the same strand as the gene indicating that SVAs are preferentially found on the 
opposite strand to the gene.   
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Percentage of SVA subtypes on same strand of DNA as 
the nearest gene within defined parameters (%) 
Subtype 
Within 10kb 
upstream of a 
gene 
Within 10kb 
downstream of a 
gene 
Within an exon 
or intron of a 
gene 
A 55.9 47.2 37.5 
B 43.1 42.9 18.0 
C 48.3 44.1 16.8 
D 39.9 43.8 27.3 
E 36.8 32.4 29.7 
F 52.7 46.9 24.9 
F1 68.8 60.0 28.2 
All 49.3 45.3 26.1 
 
Table 4.1: Intronic and exonic SVA insertions occur more frequently on the 
opposite strand to the gene they have inserted into. Using information from 
UCSC genome browser the orientation of SVAs inserted within a gene or within its 
10kb flank was compared the orientation of the gene itself and the percentage of 
SVAs on the same strand as the gene was calculated.   
 
 
 
 
129 
 
4.4.5 SVAs have the potential to form G-quadruplex DNA to varying degrees 
between subtypes  
The nature of the sequence contained within SVAs shows the potential for 
formation of secondary structures such as cruciforms and G4 DNA (Hancks and 
Kazazian 2010). G4 DNA is a secondary structure predicted to form in guanine-rich 
sequences and its function was discussed in section 1.3.2. To determine the exact 
nature of the relationship of the SVAs’ sequence and G4 formation software was 
used to analyse the SVAs potential to form this type of secondary structure. 
Of the total genomic DNA that can form G4 (predicted by Quadparser 
software (Wong et al. 2010) 1.88% is due to SVAs which only constitute 0.13% of 
the human genome. When repetitive or mobile DNA elements, which include simple 
repeats, microsatellites, LTRs, LINEs, SINEs and DNA transposons (as defined by 
UCSC genome browser Hg19) are compared; SVAs have the greatest potential 
contribution to G4 DNA for their size for any specific element (Figure 4.6A).  
It was found that the percentage of sequence in each SVA subtype with the 
potential to form G4 increased as the age of the subtype decreased, thus subtypes E, 
F and F1 have the greatest potential for G4 formation (Figure 4.6B). This can be 
explained by the increase in the potential of the central VNTR region to form G4 
DNA from subtype D through to F1. The possible amount of G4 formed by the 
CCCTCT repeat was found to increase through subtypes A to E; however the 
proportion it contributed to the total G4 potential of each subtype decreased. Subtype 
F1 does not contain a CCCTCT repeat therefore all of its G4 potential is within the 
central VNTR. 
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The average number of repeats in the CCCTCT domain and therefore its 
length varied between subtypes (Figure 4.6C) which accounts for the difference in 
G4 potential between the SVA subtypes in that particular domain; the longer the 
CCCTCT domain the greater the G4 potential. The average length of the GC-rich 
VNTRs also varied between subtypes but length did not show the same direct 
correlation with G4 potential as in the CCCTCT domain. For example the VNTRs of 
subtype A are just under half the length of those of subtype F1, however they have 
only a hundredth of the potential to form G4 DNA when compared to the VNTR 
sequences of subtype F1 (Figure 4.6D). It appears that the subtypes fall into two 
main groups when analysing their G4 potential in the VNTRs. Subtypes A, B and C 
have very low G4 potential in their VNTRs compared to subtypes E, F and F1 with 
subtype D bridging the difference between the older hominid specific and younger 
human specific subtypes. This would be explained by the development of the 
additional second VNTR of the younger subtypes with differences in the primary 
nucleotide content to the first VNTR containing sequences that have the potential for 
G4 DNA. 
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Figure 4.6: The sequences of SVAs have potential to form G-quadruplex DNA.   
A – Potential G4 DNA formation was analysed in silico. The fold difference in the 
relative contribution of each element to their proportion in the whole human genome 
was calculated and is displayed.  
B - The percentage of sequence from each SVA subtype that could potentially form 
G4 DNA in the human genome according to Quadparser software is shown; it was 
further sub-divided into the following elements: CCCTCT hexamer repeat, VNTRs 
and the remainder of the sequence (other). 
 C – Illustrates the relationship between VNTR and hexamer repeat length during 
evolution of the SVA subtypes. The average lengths are shown in base pairs.  
D – The fold difference in size of each of the central VNTRs from the SVA subtypes 
in the human genome, and their percentage contribution to form G4 compared to the 
value for SVA subtype F1 which has the highest value for both central VNTR length 
and G4 potential of the central VNTR. 
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4.4.6 SVAs and their VNTRs show some characteristics of CpG islands 
 The definition of a CpG island was taken from the UCSC genome browser 
and the literature as the following: greater than 200bp in length, more than 50% GC 
content and a ratio of observed to expected CG as greater than 0.6. The potential of 
the GC-rich sequences of the SVAs and in particular their central VNTR to be CpG 
islands were calculated for 3 of each SVA subtype. The SVAs and their VNTRs of 
all the subtypes met two of the criteria as were larger than 200bp in length and had a 
GC content greater than 50%. SVAs have a high GC content, in this analysis an 
average of 64.4% for the whole SVA and 74.0% for the central VNTR (Table 4.2A). 
The GC content of the SVAs increased as the as class of the subtype decreased. The 
SVAs analysed did not have a ratio of observed to expected CG dinucleotides greater 
than 0.6 with an average ratio of 0.53 for the whole SVA and 0.54 for the VNTR 
alone (Table 4.2A). The CpG ratio and the GC content of three CpG islands located 
at genes of interest are shown in table 4.2B for comparison to the values for the 
SVAs and their VNTRs. The GC content of the CpG islands is similar to that of the 
SVAs and lower compared to that of the VNTRs however the CpG ratio of the SVAs 
and their VNTRs is lower than that of the CpG islands.  
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 SVA VNTRS 
Subtype CpG Ratio 
GC Content 
(%) 
CpG Ratio 
GC Content 
(%) 
A 0.48 60.2 0.51 69.9 
B 0.54 60.6 0.54 71.9 
C 0.50 61.3 0.54 73.5 
D 0.54 65.1 0.55 74.4 
E 0.54 67.3 0.54 75.8 
F 0.54 66.6 0.54 75.6 
F1 0.58 69.4 0.55 77.0 
Average 0.53 64.4 0.54 74.0 
 
CpG Island CpG Ratio GC Content (%) 
FUS gene 0.94 66.0 
Major TSS of PARK7 gene 0.92 65.9 
Minor TSS of PAR7 gene 0.87 65.8 
 
Table 4.2: CpG island ratio and the GC content of a small number of the 
different SVA subtypes and their central VNTRs. A - The CpG ratio of the SVAs 
and their VNTRs using the following formula Obs/Exp CpG = Number of CpG * 
length of sequence / (Number of C * Number of G) was calculated for 3 of each 
subtype and then averaged. For a region to be considered a CpG island the ratio of 
observed CG nucleotides to the expected needs to be greater than 0.6. The sequences 
of the SVAs and their VNTRs have ratios close to but lower than the required ratio 
of 0.6. This ratio is similar between the SVA and their VNTRs alone and across the 
subtypes with subtypes A and F1 showing the greatest difference to the rest. The GC 
content of the VNTRs was greater than that of the whole SVA and for both the 
whole SVA and its central VNTR the GC content showed a general increase from 
oldest to youngest across the subtypes. B – The CpG ratios and the GC content of 
three CpG islands located at the TSS of two genes of interest in this project (see 
chapter 3 section 3.4.1 for FUS and see chapter 5 section 5.4.1 for PARK7) for 
comparison to the values for the SVA values.   
A 
B 
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4.5 Discussion 
 SVA density was correlated with gene density across chromosomes (Figures 
4.1 and 4.2) and displayed a preferential site of insertion into genic regions as 
opposed to gene deserts (Figure 4.3), which may reflect the more accessible and 
open nature of the chromatin to allow for transcription and therefore more amenable 
to retrotransposon insertions than inactive chromatin. SVAs showed a greater than 
expected presence in the 20kb flanking genes similar to that of the SINE elements 
(Figure 5.4) again supporting the hypothesis these elements insert more frequently 
into active chromatin. Further evidence for the insertion of TEs into active chromatin 
was demonstrated when a preference of Alu elements and to a lesser extent SVAs 
inserting into the region upstream of genes active in the germ line (Warnefors et al. 
2010). Similar to the data generated in this chapter Alus (majority of SINEs in 
humans) have been shown to be located at higher than expected numbers within 
genes and their flanking regions whereas LINEs and LTRs are reduced in the 
flanking regions of genes (Medstrand et al. 2002). A recent publication of the 
distribution of TEs in the mouse genome has also shown that SINEs are enriched 
within genes and their flanking regions with LINEs and ERVs depleted in functional 
regions (Nellaker et al. 2012). SVAs show a similar distribution to that of SINEs 
reported in the literature. 
 The presence of SVAs in regions 1-20kb upstream of TSSs (Figure 5.4A) 
demonstrates that these elements are located in promoter regions and have the 
potential to influence gene expression. SVAs share similar primary sequences even 
across subtypes; which provides the potential for binding similar sequence specific 
binding factors that could affect aspects of transcription. Depending on the 
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chromatin structure or access to these elements the end result could be subsets of 
SVAs which respond to similar cellular signalling pathways. SVAs were also found 
to be overrepresented in the region up to 20kb downstream of genes. This was noted 
in particular in the first kilobase downstream which showed greater numbers of 
SVAs present than in the first kilobase upstream of genes. This may due to fewer 
selective pressures in the region directly downstream of genes compared to 
upstream, allowing for the greater accumulation of SVA elements.  
 The SVAs that had inserted into the 10kb flank of genes did not show a 
preference for the orientation of their insertion relative to the gene. However the 
orientation of the SVAs when inserted into an intron or exon showed a strong 
preference to inserting on the opposite strand to the gene. Only 26.1% of SVAs have 
inserted into the same strand as the gene (Table 4.1) indicating selective pressures 
against this occurring. This may be due to the poly A tail that is part of a canonical 
SVAs structure as if on the same strand as the gene may cause pausing or even 
termination of transcription resulting in truncated mRNA. Also several splice sites 
have been identified in the sense strand of the SVA sequence but not the antisense 
with 6 out of the 7 intronic or exonic disease causing SVA insertions on the sense 
strand further indicating the potential negative effects intronic/exonic sense strand 
insertions (Kaer and Speek 2013). Alus also contain consensus splice sites within 
their sequence on both their sense and antisense strands and may introduce new 
exons into existing genes and are an important source of new exons in the primate 
genome (Sorek 2009). A study into the expression of transcripts containing 330 Alu-
derived exons across 11 adult tissues revealed that most of these new exons are 
expressed in transcripts at low levels, however in a small number of cases the Alu-
derived exons were constitutively spliced and in others the inclusion of the Alu-
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derived exon was tissue specific (Lin et al. 2008). The splice sites present in the 
SVA sequences could potentially be involved in evolutionary process similar to Alus 
in generating alternative transcripts.  
 Primary DNA sequence which contains stretches of guanine nucleotides can 
fold into four-stranded structures called G4 DNA, which are implicated in gene 
expression, replication and telomere maintenance (Huppert and Balasubramanian 
2005; Oganesian and Bryan 2007; Gonzalez and Hurley 2010), chapter 1 Figure 1.5. 
Also the presence of G4 sequences along with abnormal hypomethylation was 
shown to be enriched in breakpoints mapped in cancer genomes, leading to the 
hypothesis that loss of methylation in regions with G4 sequences is part of the 
mutagenic processes in cancer (De and Michor 2011). SVAs contain sequences with 
G4 potential, specifically in their CCCTCT hexamer and central VNTR (Figure 5.8), 
therefore they could show similar properties to already characterised functions of G4 
DNA discussed previously (chapter 1 section 1.3.2). Along with the regulatory 
properties of G4 DNA the hypothesised mutagenic properties of G4 sequences in 
demethylated regions in cancer (De and Michor 2011) is of interest as it has been 
demonstrated that SVAs experience a loss of methylation in cancer (Szpakowski et 
al. 2009). Therefore the loss of methylation of these elements in cancer may allow 
formation of G4 DNA which could play a role in gene regulation or could add to the 
mutagenic process in the tumour. The occurrence of somatic retrotransposition in the 
aging brain indicates a reduction in the silencing of these elements and could also 
allow G4 formation along with activating other transcriptional properties within the 
SVAs. The amount of G4 potential and the domain of the SVA it was predominantly 
located in varied across the different subtypes. The older subtypes (A, B and C) had 
the lowest potential; which was mostly located within the 5′ CCCTCT repeat, 
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whereas the younger human specific (E, F and F1) demonstrated the greatest 
potential for G4 with an increase in the amount located in the central VNTR. 
Subtype D showed itself to be an intermediate of the two groups (Figure 4.6). 
 The CG-rich nature of the primary sequence of the SVAs provides potential 
regions for methylation and with many SVAs located near the transcriptional start 
site of genes therefore the methylation status of these elements could influence the 
expression of genes. A small number of SVAs from each subtype were analysed for 
characteristics of CpG islands. The SVAs reached two out of three of the thresholds 
in the definition of a CpG island and were close to the third requirement. The SVAs 
analysed may not meet all the requirements to be defined as a CpG island but SVAs 
still contain many CG dinucleotides that if methylated could potentially reduce the 
expression of transcripts originating near them.  
 The analysis in this chapter of the distribution of SVAs within the human 
genome showed a preference for genic regions over gene deserts and an 
overrepresentation of these elements in regions directly upstream of TSSs placing 
them in location where they may influence gene expression. This may be through the 
binding of transcription factors, their methylation status or even the formation of 
secondary structures such as G4 DNA.  
 
 
 
138 
 
 
 
 
 
 
 
Chapter 5  
Characterisation of the PARK7/DJ-1 gene loci and 
the structure and function of a SVA upstream 
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5.1 Introduction 
 A SVA within 10kb upstream of the Parkinson protein 7 (PARK7) gene, a 
similar upstream locus to that found for the FUS SVA, was identified during the 
global analysis of SVAs in the human genome. This SVA was of particular interest 
as it was upstream of another gene involved in a neurodegenerative disease and was 
both a human specific element and contained all the domains of a canonical SVA. 
This SVA shared similar features to the FUS SVA, for example they are both of 
subtype D, but also differences that may impact on the function of these elements, 
for example the PARK7 SVA contains a CCCTCT hexamer repeat at its 5’ end 
whereas the FUS SVA does not.  
 The PARK7 gene is located on chromosome 1p36.23 and encodes for a 189 
amino acid multifunctional protein. PARK7 is also known as DJ-1 but will be 
referred to as PARK7 within this thesis. PARK7 was first identified as a protein that 
in conjugation with ras transformed the mouse NIH3T3 cell line, suggesting its 
oncogenic potential (Nagakubo et al. 1997). The PARK7 protein was found to be 
ubiquitously expressed across human tissues and found both in the nuclei and 
cytoplasm within the HeLa cell line (Nagakubo et al. 1997). The rat homologue of 
PARK7 (CAP1/sP22) is highly conserved (91% homology) and was identified as 
playing a role in male fertility (Wagenfeld et al. 1998a; Wagenfeld et al. 1998b). 
PARK7 acts as a positive regulator of the androgen receptor (AR) by binding to the 
PIASxα (protein inhibitor of activated STAT) preventing it from binding to the AR 
(Takahashi et al. 2001). Further regulatory properties of PARK7 involve the human 
specific regulation of the tyrosine hydroxylase (TH) gene, an enzyme involved in 
dopamine synthesis, by binding to a repressor of the TH preventing it from binding 
to the TH gene promoter and inhibiting expression (Ishikawa et al. 2010). PARK7 
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has also been identified as a negative regulator of the tumour suppressor PTEN’s 
function (Kim et al. 2005). Another of PARK7’s key functions is to protect against 
oxidative stress preventing cell death (Taira et al. 2004). PARK7 protects against 
oxidative stress and mitochondrial damage by undergoing oxidisation at a highly 
conserved cysteine residue (C106) causing a shift of the protein to a more acidic 
form (Canet-Aviles et al. 2004). Mitochondrial dysfunction and oxidative stress are 
mechanisms proposed to be involved in neuronal damage and ultimately cell death 
associated with Parkinson’s disease (PD) and the reduction or loss of function of the 
PARK7 protein is a trigger for PD (Ariga et al. 2013). Mutations in the PARK7 gene 
including a 14kb deletion of a large coding portion of the gene and a missense 
mutation (L166P) affecting the function of the protein are a cause of autosomal 
recessive early onset PD (Bonifati et al. 2003). PARK7 has also been shown to be 
associated with cancer including breast and non-small cell lung carcinoma (Le Naour 
et al. 2001; MacKeigan et al. 2003). PARK7 and its role in disease processes are 
discussed in further detail in chapter 6.  
 Detailed analysis of the PARK7 gene locus and the SVA upstream was 
undertaken and was used to attempt to determine the impact of the SVA on the site 
of insertion and how this may affect gene expression. 
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5.2 Aims 
 Analyse the PARK7 gene loci and the expression of PARK7 transcripts in 
two different cell lines; a human neuroblastoma cell line (SK-N-AS) and 
human adenocarcinoma cell line (MCF-7) to reflect the range of PARK7 
activities. 
 Analyse the epigenetic modifications and chromatin structure of the PARK7 
locus including the two promoters. 
 Determine the polymorphic nature of the PARK7 SVA using the CEU 
HapMap cohort. 
 Identify the potential regulatory domains of the PARK7 SVA and differential 
function of its four alleles using reporter gene constructs.  
 
 
 
 
 
 
 
 
 
142 
 
5.3 Methods 
5.3.1 Bioinformatic Analysis of the PARK7 gene loci 
 The PARK7 loci was analysed using the genome browser UCSC Hg19 
(http://genome.ucsc.edu/index.html) and Archive Ensembl 10:Jan 2013 
(http://www.ensembl.org/info/website/archives/index.html) was used to characterise 
the transcripts of the PARK7 gene. 
 
5.3.2 Analysis of expression of PARK7 transcripts 
 Section 2.2.3 outlines the methods for analysing endogenous gene expression 
in SK-N-AS and MCF-7 cell lines and Table A1 contains PCR conditions for the 
specific primer sets used to analyse the expression of the different PARK7 
transcripts. The fragments corresponding to the PARK7 transcripts on the gel were 
extracted (2.2.4.4) and sent for sequencing (2.2.4.10) with the primers that were used 
in the amplification of the transcripts. 
 
5.3.3 Analysing the chromatin structure at the PARK7 loci using chromatin 
immunoprecipitation 
 Chromatin immunoprecipitation was used to analyse the epigenetic 
parameters and transcription factor binding at specific loci of the PARK7 gene and 
SVA in the SK-N-AS and MCF-7 cell lines (2.2.9). For details of the antibodies used 
see Table A2 in the appendix. The regions of interest which were the major and 
minor promoters of the PARK7 gene and 5’ of the PARK7 SVA were amplified 
using Go Taq Flexi polymerase (2.2.3.3.2) under standard conditions and primers 
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listed in Table A1 of the appendix. A negative control primer set for a gene desert 
was used to determine if the binding observed was specific (Table A1). 
 
5.3.4 Characterisation of the PARK7 gene promoter loci in gDNA of cell lines 
and breast tumour samples 
 The two PARK7 gene promoter regions (major and minor) and several other 
loci 5’ and 3’ of the major PARK7 TSS were amplified using GoTaq Flexi 
polymerase (2.2.3.3.2) with the addition of 1M betaine final concentration. gDNA 
was extracted from the cell lines using QIAamp DNA mini kit (2.2.7) and 10ng was 
used as template in the reaction. The gDNA from breast cancer tumour samples were 
obtained from the Liverpool Cancer Tissue Bank and 5ng of gDNA was used in the 
reaction. The PCR conditions and primers used are listed in Table A1 of the 
appendix. The PCR products were analysed using gel electrophoresis on a 1.2% 
agarose gel (2.2.3.4). 
 
5.3.5 Genotyping the PARK7 SVA  
 The PARK7 SVA was amplified using KOD Hot Start DNA Polymerase 
(Novagen) under standard conditions (see 2.2.4.2 for components of KOD Hot Start 
master mix) with the addition of betaine (Sigma) at 0.5M final concentration and the 
reaction volume was reduced and optimised to 20µl to save reagents. For primers 
and cycling condition see Table A1 in the appendix. 1ng of gDNA from the CEU 
HapMap cohort was used as template in the reaction. The PCR products were run on 
a 1% agarose gel (2.2.3.4) for up to four hours for adequate separation of the alleles 
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due to the large size of the SVA. The allele frequency data was used to calculate the 
expected genotype frequencies which were compared to the observed to determine if 
the PARK7 SVA locus is in HWE. 
 
5.3.6 Cloning four identified alleles from the HapMap into an intermediate 
vector and subsequent sequencing 
 For accurate sequencing and downstream applications the four alleles of the 
PARK7 SVA were cloned into the intermediate vector pCR-Blunt (2.2.5.1). The 
plasmids containing each allele were sent for sequencing (2.2.4.10) with two primers 
in the vector (M13 reverse and M13 forward) and two within the SVA itself 
(5’CTCAGTGCTCAATGGTGCC 3’ and 5’CCGCCTTTCTATTCCACAAA 3’) to 
ensure the whole of the insert was sequenced. The plasmids generated were used as 
template in amplification of the individual repetitive regions (hexamer VNTR and 
TR/VNTR) to demonstrate the differences in size using KOD Hot Start polymerase 
(2.2.4.2), for primers and conditions used see Table A1 in the appendix. 
 
5.3.7 Generation of PARK7 SVA reporter gene constructs 
 The different sized fragments in forward and reverse orientation and the four 
alleles of the PARK7 SVA were cloned into the reporter gene vector pGL3P 
(2.2.5.2). The PARK7 SVA was also cloned in to pGL3B to test its ability to act as a 
promoter (2.2.5.2). 
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5.3.8 Cell culture of SK-N-AS and MCF-7 cell lines, transfection and dual 
luciferase assay of reporter gene constructs 
SK-N-AS and MCF-7 cells were cultured as outlined in 2.2.2.1. For 
transfection methods used and analysis of reporter gene expression methods see 
2.2.6. 
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5.4 Results 
5.4.1 Chromosomal Loci of the PARK7 gene and the SVA upstream of its 
transcriptional start site 
 The PARK7 gene is located on chromosome 1p36.23 and the locus of this 
gene was analysed using genome browsers UCSC Hg19 and Archive ensembl 
10:Jan2013. The TSS of the gene was identified in UCSC by the origin of the 
transcripts of the gene, a CpG island and ENCODE data such as active histones 
marks and DNase 1 hypersensitivity clusters which corresponded to the locus of the 
promoter characterised by Taira et al (Taira et al. 2001). A region 7kb upstream of 
the TSS of the PARK7 gene also shared many of the features of the well 
characterised TSS for the PARK7 gene such as a CpG island, DNase 1 
hypersensitivity clusters and active histone marks however there was not a known 
PARK7 transcript originating at that locus in UCSC genome browser. Intragenic 
CpG islands have previously led to the identification of previously unknown TSSs 
and promoters (Gardiner-Garden and Frommer 1994; Macleod et al. 1998; Kleinjan 
et al. 2004) and are often associated with the 5’ end of genes. The CpG alone 
therefore indicates the potential for transcription occurring at this locus. There were 
also expressed sequence tags (ESTs) expressed within the region of the second CpG 
island and the Affymetrix Human Exon Array extended probe sets predicted exons at 
this site. Data from the Archive ensembl database predicted a transcript originating 
from this second CpG island (Figure A1 of the appendix). The ENCODE data of this 
locus and the predicted transcript led me to this region being putatively termed the 
minor TSS of the PARK7 gene and the already characterised promoter termed the 
major TSS (Figure 5.1). A human specific SVA D (classified by the interrupted 
repeat masker track on UCSC genome browser) was identified 8kb upstream of the 
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major TSS and 1kb upstream of the minor TSS in UCSC genome browser (Figure 
5.1). 
 
 
 
Figure 5.1: Schematic of chromosomal loci of PARK7 gene. Data was compiled 
from UCSC genome browser (Hg19) and Archive Ensembl (Ensembl 10:Jan 2013) 
(see Figure A1 of the appendix for data screenshots from UCSC). The SVA D is 
located 8kb upstream of the major transcriptional start site (TSS) of the PARK7 gene 
and 1kb upstream of the minor TSS. There are two CpG islands present with UCSC 
browser showing ENCODE data for H3K27Ac histone mark often found near active 
regulatory elements (7 cell lines), DNase hypersensitivity clusters and transcription 
factor binding across both of these regions indicating transcriptionally active areas. 
The majority of PARK7 transcripts begin at the major TSS but Archive Ensembl 
browser indicates there is a transcript at the minor TSS adjacent to the SVA D. 
UCSC Affymetrix Human Exon Array extended probe sets show putative exons at 
this second TSS and there are also expressed sequenced tags (ESTs) at the site.  
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5.4.2 PARK7 transcripts are differentially expressed in SK-N-AS and MCF-7 
cell lines 
 The expression of the PARK7 gene mRNA was analysed under basal growth 
conditions in a SK-N-AS cell line and two MCF-7 cell lines supplied by different 
sources and of different passage number. Primers sets designed to amplify the 
transcripts originating at the major TSS and the predicted transcript originating at the 
minor TSS were used in this analysis (Figure 5.2A). The primers of PARK7 primer 
set 1 were located in exon 2 and 6 all of the known PARK7 transcripts and for 
primer set 2 the primers were within exon 1 and 2 of the transcripts originating at the 
major TSS with two specific products due to two exon 1s of different lengths. The 
third primer set was located within exon 1 and 2 of the predicted transcript in the 
Archive Ensembl database originating at the minor TSS. 
 PCR products from all three of these primers sets were identified in the SK-
N-AS cell line (Figure 5.2B). These products numbered 1 to 5 were gel extracted and 
sent for sequencing. Products 1 to 3 corresponded correctly to the sequence of the 
PARK7 gene in the UCSC genome browser. From primer set 3 there was one 
product of 108bps expected from the predicted transcript however there were two 
products from the PCR. The sequence of PCR product 4 corresponded to the known 
exon 2 of the PARK7 gene and to sequence of exon 1 of the predicted transcript in 
Archive Ensemble originating at the minor TSS. However there was 8bps less within 
the sequenced exon 1 compared to the predicted. The sequencing of PCR product 5 
showed some similarities with the PARK7 exon 2 sequence but the origin of this 
DNA could not be identified.  
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 The PCR analysis of the lower passage MCF-7 cells (P.13) detected the 
expression of the PARK7 transcripts originating at the major promoter of the gene 
but not the transcript originating at the minor (Figure 5.2C) indicating the expression 
of the latter transcript is tissue specific. The PCR analysis of the expression of the 
PARK7 gene in the higher passage MCF-7 cells (P.32) could not detect the 
expression any of the transcripts of the gene (Figure 5.2B). The housekeeping gene 
β-tubulin was consistently expressed across several cDNA samples from the high 
passage MCF-7 cells indicating the RNA extraction and cDNA conversion were 
successful, however the known oestrogen responsive gene trefoil factor 1 (TFF1) in 
MCF-7 cells (see section 6.4.3) could not be detected. The extraction of total RNA 
from these cells and subsequent conversion to cDNA was carried out multiple times 
to ensure this was a not a problem associated with the processing of the sample but 
the results remained the same. The inconsistencies of this particular passage of cells 
led to its discontinuation for further experiments. See section 5.4.5 for the analysis of 
the gDNA from the high passage MCF-7 cell line in an attempt to determine the 
mechanism underlying the lack of PARK7 expression in these cells.   
 Our analysis in these two cell lines is consistent with ENCODE data for this 
locus available on the UCSC genome browser showing that the chromatin structure 
in 9 different human derived cells lines revealed a greater variation at the minor 
promoter of PARK7 compared to the major across the different cell lines (Figure 
5.3). This information is based in ChIP data using nine factors targeting a variety of 
histone modifications that are associated with different chromatin states. The 
chromatin structure indicates the major promoter is active in all nine of the cell lines 
analysed whereas the minor is active in some of the cell lines (GM12878, K562, 
HepG2, NHEK and NHLF), weakly active in two (HMEC and HSMM) and inactive 
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in another cell line (H1-hESC). There are also ESTs located in the region of the 
minor promoter of the PARK7 gene and this indicated transcriptional activity may 
also be in part related to the expression of these ESTs not just the PARK7 transcript. 
The region of the minor PARK7 promoter is showing tissue specificity across the 9 
cell lines tested whereas the major is not.  
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Figure 5.2: Expression of PARK7 transcripts in a SK-N-AS cell line and two 
MCF-7 cell lines of different passage.   
A – Schematic of the PARK7 transcripts and the primers used in their amplification. 
PARK7 primer set 1 targets exon 2 and 6 of all identified PARK7 transcripts with a 
product size of 325bp. PARK7 primer set 2 targets exon 1 and 2 of the transcripts 
originating at the major TSS and due to transcripts with different lengths of exon 1 
would produce two specific products at 102bp and 159bp. PARK7 primer set 3 
targets exon 1 and 2 of the transcript predicted by Archive Ensembl with a product 
size of 108bp.  
B – In the SK-N-AS cell line PARK7 was shown to be expressed when amplified 
with primer set 1 however was not present in the high passage MCF-7 cell line. The 
PCR product indicated with a number 1 was gel extracted and sequenced. The 
transcripts originating at the major TSS amplified by primer set 2 and the predicted 
transcript originating at the minor TSS were present in the SK-N-AS cell line but not 
the high passage MCF-7. The PCR products labelled 2-5 were gel extracted and 
sequenced, however the origin of the unexpected band 5 could not be determined.  
S=SK-N-AS cell line, M=MCF-7 cell line (high passage), W=water control.  
C– Expression of mRNA targets in lower passage number MCF-7 cell line. The 
PARK7 transcripts amplified by primer set 1 and 2 are expressed in a MCF-7 cell 
line of a lower passage, however the transcript amplified by primer set 3 is not 
expressed.  
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Figure 5.3: ENCODE data from UCSC browser shows greater variation in 
chromatin state at the minor promoter than the major promoter across 9 
different cell lines. This screen shot from UCSC genome browser shows the 
PARK7 gene locus and upstream SVA. Boxed in blue is ENCODE data on the state 
of the chromatin in the region in 9 cell lines. The colours represent different 
chromatin states: bright red – active promoter, light red – weak promoter, orange – 
strong enhancer, yellow – weak/poised enhancer, dark green – transcriptional 
elongation, light green – weakly transcribed, dark gray - repressed and light gray - 
heterochromatin. The major promoter is shown as active across the 9 cell lines; 
however the chromatin state of the minor promoter is variable across the 9 cells lines 
showing tissue specificity. GM12878 - B-lymphocyte, lymphoblastoid, International 
HapMap Project - CEPH/Utah - European Caucasian, H1-hESC – human embryonic 
stem cell line, K562 – cell line derived from pleural effusion of a 53-year-old female 
with chronic myelogenous leukaemia in terminal blast crises, HepG2 - hepatocellular 
carcinoma cell line, HUVEC - umbilical vein endothelial cells, HMEC - mammary 
epithelial cells, HSMM - skeletal muscle myoblasts, NHEK – normal human 
epidermal keratinocytes, NHLF - lung fibroblasts. 
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5.4.3 Affymetrix probe sets show expression of regions corresponding to exons 
of the PARK7 gene at the major TSS and predicted exons at the minor TSS in 
different regions of the human brain 
 Transcriptional activity was hypothesised in the region 3’ of the PARK7 
SVA approximately 7kb upstream of the PARK7 gene based on the ENCODE data 
available on the UCSC genome browser (Figure 5.1 and Figure A1). This in part was 
confirmed by the detection of a transcript in the SK-N-AS cell line originating in that 
region termed the minor promoter/TSS of the PARK7 gene (Figure 5.2B). 
Affymetrix probes were present in the region of the minor TSS and a collaboration 
was arranged with Dr Mina Ryten at University College London to address 
expression from this locus in the human CNS using global Affymetrix data she had 
generated on normal brain expression. Probes from the Affymetrix human exon array 
core probe set corresponding to the known exons of the PARK7 gene using the 
major TSS were used to detect the expression of these exons in different regions of 
the human brain (Table 5.1). The levels detected were significant enough to confirm 
the expression of the PARK7 exons in all of the brain regions tested. Probes were 
also used from the Affymetrix human exon array extended probe sets to look for 
expression of other exons in the region of the minor TSS of the PARK7 gene. The 
location of these three probes used are shown in Figure 5.1 called putative exons and 
are downstream of the PARK7 SVA and overlapping the second CpG island of the 
gene locus. Probes 2318734 and 2318735 demonstrated significant levels of 
expression in the regions of the brain tested (Table 5.2). This shows that there is 
transcriptional activity close to the PARK7 SVA within the human brain and that the 
area is not transcriptionally silenced.  
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 This successful use of the Affymetrix human exon array extended probe sets 
to detect transcription activity in close proximity to a SVA, which would most likely 
based on dogma for the action of SVAs be considered a region of inactivity due to 
epigenetic modifications to suppress the retrotransposition of the SVA, led to the 
analysis of other probe sets located in close proximity to SVAs. The list of probes 
from the extended array was taken from UCSC genome browser and intersected with 
regions 1kb up and downstream of all the SVAs identified in the Hg19 in the Galaxy 
program. There were 1248 extended probe sets located within 1kb up or downstream 
of 729 different SVAs. These probe sets could be potentially used to assess the 
transcriptional activity occurring close to SVAs. 
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Table 5.1: Expression analysis using Affymetrix human exon array core probes 
corresponding to exons of the PARK7 gene. The probes used corresponded to the 
exons of the PARK7 gene to detect expression in several regions of the human brain. 
All the probes showed high enough levels to confirm expression of these exons. 
CRBL-cerebellum, FCTX-frontal cortex, HIPP-hippocampus, MEDU-medulla, 
OCTX-occipital cortex, PUTM-putamen, SNIG-substantia nigra, TCTX-temporal 
cortex, THAL-thalamus, WHMT-white 
 
 
 
 Affymetrix human exon array core probes 
 2318743  2318744  2318746  2318747  2318751  2318754  2318755  
CRBL  8.4399 10.6363 10.6403 9.62593 7.37805 7.31186 6.22524 
FCTX  8.58727 10.7618 10.7633 9.81867 7.66961 7.65795 6.31523 
HIPP  8.48885 10.6152 10.6728 9.82037 7.8162 7.57378 6.28323 
MEDU  8.37343 10.588 10.6495 9.88626 7.81835 7.65326 6.27821 
OCTX  8.46021 10.6742 10.6983 9.88322 7.69187 7.59721 6.29395 
PUTM  8.45257 10.6337 10.675 9.80688 7.7563 7.55543 6.28135 
SNIG  8.3719 10.5689 10.6267 9.79588 7.7587 7.58947 6.25403 
TCTX  8.59431 10.7368 10.7672 9.84449 7.75681 7.6704 6.37456 
THAL  8.3771 10.5694 10.6311 9.85412 7.84935 7.62727 6.32961 
WHMT  8.08756 10.2715 10.3104 9.43152 7.31883 7.3547 6.0241 
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Affymetrix human exon array extended probes 
Region of the 
Brain 
2318733 2318734 2318735 
CRBL 3.31776 4.93371 5.84348 
FCTX 3.37886 5.10389 6.09532 
HIPP 3.41042 4.997 6.14168 
MEDU 3.4595 5.14324 6.00946 
OCTX 3.44164 5.09881 6.06441 
PUTM 3.44475 5.06815 6.1385 
SNIG 3.45463 5.14249 6.10432 
TCTX 3.28828 5.01947 6.02525 
THAL 3.43769 5.194 6.01592 
WHMT 3.40956 5.20551 6.08322 
 
Table 5.2: Expression analysis using Affymetrix human exon array extended 
probes shows expression occurring in the region 3’of the SVA. Probe sets were 
used from the Affymetrix extended exon array corresponding to the region 3’of the 
PARK7 SVA and over the minor TSS of the PARK7 gene with their location shown 
in Figure 5.1. Probe sets 2318734 and 2318735 demonstrated significant levels of 
expression within all the brain regions analysed. CRBL-cerebellum, FCTX-frontal 
cortex, HIPP-hippocampus, MEDU-medulla, OCTX-occipital cortex, PUTM-
putamen, SNIG-substantia nigra, TCTX-temporal cortex, THAL-thalamus, WHMT-
white matter. 
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5.4.4 Epigenetic modifications and transcription factor binding at the PARK7 
locus in SK-N-AS and MCF-7 cell lines 
 The histone marks and transcription factor binding across the major and 
minor promoters of the PARK7 gene and 5’ of the PARK7 SVA were analysed 
using ChIP. ChIP allows for the identification of proteins bound to DNA and histone 
modifications to interrogate the potential transcriptional activity that is present at 
specific loci, in this case in the two cell lines, SK-N-AS and MCF-7. The histone 
modifications of interest in this assay were active (H3K4m2) and inactive (H3K9m3) 
to determine chromatin state. The presence of histone 3 (H3) was used as a positive 
control for the ChIP protocol. The regions were also analysed for the presence of the 
following proteins; RNA polymerase II, nucleolin, Sp1, CTCF and hnRNPK. Sp1 
and hnRNPK in part were chosen due the model of regulation at the c-MYC gene at 
the NHE III1 involving G4 DNA (section 1.3.2 Figure 1.5) and Sp1 is known to 
regulate the expression of the PARK7 gene at the major promoter (Taira et al. 2001). 
Nucleolin has been identified as binding to G4 DNA and stabilising its formation, 
therefore this was included to determine potential G4 DNA structures in the region 
of the SVA (Gonzalez et al. 2009). Finally the binding of CTCF was determined due 
the sequence of the hexamer repeat of the SVA that would provide multiple binding 
sites for this transcription factor. A primer set for a region located in a gene desert 
where little or no transcription is likely to be occurring was used a negative control 
to ensure the binding seen was specific. This negative primer set was chosen as had 
been used previously by a group (Richard Young’s) in the analysis of the c-MYC 
promoter using ChIP. In both ChIP assays this negative primer set only showed the 
presence of inactive histone marks and H3 indicating this region is not an active 
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region for transcription and provides a good negative control for ensuring the 
binding of the antibodies is specific (Figure 5.4 and 5.5). 
 The ChIP data for the SK-N-AS cell line indicates that the major and minor 
PARK7 promoters are transcriptionally active in this cell line due to the presence of 
RNA Pol II, active histone modifications (H3K4m2) and the transcription factor Sp1. 
These factors are also shown to be present 5’ of the SVA and therefore the SVA is 
flanked by active histone marks indicating it is an active genomic locus and not 
silenced as might be hypothesised to prevent the retrotransposition of the element. 
The lack of nucleolin at this locus, binding of Sp1 and weak binding of hnRNPK 
would suggest there is no G4 formed at this time in this cell line. The presence of G4 
is associated with the repression of transcription therefore its absence at this locus is 
consistent with the active state of the region. The ChIP data for the MCF-7 cell line 
is incomplete due to problems occurring during the PCR analysis of the 
immunoprecipitated material. The amplification of immunoprecipitated material and 
sheared chromatin used as a positive control for the PCR over the major PARK7 
promoter was unsuccessful despite the successful amplification of the same target in 
genomic DNA from MCF-7 cells carried out at the same time. This PCR was 
completed multiple times with the same outcome. The reason for this occurrence is 
unclear but could indicate the major PARK7 promoter region is particularly 
susceptible to sonication and there were not an adequate number of fragments in the 
sonicated material of this region for amplification. However the ChIP was successful 
over the minor promoter and 5’of the SVA. The data showed active transcription at 
the minor PARK7 promoter region with the presence of RNA pol II, active histone 
marks, Sp1 and hnRNPK binding. The 5’ of the SVA did not show the same active 
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histone marks as in the SK-N-AS cell line with the lack of RNA pol II and Sp1 
binding and the inconclusive equal intensity of inactive and active histone marks. 
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Figure 5.4: Chromatin modifications and transcription factor binding indicates 
activity at both PARK7 TSSs and the 5’ of the PARK7 SVA in the SK-N-AS cell 
line. The presence of specific histone modifications, RNA polymerase II and the 
binding of transcription factors across the two PARK7 TSSs and 5’ of the SVA in 
the SK-N-AS cell line was assessed using ChIP.  
A – RNA pol II was shown to be present across the regions of the major and minor 
PARK7 TSS and upstream of the PARK7 SVA. Both active and inactive histone 
modifications were identified at all three loci but the intensity of the active marks 
was much greater indicating these regions contain active chromatin. There was no 
RNA polymerase II and active histone modifications detected at the negative primer 
set locus however the presence of histone 3 (H3) and inactive histone modifications 
were detected.  
B - There was binding of the transcription factor Sp1 at the two PARK7 TSSs and 5’ 
of the SVA but not at the negative primer set locus. There was weak binding of 
hnRNPK at the major PARK7 promoter and 5’ of the SVA. There was no binding of 
CTCF and nucleolin at all three loci.  
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Figure 5.5: Chromatin modifications and transcription factor binding at the 
minor TSS of the PARK7 gene and 5’ of the PARK7 SVA in MCF-7 cell line. 
The presence of specific histone modifications, RNA polymerase II and the binding 
of transcription factors across the minor PARK7 TSS and 5’ of the SVA in the MCF-
7 cell line was assessed using ChIP.  
A – The presence of RNA pol II and active histone modifications is identified across 
the minor promoter indicating this region is transcriptionally active. RNA pol II is 
absent from the 5’of the SVA indicating this region is not transcriptionally active. 
However the active and inactive histone marks show equal intensity and is therefore 
inconclusive. The negative primer set showed the presence of inactive histone marks 
and H3. 
B – There was binding of Sp1 and hnRNPK at the minor promoter which would 
indicate active transcription. There was also binding of hnRNPK in the 5’ region of 
the SVA which may indicate the occurrence of single stranded DNA at this locus. 
The faint bands seen for nucleolin and CTCF for the minor PARK7 promoter and 5’ 
of the SVA are at the same intensity at the no antibody control suggesting non-
specific binding of DNA to the beads during the ChIP protocol and should not 
therefore been associated with the binding of the factors CTCF and nucleolin. The 
negative control for the PCR shows this is not due to contamination in the PCR.  
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5.4.5 Analysis of gDNA from MCF-7 cell lines and breast cancer tumours may 
suggest a deletion at the locus of the PARK7 gene  
 The lower passage MCF-7 cell line were chosen to be used over the high 
passage cell line based on the expression of the PARK7 transcript, however the 
reason for the differences between the two lines of MCF-7s was unclear. In a 
preliminary experiment it was addressed whether this could be due to a deletion or 
rearrangement at the PARK7 gene locus. The two PARK7 promoter regions were 
analysed in the genomic DNA from both these MCF-7 cell lines, the SK-N-AS cell 
line and from ten breast cancer tumour samples. Both promoters were present in the 
SK-N-AS and the low passage MCF-7 cell line but this region could not be 
amplified in the high passage MCF-7 cell line (Figure 5.6A). The gDNA extraction 
of the high passage MCF-7 cell line was carried out three times on separate 
occasions and the same result was seen. The PARK7 gene locus was also amplified 
in two other cell lines available in the lab (SH-SY5Y and JAr) and was present (data 
not shown). The minor promoter was present in all ten of the tumour samples tested 
and the major promoter was identified in eight of the samples (Figure 5.6A). The 
major promoter PCR was carried out in total three times and the breast cancer 
tumour samples F1 and B2 did not contain a PCR product for that region.  
 To analyse the PARK7 gene locus further primers sets were designed within 
the 7kb that separated the two promoters and up to 6kb downstream of the major 
TSS of the PARK7 gene. These regions were amplified in the SK-N-AS and the two 
MCF-7 cell lines and three of the breast cancer tumour samples (F1, G1 and B2). All 
four loci amplified were present in the SK-N-AS and low passage MCF-7 cell line 
but not in the high passage MCF-7 cell line (Figure 5.3B). This indicates that there 
may have been a deletion on chromosome 1 where the PARK7 gene is located in the 
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high passage MCF-7 cell line and is not present in another line of MCF-7s. The three 
breast cancer tumour samples (F1, G1 and B2) tested for the presence of these four 
regions all contained PCR products of the correct size (Figure 5.6B), which included 
the two samples where the major promoter of the PARK7 gene was unable to be 
amplified. This suggested that much of the gene locus was intact apart from the 
region of the major promoter in the breast tumour samples F1 and B2. There may 
have been a deletion of that region or a mutation in the region corresponding to one 
of the primers used. Therefore another primer set for a larger fragment over the 
major PARK7 promoter (PCR product of 673bp) was used to determine which 
scenario seemed most likely. The region was present in the low passage MCF-7 cell 
line, SK-N-AS cell line and tumour sample G1 but was not present in tumour 
samples F1 and B2 and the low passage MCF-7 cell line (Figure 5.6C). This 
indicated there has been a small deletion of the major PARK7 promoter in the 
tumour samples F1 and B2 and the nature of this to be the subject of further analysis 
by the lab. 
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Figure 5.6: PARK7 gene locus is altered in a high passage MCF-7 cell line.  
A - The major PARK7 promoter is present within 8/10 breast cancer tumour 
samples, the SK-N-AS and low passage MCF-7 cell lines (expected product 270bp). 
For samples F1, G1 and B2 this was repeated in total 3 times to confirm the result. 
The minor PARK7 promoter was present in all 10 breast cancer tumour samples, the 
SK-N-AS and low passage MCF-7 cell lines (expected product 158bp).  
B - The PARK7 locus was analysed further due to the unexpected lack of PCR 
products for the major promoter in samples F1 and B2. Regions upstream and 
downstream of the major TSS were amplified to determine if a deletion of this locus 
had occurred. In the high passage MCF-7 cell line all the regions of interest could 
not be amplified indicating a deletion which would support the lack of PARK7 
mRNA in these cells. These regions up and downstream of the major PARK7 TSS 
were amplified in the breast tumour samples F1 and B2 that did not have a PCR 
product for the major promoter for PARK7.  
C – Amplification of a larger fragment surrounding the major promoter of the 
PARK7 gene in three tumour samples (F1, G1 and B2) and the three cell lines 
(2xMCF-7 and SK-N-AS). The expected PCR product was 673bp which is present in 
tumour sample G1 and the low passage MCF-7 and SK-N-AS cell lines. This would 
suggest that much of the gene locus is intact but there has been a deletion in the 
region of the major promoter. M1=low passage MCF-7 cell line, M2=high passage 
MCF-7 cell line, S=SK-N-AS cell line. W=water control.      
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5.4.6 Genotype profile of CEU HapMap cohort for the SVA upstream of the 
PARK7 gene 
Genotypic analysis of the PARK7 SVA identified four distinct alleles which 
were polymorphic in length, in 87 individuals from the CEU (Utah residents with 
Northern and Western European ancestry from the CEPH collection) HapMap 
cohort. An example image of the different alleles of the PARK7 SVA in the cohort is 
shown in figure 5.7A. The alleles are numbered from 1 to 4 from the shortest to the 
longest and the PCR products labelled with these numbers were gel extracted and 
cloned into an intermediate vector. This enabled the fragments to be sequenced to 
determine where the variation in this SVA was located and the plasmids generated 
were used in amplification of specific domains of the SVA. The intermediate vectors 
containing four alleles of the SVA were used as template to amplify the two 
repetitive regions of the SVA; the 5’ hexamer repeat and the central GC-rich domain. 
The central repetitive GC-rich domain was shown to be variable in length between 
alleles 1, 2 and 3 with this region in allele 4 running at the same size as in allele 3 
(Figure 5.7B). When the hexamer repeat was amplified from the alleles within the 
intermediate vector this was also shown to be variable between alleles 1, 2 and 4 
with allele 3 running at the same size as allele 2 (Figure 5.7C). This indicates that the 
central GC-rich repetitive region is the same size in alleles 3 and 4 and that the 
CCCTCT hexamer repeat is the same size in alleles 2 and 3.  
The sequence analysis of the four alleles confirmed the allelic variation was 
found to be generated by differences in the number of repeat units present in the 
CCCTCT hexamer repeat and in central GC-rich VNTR region. The hexamer repeat 
was either a 7, 10 or 13 repeat domain and was termed a hexamer VNTR.  The 
central VNTR domain of the younger SVA subtypes can be split into two domains 
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due to differences in the sequence of the repeat units. The sequence analysis revealed 
there was no variation observed in the number of repeats in the 5’ VNTR of the 
central dual VNTR region, which was a stable 12 copy variant of 37-40bp repeat 
length and therefore termed a tandem repeat (TR). Variation was observed in the 
second 3’ VNTR domain and consisted of either 10, 11 or 12 repeats with a repeat 
length of 37-52bp in this cohort. This is summarised in figure 5.7D.  
The genotype and allele frequencies of the CEU HapMap cohort are shown in 
Table 5.3A and B respectively. Alleles 1 and 3 were the most common within this 
cohort with 94% of the individuals having at least one of these alleles. HWE analysis 
was carried out for the PARK7 SVA locus in the CEU HapMap cohort showed it is 
not in HWE as the expected genotype frequencies were significantly different to the 
observed (p<0.05).  
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Figure 5.7: The PARK7 SVA has four alleles identified in a CEU HapMap 
cohort.   
A- Image of PARK7 SVA amplified in individuals from a CEU HapMap cohort and 
run on a 1% agarose gel. The four alleles are numbered 1-4 from smallest to longest. 
The products labelled 1-4 were extracted from the gel and cloned into an 
intermediate vector (pCR-Blunt) and sequenced.  
B – An image of the amplification of the central repetitive region of the intermediate 
vectors containing each of the four alleles. This central repetitive region has 3 alleles 
of different sizes with allele 3 and 4 containing a central repetitive region of the 
same length.  
C - An image of the amplification of the hexamer repeat of the intermediate vectors 
containing each of the four alleles. This hexamer repeat has 3 alleles of different 
sizes with allele 2 and 3 containing a hexamer repeat of the same length.  
D - Table displaying the number of repeats present within the three repetitive regions 
of the SVA. The 5’CCCTCT hexamer repeat termed hexamer VNTR was shown to 
have between 7 and 13 repeats across the four alleles. The next repetitive region was 
not variable between the four alleles and contained a stable 12 copies of its repeat. 
The second variable region was a GC-rich VNTR with 10-12 repeats 3’ of the TR 
region (see figure 5.9A for schematic of PARK7 SVA structure). 
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Table 5.3: Genotype and allele frequencies of individuals in the CEU HapMap 
cohort for the PARK7 SVA. A - Table showing the frequency of each genotype 
within the 87 individuals genotyped from the CEU HapMap cohort. B - Table 
showing the frequency of each allele within the CEU HapMap cohort. The PARK7 
SVA locus is not in HWE; p<0.05 
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5.4.7 Sequence of the SVA upstream of the PARK7 gene 
 The four alleles of the PARK7 SVA identified in individuals from the CEU 
HapMap were sequenced once cloned into the intermediate vector pCR-Blunt 
(2.2.5.1). The complete sequence of all four alleles of the SVA was obtained except 
for a portion of the Alu-like sequence of allele 4 as the sequencing proved difficult 
over the area after the CCCTCT hexamer repeat. The sequence of the SVA is shown 
in Figure 5.8. The additional repeats found in alleles 2-4 are underlined. The 
sequences that have G4 potential on either strand are highlighted in bold and these 
are located in the CCCTCT hexamer VNTR and the GC-rich VNTR. The sequences 
of SVAs contain many CG sites for methylation therefore the CG dinucleotides of 
the PARK7 SVA are in green to illustrate this. 
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TCCTCTCCCTCTCCCTCTCCCTCTCCCTCTCCCTCCTCTCCCTCTCCCTCTCCCTCTCCCTC
TCCCTCTCTCTCTCC 
ACGGTCTCCTTCCACGGTCTCCCTCTGATGCCGAGCCAAAGCTGGACGGTACTGCTGCCATC
TCGGCTCACTGCAACCTCCCTGCCTGATTCTCCTGCCTCAGCCTGCCGAGTGCCTGCGCACG
CCGCCACGCCTGACTGGTTTTCGTTTTTTTTTTTTGTGGAGACGGGGTTTTGCTGTGTTGGC
CGGGCTGGTCTCCAGCTCCTAACCACGAGTGATCCGCCAGCCTCGGCCTCCCGAGGTGCCGG
GATTGCAGACGGAGTCTCGTTCACTCAGTGCTCAATGGTGCCCAGGCTGGAGTGCAGTGGCG
TGATCTCGGCTCGCTACAACCTCCACCTCCCAGCCGCCTGCCTTGGCCCCCCAA 
AGTGCCGAGATTGCAGCCTCTGCCCAGCCGCCACCCCGTC 
TGGGAAGTGAGGAGCGTCTCTGCCTGGCCCCCCATCGTC 
TGGGATACGAGGAGCCTCTCTGCCTGGCTGCCCAGTC 
TGGAAAGTGAGGAGCGTCCCTGCCCGGCCGCCATCCCATC 
TAGGAAGCGAGGAGCGCCTCTTCCCCGCCGCCATCCCATC 
TAGGAAGTGAGGAGCGTCTCTGCCCGGCCACCCATCGTC 
TGAGATGTGGGGAGCACCTCTGCCCCGCCGCCCTGTC 
TGGGATGTGAGGAGCGCCTCTGCTGGGCCGCAACCCTGTC 
TGGGAGGTGAGGAGCGTCTCTGCCCGGCCGCCCCGTC 
TGAGAAGTGAGAAAACCCTCTGCCTGGCAACCGCCCCGTC 
TGAGAAGTGAGGAGCCCCTCCGTCCGGCAGCCACCCCGTC 
TGGGAAGTGAGGAGCGTCTCCGCCCGGCAGCCACCCCGTC 
 
TGGGAGGGAGGTGGGGGGGGGGTCAGCCCCCTGCCCGGCCAGCTGCCCTGTC 
CGGGAGGTGAGGGGCTCCTCTGCCCGGCCAGCCGCCCCGTC 
CGGGAGGGAGGTGGGGGGGTCAGCCCCCCGCCCGGCCAGCCGCCCCGTC 
CGGGAGGGAGGTGGGGGGATCAGCCCCCCGCCCGGCCAGCCGCCCCGTC 
CGGGAGGGAGGTGGGGGGTCAGCCCCCCGCCCGGCCAGCCGCCCCGTC 
CGGGAGGGAGGTGGGGGGATCAGCCCCCCGCCCGGCCAGCCGCCCCGTC 
CGGGAGGGAGGTGGGGGGGTCAGCCCCCCCGCCCGGCCAGCCGCCCTATC 
CAGGAGGTGAGGGGCGCCTCTGCCCGGCCGCCCCTAC 
TGGGAAGTGAGGAGCCCCTCTGCCTGGCCAGCCGCCCCGTC 
CGGGAGGGTGGTGGGGGGGTCAGCCCCCCGCCCGGCCAGCCGCCCCATC 
CGGGAGGTGAGGGGCGCTTCTGCCCGGCCGCCCCTAC 
TGGGAAGTGAGGAGCCCCTCTGCCCGGCCAGGACCCCGTC 
 
TGGGAGGTGTGCCCAGCGGCTCATTGGGGATGGGCCATGATGACAATGGCGGTTTTGTGGAA
TAGAAAGGCGGGAAGGGTGGGGAAAAAATTGAGAAATCGGATGGTTGCCGGGTCTGTGTGGA
TAGAAGTAGACATGGGAGACTTTTCATTTTGTTTTGTACTAAGAAAAATTTTTTTGCCTTGG
AAAAAAAAAAAAAAAAAAAAAAA  
Figure 5.8: Sequence of the PARK7 SVA. The complete sequence of the SVA 
upstream of the PARK7 gene is shown with the additional repeats found in the 
CCCTCT hexamer VNTR and the GC-rich VNTR of the different alleles underlined. 
The sequences that have the potential to form G4 DNA predicted by Quadparser 
software is shown in italics. SVAs are GC rich and the CGs in the sequence are 
coloured green to show the many potential sites for methylation.  
TR 
VNTR 
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5.4.8 Distinct components of the SVA upstream of the PARK7 gene shows 
differential activity in a reporter gene construct which is orientation dependant 
in the SK-N-AS and MCF-7 cell lines 
The ability of the intact PARK7 SVA and its distinct individual domains to 
act as transcriptional regulators was tested in a cell line model using the dual 
luciferase assay. SVA insertions can be found in the same, or opposite orientation to 
a gene locus. When analysed, 49.3% of the SVAs found within 10kb upstream of 
TSSs were on the same strand as the gene (Table 4.1), for this reason we also tested 
whether their function was orientation dependant. Eight reporter gene constructs 
were generated (Figure 5.9A) containing the following fragments in both forward 
and reverse orientations:  
 the whole SVA (SVA)  
 SVA with the SINE region deleted (SVAΔSINE) 
 central TR and VNTR (TR/VNTR) as a dual component due to the 
difficulties associated with designing a specific primer to clone the TR and 
VNTR individually  
 a 5’ truncation with only the CCCTCT hexamer, Alu-like sequence and 10 of 
the 12 repeats of the TR of allele 1 of the PARK7 SVA (truncated SVA) 
present  
SVAs are described as having a CCCTCT domain at their 5’ end and a poly A-tail at 
their 3’ end and this was used to define the forward orientation. The ability of the 
eight fragments to support reporter gene expression (luciferase) directed by a 
heterologous minimal promoter was tested in two cell lines, SK-N-AS and MCF-7.   
In the SK-N-AS cell line (Figure 5.9B) the intact PARK7 SVA in forward 
orientation did not alter the levels of reporter gene expression, when compared to the 
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minimal promoter alone (pGL3P) however when the SINE domain was deleted 
reporter gene activity was significantly enhanced (P<0.05). The TR/VNTR and the 
truncated SVA in the forward orientation acted to significantly repress luciferase 
activity when compared to the minimal promoter alone (pGL3P) (P<0.001, P<0.01 
respectively). When the domains were tested in the reverse orientation the reporter 
gene levels were all significantly different when compared to the levels seen in the 
forward orientation (SVA P<0.001, SVAΔSINE P<0.05, TR/VNTR P<0.05, 
truncated SVA P<0.01). The activity of the SVA and SVAΔSINE in reverse 
orientation were reduced compared to when in the forward orientation whereas the 
activity of the TR/VNTR and truncated SVA showed the opposite trend.  
The reporter gene constructs supported distinct reporter gene activity levels 
in the MCF-7 cell line when compared to that observed in the SK-N-AS cell line 
(Figure 5.9C). In the forward orientation the complete SVA had a significant 
increase in reporter gene activity in MCF-7 cells (P<0.01), distinct from its function 
in SK-N-AS, however similarly to SK-N-AS cells the SVAΔSINE showed the 
greatest ability to enhance reporter gene activity. In contrast the TR/VNTR showed 
similar activity to that of the minimal promoter alone. The truncated SVA acted as a 
repressor as it did in the SK-N-AS cell line (P<0.05). The domains in the reverse 
orientation all showed a significant difference to the activity of the domains in the 
forward orientation (SVA P<0.001, SVAΔSINE P<0.001, TR/VNTR P<0.001, 
truncated SVA P<0.01). The SVA, SVAΔSINE and TR/VNTR all showed decreased 
activity in the reverse orientation when compared to the domains in the forward 
orientation. The truncated SVA showed greater activity in the reverse orientation 
than when in the forward orientation. 
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Classical enhancers show similar functional properties in both orientations 
however the PARK7 SVA does not. Therefore the orientation of the SVA relative to 
the gene it has inserted near to could alter the affect of the SVA on transcription of 
the gene.  
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Figure 5.9: The PARK7 SVA showed the ability to affect expression in a 
reporter gene construct. A – Schematic showing the genomic structure of the 
PARK7 SVA and the relationship to the fragments tested in the reporter gene 
constructs. B - The average fold activity of the different fragments from the SVA 
tested in both forward and reverse orientation over the minimal SV40 promoter alone 
(pGL3P) in the SK-N-AS cell line. Data was normalised to compensate for 
transfection efficiency (N=4). C - The average fold activity in the MCF-7 cell line of 
the different fragments of the SVA in forward and reverse orientation over the 
minimal SV40 promoter alone (pGL3P) normalised to the internal control to account 
for transfection efficiency. N=4. One tailed t-test was used to measure significance 
of fold activity of PARK7 SVA fragments over SV40 minimal promoter alone 
(pGL3P) *P<0.05, **P<0.01, ***P<0.001 and to compare fold activity of forward 
and reverse orientations #P<0.05, ##P<0.01, ###P<0.001. 
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5.4.9 The PARK7 SVA did not display the ability to initiate transcription in a 
promoter less reporter gene vector in SK-N-AS and MCF-7 cell lines 
 The ability of the whole PARK7 SVA in forward and reverse orientations to 
initiate transcription was tested in the promoter less vector pGL3B in both the SK-N-
AS and MCF-7 cell lines (Figure 5.10). The activity of the SVA in the forward 
orientation was significantly increased over that of the pGL3B vector in both the SK-
N-AS and MCF-7 cell lines (P<0.01). Despite this increased activity I did not think 
to a great enough degree to determine that the SVA can act as promoter, compared to 
pGL3P. At the very low levels of expression observed in pGL3B the experiment is 
very sensitive to small changes which could occur from background.  Even though 
the pGL3B vector alone does not contain a promoter the bioluminescence from the 
luciferase assay was above that of background indicating minimal amount of 
transcription of the firefly luciferase reporter gene from spurious binding of RNA 
polymerases, which is 2-3% of that of the pGL3P vector containing the minimal 
SV40 promoter. Therefore the PARK7 SVA maybe enhancing this spurious activity 
when in the forward orientation. The SVA in the reverse orientation showed a 
significant decrease in activity over that of the pGL3B vector alone in both the SK-
N-AS and MCF-7 cell lines (P<0.01 and P<0.001 respectively).  However again due 
to the low levels of activity of the pGL3B vector this difference is most likely due to 
the SVA in the reverse orientation repressing this minor amount of transcription. In 
both cell lines there was a significant difference between the activity of the SVA in 
the forward and the reverse orientations (P<0.001). This data has been added for 
completeness but due to the low levels of expression in this assay the resulting fold 
changes of the constructs containing the SVA cannot determine that the SVA is 
acting as a promoter.  
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Figure 5.10: The PARK7 SVA did not display the ability to initiate 
transcription in a promoter less reporter gene vector. The average fold activity of 
the whole PARK7 SVA tested in both forward and reverse orientation over the 
promoter less vector pGL3B in the SK-N-AS and MCF-7 cell lines. Despite showing 
significant differences over the empty vector the SVA could not be defined as having 
promoter function as the fold activity change was low over the very low levels of 
background transcription occurring from the pGL3B vector. Data was normalised 
using an internal control to compensate for transfection efficiency. One tailed t-test 
was used to measure the significance of fold activity of the PARK7 SVA in each 
orientation over the promoter less vector pGL3B. **P<0.01, ***P<0.001 and to 
compare the activity of the SVA in the forward and reverse orientation to each other 
###P<0.001 N=4  
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5.4.10 Alleles of SVA upstream of the PARK7 gene show differential activity in 
a reporter gene construct in SK-N-AS and MCF-7 cell lines 
 The regulatory activity of the four alleles of the PARK7 SVA was tested in 
the pGL3P vector, which contains a minimal SV40 promoter, in the SK-N-AS and 
MCF-7 cell lines (Figure 5.11A). In the SK-N-AS cell line all four alleles showed a 
minor repressive function with allele 1, 3 and 4 with activity significantly below that 
of the pGL3P vector alone (P<0.05). The four alleles showed very similar levels of 
activity with a small but significant difference between alleles 1 and 3 and alleles 2 
and 3 (P<0.05) (Figure 5.11B). 
 All four alleles showed a differential level of activity in the MCF-7 cell line 
compared to in the SK-N-AS cell line (Figure 5.11A). Alleles 1, 3 and 4 showed 
similar activity to that of pGL3P alone and were not significantly different. Allele 2 
in the MCF-7 cell line showed the greatest activity of all the alleles and was 
significantly above that of pGL3P alone (P<0.01). There was a significant difference 
between the activity of allele 2 when compared to the activity of allele 1, 3 and 4, 
P<0.001, P<0.001, P<0.01 respectively (Figure 5.11B).   
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Figure 5.11: Reporter gene constructs containing alleles of the SVA upstream of 
PARK7 show differential activity in MCF-7 and SK-N-AS cell lines. A – The 
average fold activity of the reporter gene constructs containing the four alleles of the 
SVA over control vector pGL3P normalised to the internal control TK renilla in SK-
N-AS and MCF-7 cell lines. *P>0.05, **P>0.01 B – Table showing the significant 
difference in fold activity between the alleles of the SVA within SK-N-AS and 
MCF-7 cell lines. N=4 
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5.5 Discussion 
 The bioinformatic analysis of the PARK7 gene locus identified a human 
specific SVA D 8kb upstream of the start of transcription. In the UCSC genome 
browser the TSS of the PARK7 gene showed characteristics such as a CpG island, 
active histone marks and DNase 1 hypersensitivity clusters which were also present 
in the region less than 1kb downstream of the SVA and the browser Archive 
Ensembl predicted a transcript originating at this locus (Figure 5.1). This indicated a 
second putative TSS of the PARK7 gene adjacent to the SVA. The expression of the 
well characterised PARK7 transcripts originating from the major TSS were 
confirmed in the SK-N-AS human neuroblastoma cell line and the human 
adenocarcinoma MCF-7 cell line whereas as the predicted transcript originating near 
the SVA was only identified in the SK-N-AS cell line (Figure 6.2). The two TSSs of 
the PARK7 gene were named major (the already characterised promoter) and minor 
(the putative promoter). ENCODE data showing the state of the chromatin across 9 
different cell lines available in UCSC also indicated a tissue specific expression at 
the minor promoter but not at the major (Figure 6.3). The new transcript differs from 
the known transcripts by differential exon usage for exon 1 which is non-coding 
therefore would not result in differences at the protein level. However it may be the 
regulation of the expression of these transcripts which is more important with the 
two promoters differentially responding to environmental cues as noted by the tissue 
specific expression pattern of the new transcript.  
 ChIP data in the SK-N-AS cell line supports the finding that both of these 
promoters are active with the identification of active histone marks (H3K4m2), RNA 
polymerase II and Sp1 binding at both these sites (Figure 5.4). There is also evidence 
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of active chromatin at the 5’ of the PARK7 SVA indicating this region is not 
silenced as may have been assumed to prevent this element from undergoing 
retrotransposition. The ChIP data from the MCF-7 cell line is inconclusive due to 
problems amplifying the major promoter in the sheared chromatin. Although there is 
evidence of transcriptional activity at the minor promoter the expression of the new 
PARK7 transcript was not identified in this particular cell line, this may be due to 
the presence of ESTs in this region. Affymetrix probe array data, carried out by a 
collaborator Mina Ryten, also confirmed expression occurring at this locus in several 
human brain regions (Table 5.1 and 5.2). This may not directly correspond to the 
new transcript but does confirm there is active transcription at this locus.  
 Retrotransposons have been thought to be silenced through mechanisms such 
as methylation to prevent their retrotransposition; however the data shown for the 
PARK7 SVA locus in the UCSC genome browser and the analysis of the transcripts 
of the PARK7 gene (5.4.1 and 5.4.2) indicate that the region near to the SVA is 
transcriptionally active and not silent at least in cell lines. This preliminary analysis 
identified another transcript of the PARK7 gene that originates close to the PARK7 
SVA (within 750bp) that was predicted by the Archive Ensembl browser. Further 
bioinformatic analysis determined there are 172 SVAs in the human genome within 
1kb upstream of Archive Ensembl predicted transcripts compared to the 58 SVAs 
within 1kb of known genes. The confirmation of the existence of this new PARK7 
transcript indicates there could be other mRNAs originating close to SVAs that are 
yet to be identified. There are also 1248 Affymetrix extended probe sets located 
within 1kb up or downstream of 729 different SVAs which could be used to 
characterise expression patterns in those regions as seen for the PARK7 SVA. 
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 Four alleles of the PARK7 SVA were identified in the CEU HapMap cohort 
(Figure 5.7). The PARK7 SVA shared similar characteristics as the FUS SVA in 
terms of the central repetitive region in which there was a TR and a VNTR. However 
the PARK7 SVA not only showed variation in the number of repeats in this central 
VNTR as was observed for FUS SVA but also in the CCCTCT hexamer repeat 
therefore this was termed a hexamer VNTR. The genetic variation at this locus 
provides potential for differential function and association with disease. 
 The ability of the PARK7 SVA to act as a transcriptional regulator in a 
classical reporter gene model was analysed similar to the assay carried out for the 
FUS SVA in chapter 3 section 3.4.3. Different sized fragments of the PARK7 SVA 
were tested in a reporter gene vector with a minimal promoter to determine the 
domains of the SVA may influence gene expression as were the four alleles of the 
SVA. The activity of these constructs was tested in both the SK-N-AS and MCF-7 
cell lines. The TR/VNTR showed differential properties between the two cell lines; 
in the SK-N-AS the TR/VNTR showed repressive qualities whereas in the MCF-7 
this construct showed activity just above that of the minimal promoter. The complete 
SVA showed no activity in the SK-N-AS cell line but enhanced reporter gene 
expression in MCF-7 cells. Interestingly the deletion of the SINE element from the 
SVA fragment resulted in significantly higher levels of reporter gene expression than 
the SVA alone in both cell lines which was consistent with the loss of the SINE from 
the FUS SVA resulting in increased reporter gene activity in the SK-N-AS cell line. 
There are therefore probably a minimum of three distinct functional elements in the 
PARK7 SVA that adjust its ability to modulate expression, the central TR/VNTR, 
SINE and the CCCTCT and Alu-like sequences. The activity of the constructs 
showed an orientation dependency and therefore the orientation of SVAs relative to 
182 
 
genes may affect how they could impact on gene expression. The data on the central 
TR/VNTR indicated they support distinct transcriptional properties dependent on 
cell type. This is consistent with the action of VNTRs we have previously observed 
in the human serotonin and dopamine transporter genes (Guindalini et al. 2006; 
Haddley et al. 2008; Ali et al. 2010; Vasiliou et al. 2012) with different complements 
of transcription factors present in both these cell lines responsible for the activity of 
the reporter gene directed by the TR/VNTR. The four alleles of the PARK7 SVA 
showed very similar activity to each other in the SK-N-AS cell line. In the MCF-7 
cell line allele 2 showed the greatest activity and was significantly different to all the 
other 3 alleles. The alleles may show greater functional differences in response to 
challenge than under basal conditions. In an attempt to identify if the PARK7 SVA 
can initiate transcription itself the whole SVA was tested in a promoter less reporter 
gene construct in which the SVA did not display the ability to act as a promoter. 
 The differences in the expression of the PARK7 gene between two different 
passages of MCF-7 cell lines led to the identification of a large deletion of the 
PARK7 locus in the higher passage cells. A deletion across the major promoter of 
the PARK7 gene was also indicated in two out of ten breast tumour samples 
obtained from the Liverpool Cancer Tissue Bank (Figure 5.6). The exact nature of 
this deletion is yet to confirmed but further analysis is to be completed by the 
research group, for example if this variant is present in the population or is the 
consequence of  a deletion during the tumourigenic process. In the literature there 
have been examples of variants in the promoter region of the PARK7 gene but these 
could not explain the finding observed in the tumour samples. There is a 18bp 
insertion/deletion polymorphism is located in the promoter region of PARK7 and a 
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16bp deletion across the major TSS of the PARK7 gene was identified in a South 
African PD patient (Eerola et al. 2003; Keyser et al. 2009).  
 This chapter analysed the PARK7 SVA in detail, demonstrated its ability to 
differentially affect transcription within a reporter gene construct in two different 
cell lines with multiple regulatory domains. A new transcript of the PARK7 gene 
was identified originating within 1kb of the SVA with tissue specific expression. 
Active histone marks, RNA polymerase II and Sp1 binding was determined in the 
region of both PARK7 promoters and 5’ of the SVA in the SK-N-AS cell line 
supporting the hypothesis that the region of the PARK7 SVA is active and is not 
transcriptionally silenced. The genetic variation of the PARK7 SVA also provides 
potential functional differences between individuals and this variation would be 
important to be assessed in terms of association with disease.  
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Chapter 6 
Can SVAs provide novel biomarkers for disease? 
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6.1 Introduction 
 There were 2676 SVAs identified in the Hg19 with a preference for inserting 
into genic regions (chapter 4) with two of these elements demonstrating the ability to 
affect transcription in a reporter gene model in vitro and one of these element tested 
demonstrated this ability in vivo as well (chapter 3 and 5). Two approaches were 
undertaken in an attempt to functionally group sets of these elements and identify 
potential genetic markers linked to disease through the analysis of the PARK7’s 
primary sequence and the presence of SVAs in genes linked to the same disease.   
  The primary sequence of an element can define potential function such as 
methylation state and secondary structure formation (discussed for SVAs in chapter 
4) but also the transcription factors that could bind. Of particular interest to me in 
that regard were the repetitive domains of the SVA, such as the central VNTR, as 
this would provide multiple transcription factor (TF) binding sites. It is hypothesised 
that weak binding sites that are repeated several times can maintain the presence of a 
TF better than a single site as when a TF dissociates from its binding site it scans the 
neighbouring region of DNA for additional sites before completely leaving that 
section of DNA (Breen et al. 2008). For example the VNTR located within intron 2 
of the serotonin transporter gene has been shown to bind the TF YB-1 and CTCF and 
the transcriptional properties of this VNTR and its alleles are differentially regulated 
by the action of theses TF in vitro (Klenova et al. 2004; Roberts et al. 2007). SVAs 
are located throughout the human genome and share similar primary sequence 
therefore could provide multiple loci that could bind and respond to similar TFs. The 
sequences of the repeat units of the central VNTR of the SVAs are imperfect and 
vary, most notably the presence of two VNTR domains, especially in the younger 
SVAs, that have distinct sequences. Therefore three of the repeat units of the PARK7 
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SVA were taken and used to search the genome for other SVAs with high homology 
for these specific sequences to identify other SVAs and the genes they are near. The 
genes generated from this list would be analysed for their potential to be linked in 
networks and response to specific TFs and if these same TFs may modulate the SVA 
to identify TF pathways that link the SVAs with a subset of target genes. This model 
will use the nearest gene to the SVA as the target gene however the SVAs do not 
have only modulate the nearest but provides a good starting point. 
 The second method of creating a subset of SVAs involved the analyses of a 
list of genes related in a disease process. Mutations in the PARK7 gene have been 
linked to Parkinson’s disease (PD) along with many other genes, including α 
synuclein (SNCA), parkin (PARK2) and leucine repeat rich kinase 2 (LRRK2) 
(Corti et al. 2011). The mutations within these genes cause autosomal dominant 
(SNCA, LRRK2) or recessive PD (PARK2 and PARK7) with their own particular 
disease progression and onset (Houlden and Singleton 2012). PD is a 
neurodegenerative disease associated with the loss of dopamine producing neurons 
in the substantia nigra pars compacta with symptoms only becoming apparent when 
70-80% of nigrostriatal terminals have been lost (Bernheimer et al. 1973). PD affects 
0.5-1% of people aged 65-69 and 1-3% of those aged over 80 (Nussbaum and Ellis 
2003) with 5-10% of these patients carrying a mutation in one of the known disease 
causing genes (Corti et al. 2011). The vast majority of PD cases are sporadic and are 
due to a combination of genetic and environmental factors (Migliore and Coppede 
2009). Since the identification of the mutations in the SNCA causing PD 
(Polymeropoulos et al. 1997) there have been hundreds of studies to identify 
mutation in genes linked to familial PD and to identify genetic variants that are risks 
for sporadic PD (Coppede 2012). A list of known PD causing genes were taken from 
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a review on the genetics of PD (Corti et al. 2011) and UCSC genome browser was 
used to determine if a SVA was present within those genes or their flanking region. 
This could provide novel genetic variation within these genes and it may be 
important to consider genetic variants across several genes in disease association 
studies. It could be a combination of genetic variants in a pathway that confer a risk 
for a specific disease; for example specific alleles of the VNTR within the 3’UTR of 
the SLC6A3 gene and a VNTR within the dopamine 4 receptor (DRD4) in 
combination are considered a risk for attention deficit hyperactivity disorder but 
these genotypes do not show the same association when analysed on their own 
(Carrasco et al. 2006). The presence of SVAs in PD genes may affect the 
transcriptional regulation of the gene through binding of TFs, secondary structure 
formation, introduction of new splice sites, transcription pausing at their poly A tail 
and differential methylation patterns. An SVA insertion in the TAF1 gene has been 
linked to a disease with parkinsonism (X-linked dystonia-parkinsonism) in a 
Philippine cohort through differential methylation of this element in the caudate 
nucleus of sufferers resulting in reduced mRNA reduction of TAF1 (Makino et al. 
2007). Differential methylation state of PD genes has also been shown in specific 
brain regions; decreased methylation of intron 1 of the SNCA was identified in the 
substantia nigra, putamen and cortex of patients with sporadic PD indicating a role 
for epigenetic regulation of gene expression in PD (Jowaed et al. 2010). Genetic 
variation of the elements, including both variants in copy number within the VNTR 
and the absence or presence of these elements, could result in differential response to 
their environment in a tissue specific manner.  
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6.2 Aims  
 Use two different approaches to analyse the potential role of SVAs across 
networks of genes; firstly use the primary sequence of the PARK7 SVA in 
search of other SVAs within the genome and secondly take a known group of 
genes associated with PD and determine how many contain a SVA. 
Section A 
 Analyse the primary sequence of the PARK7 SVA to identify potential 
transcription factors that may act on the domain and how this may be linked 
in networks across genes with SVAs near their locus.  
 Expand on the bioinformatic data generated to test the hypothesis how 
transcription factors may regulate endogenous gene expression and 
potentially influence regulatory properties of the SVA as well, using the 
oestrogen receptor alpha as an example.  
 Determine if the genetic variation of the PARK7 SVA is associated with a 
disease cohort of breast cancer patients with wild-type BRCA genes.  
Section B 
 To use a list of PD associated genes from Corti et al 2011 to determine how 
many contain a SVA. 
 Analyse the genetic variation of any SVAs identified within the gene loci.  
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6.3 Methods 
6.3.1 Identification of other SVAs containing similar repeat unit sequence to the 
PARK7 SVA 
 The primary sequence of the central repetitive region of the PARK7 SVA 
was used to identify potentially similar SVAs based on the TR and VNTR repeat 
unit sequences. The Blat search tool on the UCSC genome browser was used to 
search the whole genome for the sequences of interest. The Blat tool results provided 
the locus of the sequence identified within the genome, the percentage homology of 
the sequence compared to the original query sequence and the number of bases that 
the sequence spans. The sequences from the TR and VNTR shown in Figure 6.1 
were chosen as they contained features consistent throughout many of the repeat 
units of those repetitive regions.  
 The results from each Blat search were removed if they didn’t reach the 
following criteria: at least 90% homology with the original sequence and to have a 
score and span of +/- 15% of the length of the original sequence. After the 
exclusions 178 SVAs containing the repeat sequence from the TR, 168 SVAs 
containing the repeat sequence from the VNTR and 94 SVAs containing the 
sequence of the junction of the TR and VNTR remained.  The results from all three 
Blat searches were then aligned to generate a list of SVAs containing the repeat units 
from the TR and VNTR of the PARK7 SVA, however there were no SVAs 
containing all the threes repeat sequences when using the criteria previously 
described.  
 The loci of these SVAs were analysed for the genes within 100kb of them. 
The loci of the gene, the strand the gene was located on and the distance of the SVA 
from gene was recorded.  
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Figure 6.1: Schematic of the PARK7 SVA and sequences used in the Blat search 
analysis. The structure of the PARK7 SVA and the sequence of the repeat units used 
in the Blat search analysis.  
 
6.3.2 Pathway analysis of genes containing SVAs with similar repeat unit 
sequence to the PARK7 SVA 
 Using the analytical program MetaCore from Thomson Reuters 
(https://portal.genego.com/) the list of genes generated from the search in 6.3.1 was 
analysed for potential regulatory factors and interactions within pathways. The 
MetaCore software can be used to analyse experimental data or gene lists to look for 
protein-protein, protein-DNA and protein-compound interactions. It highlights 
pathways that may be enriched for your genes of interest how they are interacting 
with one another.  
 The gene list was uploaded and analysed using the transcription regulation 
tool which generated a list of transcription factors that regulated or were regulated by 
the list of genes generated. The list was also analysed to determine the pathway these 
genes are linked in using the build network tool. This tool allows the user to analyse 
direct interactions of their chosen genes or indirect interactions that may involve one 
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or more factors separating your genes of interest. For this particular list of genes the 
pathway analysis was completed for interactions within two steps, therefore there 
would be at most one factor between the genes in the network. The resulting network 
would not be too complex for analysis but would allow identification of common 
pathways involving these genes.   
 To complement the transcription factor regulation data for the gene lists the 
sequence of the PARK7 SVA was analysed for predicted transcription factor binding 
sites using PROMO software to determine if any of these factors may overlap. The 
PROMO program available on the internet (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) and is a virtual laboratory for 
the study of transcription factor binding sites in DNA sequences and uses the 
TRANSFAC 8.3 database (Messeguer et al. 2002; Farre et al. 2003).  
 
6.3.3 Analysis of endogenous gene response to 17-β-estradiol in the MCF-7 cell 
line 
 MCF-7 cells (low passage, see chapter 5) were maintained in normal media 
in T175 flasks (2.1.4.2). For treatment with 17-β-estradiol the growth media of the 
cells was replaced with phenol red free and charcoal stripped media (2.1.4.3) for two 
days. The cells were then counted (2.2.2.2) and plated into 6-well plates (400000 
cells per well) to complete the experiment in triplicate and left for 24hrs. The media 
was then changed for each well and replaced with either fresh media, media 
containing 1µl/ml of molecular grade ethanol or media with 10nM of 17-β-estradiol 
(dissolved in molecular grade ethanol). 1µl/ml of molecular grade ethanol was used 
as this was the same volume that was added for the 17-β-estradiol to test the effect of 
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the vehicle of the stimulus. The cells were then incubated for 18hrs and RNA 
extracted for analysis of endogenous gene expression (2.2.3). Several genes were 
analysed including the housekeeping gene β-actin, a known oestrogen responsive 
gene trefoil factor 1(TFF1), and test genes of interest (PARK7, MAN1C1 and TFPI). 
GoTaq flexi polymerase was used in the amplification of these targets (2.2.3.3.2) and 
the conditions for each primer set are detailed in Table A1 of the appendix. The PCR 
products were run on 1.2-1.5% agarose gels for analysis (2.2.3.4).  
 
6.3.4 Analysis of the response of reporter gene plasmids to 17-β-estradiol in the 
MCF-7 cell line 
 The MCF-7 cells were grown in normal media (2.1.4.2) in T175 flasks until 
two days prior to being plated into 24 well plates the media was changed for phenol 
red free media with charcoal stripped serum, to remove steroid hormones (2.1.4.3) 
which the cells were maintained in for the remainder of the experiment. The cells 
were transfected and the dual luciferase assay performed as outlined in 2.2.6. 
However for the 17-β-estradiol treatment when the media was to be changed 4hrs 
after transfection it was replaced with either fresh media for the basal condition, 
media containing 1µl/ml of molecular grade ethanol for the vehicle control or media 
with 10nM of 17-β-estradiol (dissolved in molecular grade ethanol) and incubated 
with the cells for 18hrs. The media was then changed again after 18hrs with fresh 
media and the dual luciferase assay was performed 48hrs after the cells had been 
transfected.   
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6.3.5 Genotyping the PARK7 SVA in a breast cancer cohort without BRCA 
mutations 
The PARK7 SVA was genotyped in the breast cancer BRCA wild-type and 
matched female control cohort from the National Genetics References Laboratory, St 
Mary’s Hospital, Manchester with 5ng of gDNA as template. The controls were sex 
matched to the breast cancer samples and screened for BRCA mutations. The final 
concentration of betaine for this PCR was optimised at 1M, which was higher than 
previously used. The data set was also analysed to determine if the PARK7 SVA 
locus was in HWE. 
 
6.3.6 Identification of tagging SNPs for the PARK7 SVA alleles in the HapMap 
cohort 
 In the identification of tagging SNPs for the PARK7 SVA alleles the same 
method was used as for the FUS loci for SNPs that would tag the FUS SVA (section 
3.3.4). The genotype of the individuals from the CEU HapMap cohort for the 
PARK7 SVA was used in conjunction with the SNP data available for the PARK7 
locus. Four ‘SNPs’ were created for the four alleles of the PARK7 SVA and the 
genotype of each individual for the PARK7 SVA was converted into the genotypes 
of these ‘SNPs’. The genotype data for the individuals in the CEU HapMap cohort 
for the SNPs 200kb either side of the PARK7 SVA were downloaded from the 
International HapMap database (http://hapmap.ncbi.nlm.nih.gov/) using release 28. 
The ‘SNP’ genotypes for the PARK7 SVA were inserted into this data at the locus 
corresponding to the SVA. This was then uploaded into Haploview for linkage 
analysis. All the genotyped individuals’ data for all four alleles of the SVA were 
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uploaded and then separately the data for just the individuals that had allele 1 and/or 
3 of the SVA (the most common alleles).  
 
6.3.7 Identification of Parkinson’s disease causing genes containing a SVA 
within 10kb 
 A list of Parkinson’s disease associated genes was taken from table 1 of Corti 
et al 2011 and UCSC genome browser was used to identify if a SVA was present 
within the gene or up to 10kb in its flanking region. The SVA subtype and relative 
position and orientation to the gene were recorded.  
 
6.3.8 Amplification of the PARK2 SVA  
 The SVA F within an intron of the PARK2 gene was amplified using GoTaq 
polymerase (master mix outlined in 2.2.3.3.2) with the addition of betaine at a final 
concentration of 1M. 10ng of gDNA from the CEU HapMap cohort was used as 
template in the reaction. The primer set and cycling conditions can be found in Table 
A1 of the appendix. The PCR products were run on a 1% agarose gel (2.2.3.4).  
 
6.3.9 Amplification of the LRRK2 SVA  
 KOD Hot Start polymerase (2.2.4.1) was used to amplify the SVA C located 
within an intron of the LRRK2 gene with the addition betaine to a final concentration 
of 1M. 1ng of gDNA from individuals in the CEU HapMap cohort was used as 
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template. The PCR products were run on a 1% agarose gel (2.2.3.4). The primers and 
cycling conditions are shown in Table A1 of the appendix. 
 
6.3.10 Amplification of the TAF1 SVA  
 The SVA located within intron 32 of the TAF1 gene that is present in the 
UCSC genome browser was amplified using KOD Hot Start polymerase as outlined 
in 2.2.4.1 however the MgSO4 was optimised to a final concentration of 2mM and 
betaine was added to a final concentration of 1M. 1ng of gDNA from the CEU 
HapMap cohort was used as template for the reaction. The PCR products were run 
on a 1% agarose gel (2.2.3.4). The primers and cycling conditions are shown in 
Table A1 of the appendix. 
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6.4 Results 
Section A 
6.4.1 List of genes within 100kb of a SVA sharing similar primary sequence to 
specific repeat units of the TR/VNTR of the PARK7 SVA 
 As outlined in section 6.3.1 a list of 19 SVAs with repetitive central domains 
that shared homology to specific repeats of the TR/VNTR of the PARK7 SVA were 
identified and the genes within 100kb of these SVAs were recorded and are shown in 
Table 6.1. Regulatory domains for genes can be located considerable distances from 
the genes they regulate (Shanley et al. 2010; Shanley et al. 2011), however the 
nearest gene within 100kb of the SVA up and downstream was chosen as this would 
provide a manageable number of genes for this preliminary analysis and would 
include the genes closest to the SVA. The majority of these SVAs were from the 
subtype D with three from each subtype E and F. All except one of these SVAs were 
human specific; the SVA within ZNF670-ZNF695 was also found in the chimpanzee 
genome according to the UCSC genome browser. The length of the repetitive 
domains between each of these individual SVAs varied, this is not a polymorphic 
range but the differences in size of SVA insertions at different loci. The hexamer 
repeat at the 5’ end of each of the SVAs ranged from 4-20 repeat units in length with 
three SVAs without a hexamer domain. The domain termed a TR in the PARK7 
SVA ranged from 10-13 repeat units and the domain termed a VNTR ranged from 5-
25 repeat units in length across the 19 SVAs. There were 32 genes identified that 
were within 100kb of the 19 SVAs and the SVAs were found in a range of distances 
up or downstream of the genes and intronically. For simplicity this list of genes will 
be referred to as the SVA gene list.  
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Chr Start Stop Size Subtype Gene Upstream Downstream Intronic 
1 8012111 8013640 1529 
SVA D 
(+) 
PARK7 (+) 
TNFRSF9 
(-) 
8kb 
9kb 
- 
- 
- 
- 
1 21141242 21143749 2507 
SVA E 
(+) 
EIF4G3 (-) 
HP1BP3  
(-) 
- 
28kb 
- 
- 
Y 
- 
1 25929721 25931433 1712 
SVA D 
(+) 
MAN1C1 
(+) 
LDLRAP1 
(+) 
12kb 
- 
- 
34kb 
- 
- 
1 26921936 26924007 2071 
SVA D 
(+) 
RPS6KA1 
(+) 
ARID1A 
(+) 
- 
99kb 
20kb 
- 
- 
- 
1 37545339 37547744 2405 
SVA D 
(+) 
GRIK3 (-) 45kb - - 
1 39699459 39701100 1641 
SVA F 
(-) 
MACF1 (+) - - Y 
1 46189629 46191758 2129 
SVA E 
(+) 
IPP (-) 
TMEM69 
(+) 
GPBP1L1 
(-) 
- 
- 
37kb 
- 
30kb 
- 
Y 
- 
- 
1 63938105 63940580 2475 
SVA D 
(+) 
ITGB3BP 
(-) 
ALG6 (+) 
EFCAB7 
(+) 
- 
- 
48kb 
- 
34kb 
- 
Y 
- 
- 
1 112149661 112151498 1837 
SVA D 
(-) 
RAP1A (+) 
 
ADORA3  
(-) 
11kb of 
transcripts 
1 and 3 
 
43kb 
 
- 
 
 
- 
Y 
 transcript 2 
 
 
- 
 
1 170387365 170389034 1669 
SVA D 
(+) 
- - - - 
1 176364624 176366749 2125 
SVA D 
(-) 
PAPPA2 
(+) 
- 66kb - 
1 206276044 206278006 1962 
SVA D 
(-) 
C1orf186  
(-) 
CTSE (+) 
AVPR1B 
(+) 
- 
39kb 
- 
- 
- 
45kb 
Y 
- 
- 
1 227897703 227899534 1831 
SVA D 
(-) 
ZNF678 
(+) 
SNAP47 
(+) 
JMJD4 (-) 
- 
 
17-23kb 
- 
48kb 
 
- 
19kb 
Y 
- 
- 
1 247194849 247196269 1420 
SVA D 
(+) 
ZNF670-
ZNF695 (-) 
ZNF670 (-) 
ZNF695 (-) 
- 
 
- 
23kb 
- 
 
2kb 
- 
Y 
 
- 
- 
2 11042073 11044034 1961 
SVA D 
(-) 
KCNF1 (+) 
PDIA6 (-) 
8kb 
64-89kb 
- 
- 
- 
- 
2 42831720 42834257 2537 
SVA F 
(-) 
MTA3 (+) - - Y 
2 63948844 63950437 1593 
SVA F 
(+) 
- - - - 
2 188420653 188422627 1974 
SVA D 
(+) 
TFPI (-) 1kb - - 
4 109329937 109331742 1805 
SVA E 
(+) 
- - - - 
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Table 6.1: Table showing the SVAs that share the repeat sequence from the TR 
and VNTR of the PARK7 SVA and the genes that are within 100kb of these 
SVAs. This includes the chromosomal location, size, subtype of the SVA and the 
relative loci of the genes within 100kb of these genes. The SVAs without a gene 
listed are not within a 100kb of a gene. (+) – located on sense strand, (-) – located on 
antisense strand. See list below for full name of each gene.  
Gene ID Gene Name 
PARK7 (DJ-1) Parkinson protein 7 
TNFRSF9 tumour necrosis factor receptor superfamily, member 9 
EIF4G3 eukaryotic translation initiation factor 4 gamma 3 
HP1BP1 heterochromatin protein 1 binding protein 3 
MAN1C1 mannosidase, alpha, class 1C, member 1 
LDLRAP1 (ARH) low density lipoprotein receptor adaptor protein 
RPS6KA1 (p90RSK1) ribosomal protein S6 kinase, 90kDa, polypeptide 1 
ARID1A (BAF250) AT rich interactive domain 1A (SWI-like) 
GRIK3 (GluR7) glutamate receptor, ionotropic, kainate 3 
MACF1 microtubule-actin crosslinking factor 1 
IPP intracisternal A particle-promoted polypeptide 
TMEM69 transmembrane protein 69 
GPBP1L1 GC rich promoter binding protein 1 like 1 
ITGB3BP (NRIF3) integrin beta 3 binding protein (beta3-endonexin) 
ALG6 alpha 1,3 glucosyltransferase, 
EFCAB7 EF hand calcium binding domain 7 
RAP1A member of RAS oncogene family 
ADORA3 adenosine A3 receptor 
PAPPA2 pappalysin 2 
C1orf186 chromosome 1 open reading frame 186 
CTSE cathepsin E 
AVPR1B arginine vasopressin receptor 1B 
ZNF678 zinc finger protein 678 
SNAP47 synaptosomal-associated protein, 47kDa 
JMJD4 jumonji domain containing 4 
ZNF670-ZNF695 ZNF670-ZNF695 readthrough 
KCNF1 (Kv5.1) potassium voltage-gated channel, subfamily F, member 1 
PDIA6 (ERP5) protein disulfide isomerase family A, member 6 
MTA3 metastasis associated 1 family, member 3 
TFPI tissue factor pathway inhibitor 
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6.4.2 Transcriptional regulation and pathway analysis of the genes from the 
SVA gene list  
 The MetaCore program from Thomson Reuters was used to determine if the 
genes from the SVA gene list were linked by similar transcriptional regulation or 
within specific pathways. The analysis of the transcriptional regulation of these 
genes generated a list of 31 networks involving transcription factors and the genes 
uploaded. The top five of these networks were listed in Table 6.2 and include the 
transcription factors CREB1, ESR1, Sp1, GCR alpha and PR. It is interesting to note 
that three of these factors (ESR1, PR and GCR alpha) are regulated through 
hormones and that CREB1 can induce transcription of genes in response to hormonal 
stimulation of the cAMP pathway. 15 genes from the SVA gene list are regulated by 
these factors or regulate the factors themselves and are listed in the final two 
columns of Table 6.2.  
 The SVA gene list was then analysed to determine pathways linking these 
genes within two steps of each other. 14 of these genes were identified to be linked 
through pathways using this analysis and are shown circled in blue in Figure 6.2. 
Two of the transcription factors listed in table 6.2 (CREB1 and ESR1) are also 
shown in this pathway. 
 The repetitive nature of the sequence of SVAs could provide multiple 
sequence specific transcription factor binding sites within the genome if the region 
was not ‘silenced’ and available for interaction with such transcription factors. 
Therefore these SVAs could potentially be involved in gene regulation through the 
binding of these factors. The sequence of the PARK7 SVA was analysed using the 
PROMO software to predict transcription factor binding sites (Figure 6.3A). 62 
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different transcription factors had predicted binding sites within the PARK7 SVA 
sequence; many of these had multiple predicted binding sites. Four of the top five 
transcription factors regulating the genes from the SVA gene list (Table 6.2) had 
predicted binding sites within the SVA sequence and are boxed in red (Figure 6.3A) 
(ESR1, Sp1, GCR alpha and PR). The specific sequence of the three repeat units 
used in the Blat search (section 6.3.1) were also analysed for predicted transcription 
factor binding (Figure 6.3B) and 19 factors had predicted binding sites. Sp1, ESR1 
and GCR alpha (boxed in red in Figure 6.3B) that regulate the genes from the SVA 
gene list were found to potentially bind to the SVA sequence. 
 This bioinformatic analysis of factors that regulate a number of genes from 
the SVA gene list and predicted transcription factor binding sites within the SVA 
itself provided a list of factors that may regulate these genes and have the potential to 
alter transcription through binding to the SVA. The potential for ESR1 to regulate 
both the endogenous PARK7 gene and the ability of the PARK7 SVA to alter 
transcription in a reporter gene model was chosen out of the list of transcription 
factors (Table 6.2) to be investigated in a cell line model. ESR1 was chosen for 
several reasons: it was shown to regulate several genes on the SVA gene list and 
there are predicted half sites of the palindromic oestrogen response elements (ERE) 
in the sequence of the SVA, the response of MCF-7 cells to oestrogen is widely used 
in the literature as they are oestrogen responsive and PARK7 is reported in the 
literature to be associated with breast cancer therefore the oestrogen pathway could 
potentially be a important in the modulation of this gene.  
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Table 6.2: Data generated on the transcriptional regulation of the gene list from 
table 6.1 using MetaCore. The table lists the top five transcription factors that 
regulate or are regulated by the genes generated by sequence analysis of the PARK7 
SVA TR/VNTR when analysed using MetaCore. CREB1 - cAMP responsive 
element binding protein 1, Sp1 – specificity protein 1, ESR1 – oestrogen receptor 1, 
GCR alpha – glucocorticoid receptor alpha, PR – progesterone receptor, TF – 
transcription factor. PARK7 is referred to as DJ-1 in the MetaCore software. 
 
 
 
 
 
 
 
 
Network 
Total 
nodes 
Seed 
nodes 
p-Value 
Genes regulated by 
TF 
Genes regulating 
the TF 
1 
CREB1 9 8 1.770E-27 
DJ-1, MTA3, 
p90RSK1, GluR7, 
ADORA3, JMJD4, 
Kv5.1, PAPPA2 
p90RSK1 
2 
ESR1 
(nuclear) 
7 6 1.550E-20 
ERP5, MTA3, 
GluR7, ADORA3 
p90RSK1, NRIF3 
3 
Sp1 5 4 1.020E-13 
DJ-1, MTA3, 
ADORA3, CTSE 
- 
4 
GCR-
alpha 
4 3 2.300E-10 
ADORA3, TFPI, 
AVPR1B 
- 
5 
PR 
(nuclear) 
4 3 2.300E-10 
MAN1C1, ADORA3, 
MACF-1 
- 
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Figure 6.2: Pathway analysis for the list of genes generated from the SVAs 
sharing similar repeat units with the PARK7 SVA TR/VNTR. The list of genes 
was analysed to determine the shortest pathway within two steps of each other. The 
genes from Table 6.1 are circled in blue with 14 out of 32 linked within this 
pathway. Two of the top five transcription factors from table 6.2 (CREB1 and ESR) 
are found within this network.  
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Figure 6.3: Predicted transcription factor binding sites within the sequence of 
the PARK7 SVA using PROMO software. A – These are the transcription factor 
binding sites that were predicted within the sequence of the complete PARK7 SVA 
(allele 1). B – The predicted transcription factor binding sites of the sequence of the 
three repeat units of the TR/VNTR used in the Blat search. In both A and B the 
transcription factors that were identified in Table 6.2 are highlighted with a red box.  
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6.4.3 Endogenous PARK7 mRNA expression is modulated by 17-β-estradiol in a 
MCF-7 cell line 
 The expression levels of several of our target genes were analysed in 
response to 17-β-estradiol in a MCF-7 cell line. The genes of interest were amplified 
with specific primers sets and the PCR products run on an agarose gel (Figure 6.4). 
The housekeeping gene, β-actin, expression remained stable across the three 
conditions; basal, vehicle control (ethanol) and 10nM 17-β-estradiol (bottom panel 
of Figure 6.4). The gene TFF1 (trefoil factor-1) is a known oestrogen responsive 
gene in the MCF-7 cell line in the literature (Amiry et al. 2009) and was therefore 
used as a positive control for this experiment. The increase in expression of TFF1 in 
response to 10nM 17-β-estradiol can be seen in the top panel of Figure 6.4. The 
expression of PARK7 and MAN1C1 was also increased in response to exposure to 
10nM 17-β-estradiol but not that of TFPI (see middle three panels of figure 6.4). The 
expression of the genes MAN1C1 and TFPI from the SVA gene list were chosen to 
be analysed due to location of their SVA relative to the gene, 12kb and 1kb upstream 
respectively, that was similar to the position of the PARK7 SVA relative to the 
PARK7 gene (1-8kb upstream).  
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Figure 6.4: The endogenous levels of TFF1, PARK7 and MAN1C1 mRNA are 
upregulated in the MCF-7 cell line in response to oestrogen. Agarose gel 
electrophoresis images of the PCR products from the amplification of the following 
genes TFF1 (209bp), PARK7 primer set 1 (325bp), MAN1C1 (159bp), TFPI 
(218bp) and β-actin (158bp) under different conditions; basal, vehicle control 
(ethanol) and 10nM 17-β-estradiol. N=3  
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6.4.4 PARK7 SVA does not respond to oestrogen in a transient transfection 
reporter gene assay 
 An ERE-TK Luc vector and the control vector (TK Luc) were provided by 
Karen Chapman (Martin et al. 2004) and were used in the validation of the oestrogen 
response of a transiently transfected vector in the MCF-7 cell line. The ERE-TK Luc 
vector had significantly increased activity over the minimal promoter alone under 
basal conditions (P<0.01). When exposed to the vehicle control (ethanol) the activity 
of the ERE-TK Luc vector over the minimal promoter alone did not significantly 
increase when compared to the vector under basal conditions. When the MCF-7 cells 
were exposed to 10nM 17-β-estradiol the activity of the ERE-TK Luc vector 
significantly increased by 8.3 fold when compared to the activity of the vector 
exposed to the vehicle control (P<0.001).  
 The different sized fragments of the PARK7 SVA in the forward orientation 
used in 5.4.8 were tested in this validated MCF-7 cell model response to 17-β-
estradiol. There was no significant difference in the activity of these reporter gene 
constructs containing the different domains of the PARK7 SVA in response to 
stimulation of the MCF-7 cells with 10nM 17-β-estradiol. 
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Figure 6.5: The activity of the ERE containing plasmid increases after MCF-7 
cells are exposed to 10nM 17-β-estradiol. The average fold activity of the ERE 
containing vector (ERE-TK Luc) over the TK promoter alone (TK Luc) under 
different conditions: basal, vehicle control (ethanol) and 10nM 17-β-estradiol. Data 
was normalised to the internal control to compensate for transfection efficiency. One 
tailed t-test was used to measure significance of fold activity of ERE over TK 
promoter alone (TK Luc) **P<0.01, ***P<0.001 and to compare the fold activity of 
ERE-TK Luc across different conditions ### P<0.001.  N=4 
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Figure 6.6: There was no significant difference in the activity of the reporter 
gene constructs containing the different domains of the PARK7 SVA in 
response to 10nM 17-β-estradiol. The average fold activity of the different 
fragments of the PARK7 SVA in forward orientation over the minimal SV40 
promoter alone (pGL3P) under different conditions: basal, vehicle control (ethanol) 
and 10nM 17-β-estradiol. The activity of the test constructs were normalised to the 
internal control to account for transfection efficiency. N=4. One tailed t-test was 
used to measure significance of fold activity of PARK7 SVA fragments over SV40 
minimal promoter alone (pGL3P) and to compare fold activity across the different 
conditions. * P<0.05, **P<0.01, N=4 
 
 
 
0.0 
0.2 
0.4 
0.6 
0.8 
1.0 
1.2 
SVA  SVA Δ SINE  TR/VNTR Truncated 
SVA  
A
v
e
ra
g
e
 f
o
ld
 d
if
fe
re
n
c
e
 o
f 
fi
re
fl
y
  
lu
c
if
e
ra
s
e
 
a
c
ti
v
it
y
 o
f 
te
s
t 
c
o
n
s
tr
u
c
t 
to
 p
G
L
3
P
 n
o
rm
a
lis
e
d
 
to
 t
h
e
 i
n
te
rn
a
l 
c
o
n
tr
o
l 
(p
M
L
u
c
-2
) 
Construct 
Basal 
Vehicle 
Control 
10nM 17-
β-Estradiol 
* 
* 
** 
** 
** 
* 
** 
209 
 
6.4.5 In a preliminary analysis there was no association of the PARK7 SVA 
genotype with a BRCA wild-type breast cancer cohort  
 The PARK7 SVA was genotyped in a cohort of BRCA wild-type breast 
cancer patients and matched controls as PARK7 has been linked to breast cancer (Le 
Naour et al. 2001; Oda et al. 2012). The frequencies of the different genotypes 
between the breast cancer patients and controls were not significantly different when 
analysed using CLUMP (T1 P=0.65 and T4 P=0.65) and are shown in Table 6.3. The 
most notable difference between the two groups was a 7.2% reduction in the 1/1 
genotype from the control group compared to the breast cancer patients. 
 The PARK7 SVA had also been genotyped in the control samples from the 
King’s cohort used in chapter 3 for studies of the FUS SVA and its association to 
ALS and it was noted that there were differences between the all female controls 
from the breast cancer cohort and the King’s control cohort of mixed gender. 
Therefore the sexes of the individuals from the King’s control cohort were obtained 
from collaborators at King’s College London who had provided the samples and this 
cohort was broken down into females and males (Table 6.3). There were differences 
between the frequencies of the genotypes of the PARK7 SVA across the four groups 
but most notably were the differences between the female groups and the male 
group. In particular was the underrepresentation of genotype 1/3 in the King’s 
control male group of 28.7% compared to 41.1%, 46.5% and 40.4% in the three 
female groups. The frequency of genotype 3/3 was higher in the male group (25.3%) 
compared to the three female groups (19.9%, 19.1% and 15.4%). Also an allele 5, 
larger than allele 4, had been identified in this King’s control cohort and all three 
individuals with this previously unidentified allele were male. The frequency of the 
alleles between the four groups were then compared (Table 6.4). Despite the 
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differences in genotype frequencies the frequency of the alleles was much more 
similar between males and females. There was a slightly lower frequency of allele 2 
(3.4%) in the males compared to the three female groups, (6%, 7.2% and 5.8%). It 
was also noted than the frequency of allele 1 (46.5%) in the BRCA wild-type breast 
cancer group was lower than that of the other three groups (50.7%, 51.9% and 
51.1%).  
 These unexpected differences between males and females for the genotypes 
of the PARK7 SVA were not significant when the frequencies for the males and 
females of the King’s control cohort were analysed using CLUMP (T1 P=0.11 and 
T4 P=0.16). These are still relatively small cohorts and if this difference between 
males and females was to be validated, larger cohorts would be needed and is not 
clear why this difference may occur. The genotyping of such large pieces of DNA is 
time consuming and labour intensive so if a tagging SNP could be identified for the 
different alleles of the SVA larger cohorts could be analysing in a more efficient 
way. This had already been achieved for the two alleles of the FUS SVA in chapter 
3, however the larger number of alleles of the PARK7 SVA would make it more 
difficult to attempt to identify tagging SNPs. 
 HWE was analysed for all four cohorts mentioned in this section and all were 
found to be in HWE with the following p values: female breast cancer control 
p=0.30, BRCA wildtype p=0.72, females in ALS control p=0.88 and males in ALS 
control p=0.37. 
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Table 6.3: Frequencies of the PARK7 genotypes in a BRCA wild-type breast 
cancer and control cohort. The frequencies are shown of the different genotypes of 
the PARK7 SVA in the breast cancer BRCA wild-type and control cohort that are all 
female and the frequencies in the control samples from the King’s control cohort 
from chapter 3 broken down by sex to compare the differences between the two 
sexes.  
 
 Frequency of Alleles (%) 
Allele 
Female 
Controls 
(302) 
BRCA Wild-
type Breast 
Cancer 
(376) 
Females 
from ALS 
control 
cohort (208) 
Males from 
ALS control 
cohort (174) 
1 50.7 46.5 51.9 51.1 
2 6.0 7.2 5.8 3.4 
3 41.7 44.9 39.9 42.5 
4 1.7 1.3 2.4 1.1 
5 0 0 0 1.7 
Table 6.4: Frequencies of the PARK7 alleles in the BRCA wild-type breast 
cancer and control cohort. The frequencies are shown of the different alleles of the 
PARK7 SVA in the breast cancer BRCA wild-type and control cohort that are all 
female and the frequencies in the control samples from the ALS cohort from chapter 
4 broken down by sex to compare the differences between the two sexes. All four 
cohorts were shown to be in HWE with the following p values corresponding to the 
cohorts in the table from left to right: p=0.30, p=0.72, p=0.88 and p=0.37.   
 
 Frequency of Genotype (%) 
Genotype 
Female 
Controls 
(151) 
BRCA Wild-
type Breast 
Cancer 
(188) 
Females 
from ALS 
control 
cohort (104) 
Males from 
ALS control 
cohort (87) 
1/1 25.8 18.6 28.8 33.3 
1/2 6.0 7.4 2.9 4.6 
1/3 41.1 46.3 40.4 28.7 
1/4 2.6 2.1 2.9 2.3 
2/2 1.3 1.1 1.0 0 
2/3 2.6 4.8 6.7 2.3 
2/4 0.7 0 0 0 
3/3 19.9 19.1 15.4 25.3 
3/4 0 0.5 1.9 0 
3/5 0 0 0 3.4 
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6.4.6 Two tagging SNPs can be used to identify alleles 1, 2 and 3. 
 The PARK7 SVA has more than two alleles so more than one SNP would be 
required to tag the alleles. To identify tagging SNPs the genotyping of the CEU 
HapMap cohort (section 5.4.6) was used and the SNP data for that region of those 
individuals which was freely available from the International HapMap database. This 
however would limit the potential identification of tagging SNPs for alleles 1-4 as 
allele 5 was not present in this cohort (for methods see section 3.3.4 and 6.3.6). 
  Analysis of linkage in the PARK7 region revealed two SNPs that in 
conjunction can be used to identify the genotype of the SVA for alleles 1, 2 and 3, 
however a SNP to tag allele 4, the rarest of the alleles, could not be identified. The 
analysis of the individuals in the CEU HapMap cohort with alleles 1 and/or 3, the 
most common of the alleles, determined at the SNP rs2493215 a genotype of G 
corresponded to allele 1 and a genotype of A corresponded to allele 3 with a r
2
 of 
0.909 (Figure 6.7A). When the analysis was expanded to include individuals with 
allele 2 and 4 it was shown that the A genotype corresponded to these alleles as well. 
The genotype data was analysed further in Haploview software to include all four 
alleles of the PARK7 SVA, which identified a SNP (rs226476) that would tag allele 
2 with a r
2
 of 0.903 (Figure 6.7B); a genotype of T corresponds to allele 2 and a 
genotype of G corresponds to alleles 1, 3 and 4. Therefore using these two SNPs in 
combination alleles 1, 2 and 3 can be tagged by their specific genotypes. This work 
was ongoing at the end of my thesis by others in the group as a method to more 
rapidly link SVA polymorphisms to the vast SNP data available and therefore to 
disease pathways. 
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Figure 6.7: The genotype of the SNPs rs2493215 and rs226476 can be used to 
determine the genotype of the PARK7 SVA alleles 1, 2 and 3. A – A screen shot 
from Haploview software showing that the SNP rs2493215 (highlighted in blue) tags 
the ‘SNPs’ for alleles 1 and 3 of the PARK7 SVA (outlined in the black box) with a 
r
2
>0.8. B – A screen shot from Haploview software showing that the SNP rs226476 
(highlighted in blue)  tags the ‘SNP’ for allele 2 of the PARK7 SVA (outlined in the 
black box) with a r
2
>0.8. 
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Section B 
6.4.7 Five Parkinson’s disease associated genes contain a SVA within 10kb of 
their gene loci 
 In the first section of this chapter a list of SVAs were identified by their 
primary sequence and transcription factors that might regulate them and the genes 
they are near. In the second section another list of SVAs was generated by 
identifying the genes that are known to be associated with the same disease, 
determining if there is an SVA within their locus and if the numbers of SVAs in the 
gene subset are overrepresented. Mutations in the coding region the PARK7 gene 
have been associated with autosomal recessive Parkinson’s disease (PD) (Bonifati et 
al. 2003). There are several other PARK genes including SNCA, LRRK2 and PINK1 
that are causative genes for PD. Therefore a list of known associated genes for PD 
was taken from Corti et al 2011. Five out of the thirteen genes analysed using UCSC 
genome browser had a SVA that was within the gene or its 10kb flanking region 
(PARK2, PARK7, LRRK2, PLA2G6 and ATXN2). The gene locus, association with 
PD and whether a SVA was present was summarised in Table 6.5. The SVAs 
identified belonged to either subtype C, D or F and their conservation across primate 
species varied. Four of the SVAs were located within the intron of one of the genes 
(PARK2, LRRK2, PLA2G6 and ATXN2) whereas the previously characterised 
PARK7 SVA was 1-8kb upstream of the major TSS. Previous analysis in chapter 4 
analysing the relative orientation of the SVAs to genes they have inserted into or 
within the 10kb flank had generated the number of genes with a SVA in these 
regions. 6.3% of genes had a SVA within an intron or their 10kb flank whereas 38% 
(5/13) of the PD associated genes had a SVA in these regions. This preliminary data 
suggests the subset of PD associated genes have a greater number of SVA insertions 
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than genes on average. It has already been shown that the PARK7 SVA is 
polymorphic (5.4.6 and 6.4.5) so the genetic variation of two more SVAs from this 
list was analysed (6.4.8).  
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Table 6.5: Five of these Parkinson’s Disease associated genes contain a SVA. This table lists the genes that are known to be associated with 
PD taken from table 1 of Corti et al (2011). The UCSC genome browser (Hg19) was used to identify the presence of a SVA within the gene or 
within 10kb. Three out of the four SVAs identified within this gene set were analysed for their polymorphic nature. N= no SVA present (+) – on 
sense strand, (-) – on antisense strand. SNCA – alpha synuclien, UCHL1 – ubiquitin COOH-terminal hydrolase 1, PINK 1 – PTEN-induced 
kinase 1, LRRK2 – leucine rich repeat kinase 2, ATP12A2 – ATPase type 13A2, GIGYF2 – GRB10-interacting GYF protein 2, HTRA2 - HtrA 
serine peptidase 2, PLA2GB – group VI phopholipase A2, FBXO7 – F-box protein 7, ATXN2/SCA2 – Ataxin 2, GBA – beta 
glucocerebrosidase. ND – not done. 
PARK 
Loci 
Gene Chr Position Involvement in PD SVA Chr Loci of SVA  SVA loci to 
Gene 
Alleles of 
SVA 
PARK1/4 SNCA 4q21 Early onset, dominant N - - - 
PARK2 Parkin 
(-) 
6q25-q27 Juvenile and early onset, 
recessive and sporadic. 
SVA F 
(+) 
Chr6:162759277-
162761189 
Intron 2 
PARK5 UCHL 1 4p14 Late onset, dominant N - - - 
PARK6 PINK 1 1p35-p36 Early onset, recessive N - - - 
PARK7 
 
PARK7/DJ-1 
(+) 
1p36 Early onset, recessive SVA D 
(+) 
Chr1:8012111- 
8013640 
1-8kb 
upstream 
5 
 
PARK8 LRRK2 
(+) 
12q12 Late onset, dominant 
and sporadic 
SVA C 
(-) 
Chr12:40746271- 
40747834 
Intron 2 
PARK9 ATP13A2 1p36 Early onset recessive  N - - - 
PARK11   GIGYF2 2q36-q37 Late onset, dominant N - - - 
PARK13 Omi/HTRA2 2p13 Unclear N - - - 
PARK14 PLA2G6 22q12-q13 Atypical PD, recessive. Fragment 
of SVA F 
Chr22:38549308- 
38549389 
Intron ND 
PARK15 FBXO7 22q12-q13 Atypical PD, recessive. N - - - 
- ATXN2/SCA2 
(-) 
12q24.1 Unclear SVA D 
(+) 
Chr12:111944423-
111945974 
Intron ND 
- GBA 1q21 Unclear N - - - 
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6.4.8 The SVAs identified within PARK2 and LRRK2 genes are polymorphic  
 Two of the SVAs identified to be present with genes associated with 
Parkinson’s disease were amplified in 11 of the CEU HapMap samples to determine 
if these SVAs were polymorphic as seen in the PARK7 and FUS SVAs. Both of the 
SVAs were located within the introns of their respective genes but were members of 
different subtypes. The SVA within the PARK2 gene is a member of the subtype F 
and is human specific. Two alleles were identified for this SVA in the small group of 
HapMap samples tested (Figure 6.8A). The SVA within the LRRK2 gene was a 
subtype C and is present within humans, chimpanzees and gorillas according to 
UCSC. There also appears to be two alleles of this SVA so far identified in the 11 
HapMap samples tested however there were no heterozygous individuals (Figure 
6.8B). 
 Previous analyses of the PARK7 and FUS SVAs in the HapMap cohort led to 
the identification of tagging SNPs for the different alleles which would enable much 
larger cohorts of individuals to be genotyped for these elements in a less labour 
intensive manner. Genetic variation implicated in disease processes may not be 
limited to alleles located at one specific gene but across several linked in similar 
pathways and it would be important to assess these genetic variants in combination 
as well as in their own right.   
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Figure 6.8: SVAs present within the PARK2 and LRRK2 genes are 
polymorphic. A - The SVA F within an intron of the PARK2 gene has two alleles in 
11 individuals analysed form the CEU HapMap cohort. Expected product - 2090bp. 
The bands are running slightly higher than expected but are specific therefore the 
alleles of the SVA here may be larger than the sequence available on UCSC. B - The 
SVA C within an intron of the LRRK2 gene has two alleles in 11 individuals from 
the CEU HapMap cohort but no heterozygotes. Expected product – 1812bp.  
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6.4.9 The SVA associated with X-linked dystonia-parkinsonism inserted in to 
intron 32 of the TAF1 gene where a SVA was already present 
 An insertion of a SVA F has been linked to X-linked dystonia-parkinsonism 
(XDP) in a Philippine cohort (Makino et al. 2007; Hancks and Kazazian 2010) where 
males with this insertion into intron 32 of the TATA-binding protein-associated 
factor 1 gene (TAF1) located at Xq13.1 suffered from the disease. The SVA 
insertion was absent from other ethnic groups such as Japanese and European and 
African Americans tested and female carriers with this SVA insertion present on one 
of their X chromosomes were observed in the Philippine population. Therefore this 
SVA insertion is polymorphic in terms of its presence or absence and its presence is 
associated with disease. The sequence of the DYT3 (dystonia-parkinsonism 
syndrome locus) region provided by the authors (http://www.ddbj.nig.ac.jp, 
accession number AB191243) was analysed. The disease associated SVA (2627bp) 
within intron 32 was located and during this analysis I noted that there was the 
sequence of another SVA less than 11kb downstream and still within intron 32. This 
second SVA was also located on the negative strand of DNA but was shorter at 
1606bp. The TAF1 gene was analysed on the UCSC genome browser and there was 
a SVA D found in humans and chimpanzees within intron 32 of the gene that was 
1665bp long. The schematic in Figure 6.9 represents the structure of intron 32 from 
the sequence of the DYT3 region (AB191243) and from the UCSC genome browser 
Hg19.  
 The SVA F insertion was not present in the UCSC genome sequence; 
however the site of the insertion could be identified using the flanking sequence of 
SVA F in the published sequence from Makino et al (underlined in Figure 6.9). 
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There is evidence of a target site duplication (TSD) caused by the insertion of the 
SVA F which is highlighted in red, Figure 6.9. The flanking sequences of the SVA D 
from both sequences were compared and these matched indicating they were the 
same SVA insertion. I compared the sequences of the two SVA Ds and they were 
identical apart from within the central VNTR region. The VNTR of the SVA in the 
UCSC genome browser (Figure 6.10A) was larger and contained two additional 
repeats compared to the VNTR of the SVA in the sequence published by Makino et 
al (Figure 6.10B). There were also additional bases present in repeats 9 and 15 of the 
Makino et al sequence compared the UCSC sequence and are highlighted in red 
(Figure 6.10).  
 The difference in the VNTR region of the two SVA D sequences indicate that 
it is polymorphic in terms of the number of repeats as shown previously for the FUS 
and PARK7 SVAs (chapter 3 and 5/6 respectively). The potential variation of this 
SVA was analysed in a small number of individuals from the CEU HapMap cohort 
and the controls from the SALS cohort used in chapter 3. The SVA D was present in 
all 11 individuals from the CEU HapMap (Figure 6.11) and 21 individuals tested 
from the control cohort for the SALS group used in chapter 4 (data not shown). 
There was no variation that could be identified in the analysis in the size of the SVA 
D observed across these individuals. This could indicate the differences in VNTR 
size are unique to specific ethnic groups or is extremely rare and could not be 
identified in the small number of samples tested.  
 In chapter 4 the insertion of SVAs was determined to be more frequent in 
genic regions as opposed to gene deserts was therefore not randomly spread 
throughout the genome. This occurrence of a SVA inserting in close proximity to 
another, seen in the Makino et al sequence, raised the question of how many SVAs 
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had inserted near to other SVAs. The coordinates of all the SVAs from the Hg19 
from UCSC used in the analysis in chapter 4 was used to determine how many SVAs 
had inserted within 100kb and 10kb of another SVA. 863 SVAs were found to have 
inserted within 100kb of another SVA and there were 110 SVAs that had inserted 
within 10kb of another SVA similar to the SVA F and SVA D insertions. Many of 
these SVA insertions within 10kb of another SVA have occurred at evolutionary 
distinct periods due to differences in their presence across primate species. If the 
number of SVA insertions into these regions, within 100kb and 10kb of another 
SVA, were predicted based purely on the size of the region the number of SVA are 
overrepresented. The 100kb flanking regions of SVAs encompasses 14.3% of the 
human genome but contains 32.3% of the SVAs (a 2.3 fold increase) and the 10kb 
flanking regions of the SVAs constitutes 1.7% of the human genome but contains 
4.1% of the SVAs (a 2.4 fold increase). It was also noted in UCSC there were two 
more SVAs within the TAF1 locus; a SVA A 14kb downstream of the SVA D and 
another SVA D 109kb upstream of the SVA D. There have been other ‘clusters’ of 
SVA insertions observed while using UCSC where several SVAs were located in 
relatively small regions. Examples of these ‘clusters’ include chr19p12 (genes in this 
region include ZNF90 and ZNF486) where 7 SVAs have inserted within a 235kb 
region and at chrXp11.22 (genes in this region include HUWE1, Mir98 and PHF8) 
where there are four SVA insertions within 270kb. If SVAs had inserted randomly 
across the human genome there on average would be less than one SVA per million 
bases so to have several loci of SVAs in such close proximity would further supports 
that the site insertion of these elements is not random and that certain regions of the 
genome are more susceptible to these events than others.   
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Figure 6.9: Schematic representing intron 32 of the TAF1 gene from the 
Makino at al 2007 and UCSC Hg19 sequences. The blue box in the top image 
represents the disease causing human specific SVA F insertion reported by Makino 
at al which is 2627bp in length and located on the negative strand (opposite to the 
orientation of the gene). This SVA is not present in the UCSC genome sequence but 
the site at which it inserted can be identified and shown underlined. The sequences 
flanking the SVA insertion identified in Makino et al correspond to this locus except 
there is a TSD highlighted in red caused by the insertion of the SVA. There is also a 
SVA D present within intron 32 (indicated by red box) 10.9kb downstream of the 
SVA F insertion or site of insertion in both the Makino et al and UCSC sequence. 
This SVA D is present with the chimpanzee genome as well as the human according 
UCSC and is a located on the negative strand. The flanking sequences of the SVA 
Ds match between the Makino et al and the UCSC sequences indicating it is the 
same insertion. The length of the SVA D differs between the two sequences by 59bp. 
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 Figure 6.10: Comparison of the central VNTR sequences of a SVA inserted at 
the same loci from UCSC genome browser and Makino et al 2007. The VNTR 
from the SVA sequence within the Makino et al publication is smaller with two 
fewer repeats (10 and 12) compared to the VNTR from the sequence available in 
UCSC but with additional bases present in repeat 9 and 15 (highlighted in red). A – 
The sequence of the VNTR of a SVA D from the UCSC genome browser located in 
intron 32 of the TAF1 gene. This VNTR if 688bp long with 17 repeat units. B - The 
sequence of the VNTR of an additional SVA to the disease associated SVA in 
Makino et al located in intron 32 of the TAF1 gene. This VNTR if 629bp long with 
15 repeat units.  
 
 
Figure 6.11: Amplification of the SVA D located within intron 32 of the TAF1 
gene in UCSC genome browser in CEU HapMap samples. The presence of this 
SVA was confirmed in a Caucasian population however there was no variation noted 
in the 11 individuals tested from the CEU HapMap cohort. Expected product size 
1956bp. This SVA is located on the X chromosome therefore the sex of the 
individual was noted (F=female M=male). This SVA was also tested in an additional 
21 samples from the King’s controls of the ALS cohort used in chapter 3 and no 
genetic variation was seen. 
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6.5 Discussion  
 A search for SVAs that shared sequence homology to repeats of the TR and 
VNTR of the PARK7 SVA identified 19 SVAs (including the PARK7 SVA) which 
were located within 100kb of 32 different genes (Table 6.1). The MetaCore 
programme was used to determine TFs known to regulate these genes with CREB1, 
ESR1, Sp1, GCRα and PR the top five of these factors (Table 6.2). Of these GCRα, 
Sp1 and ESR1 were shown to have binding sites present in the sequences of the 
repeats of the PARK7 SVA to identify this list of SVAs and subsequent genes 
(Figure 6.3B). It was hypothesised that these factors may bind to the SVAs and play 
a role in regulating the expression of the gene they are near. ESR1 was chosen to test 
this hypothesis as the MCF-7 cell line is oestrogen responsive so provided a good 
cell line model for this experiment and PARK7 has been linked to breast cancer so 
modulation of PARK7 by oestrogen could be an important mechanism in the disease 
process. The endogenous PARK7 mRNA levels increased when exposed to 10nM 
17-β-estradiol for 18hrs as did the mRNA of the MAN1C1 gene, however the 
mRNA of TFPI gene did not increase (Figure 6.4). The expression levels of the 
reporter gene constructs containing different sized fragments of the PARK7 SVA 
(previously used in section 5.4.8) transfected into the MCF-7 cell line were not 
significantly altered by the exposure of the cells to 10nM 17-β-estradiol for 18hrs 
(Figure 6.6). A plasmid containing an oestrogen response element (ERE) was used as 
a positive control for this assay which showed a significant and robust increase in 
response to 17-β-estradiol (Figure 6.5). This would suggest that there is not 
modulation of these genes occurring through the binding of the ESR1 to the SVAs at 
multiple loci as hypothesised due to the lack of response of the expression of the 
TFPI gene and the PARK SVA modulation of the reporter gene unaffected by the 
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cell exposed to oestrogen. The modulation of the PARK7 and MAN1C1 genes is 
likely to be through other oestrogen responsive pathways. Analysis using the 
MetaCore programme did not show that PARK7 is regulated directly by the ESR1 
however it is by Sp1. It has been shown in the literature that the ESR1 and Sp1 can 
associate through protein-protein interactions and mediate a response to oestrogen 
that does not require the ESR1-DNA binding and may only require Sp1 binding sites 
(Porter et al. 1997). This may be the mechanism that is involved in the up regulation 
of the PARK7 gene in response to oestrogen demonstrated in this cell line model as 
there are Sp1 binding sites in the major PARK7 promoter and it is known to be 
modulated by Sp1 (Taira et al. 2001). MAN1C1 although not shown to be directly 
regulated by the ESR1 (Table 6.2) it is regulated by the PR that is an oestrogen 
responsive gene and therefore expression could be indirectly modulated by 
stimulation with oestrogen. The TFPI gene was not predicted to be modulated by the 
ESR1, Sp1 or the PR therefore its lack of response to oestrogen is consistent with 
TFPI not being part of an oestrogen responsive pathway.  
 The response of PARK7 expression to oestrogen could be important in 
disease process as PARK7 is known to be involved in breast cancer. PARK7 was 
first linked to breast cancer when the PARK7 protein was identified at higher levels 
in the sera of breast cancer patients than controls (Le Naour et al. 2001). PARK7 
protein is secreted by breast cancer cells with PARK7 protein detected in the nipple 
fluid of patients with breast cancer at higher levels than those with benign lesions 
and this high level of PARK7 protein in the nipple fluid was correlated with low 
protein expression but high mRNA expression in the tumour (Oda et al. 2012). This 
low expression of PARK7 protein but high mRNA expression in the tumours of 
patients with invasive ductal carcinoma (IDC) was a predictor of poor outcome 
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(Tsuchiya et al. 2012). Although in another study low PARK7 protein levels was an 
indicator of pathological complete remission after neoadjuvent chemotherapy in 
patients with IDC indicating chemotherapy is an important component of improving 
the survival of patients with IDC and low levels of PARK7 protein (Kawate et al. 
2013). Increased levels of PARK7 protein offer resistance to cellular apoptosis most 
likely through multiple mechanisms including its protection against oxidative stress 
and PARK7’s negative regulation of PTEN an inducer of apoptosis (Canet-Aviles et 
al. 2004; Kim et al. 2005; Clements et al. 2006). Therefore the levels of PARK7 are 
important for the potential treatment of the disease with a reduction in PARK7 
increasing the response to chemotherapy. The up regulation of PARK7 in response 
to oestrogen could be an important mechanism in oestrogen receptor positive cancer 
cells as increased levels of PARK7 protein can increase the cells resistance to 
apoptosis. 
 The genetic variation of the PARK7 SVA was analysed in a cohort of breast 
cancer patients without mutations in their BRCA genes and a female matched control 
group from the National Genetics References Laboratory, St Mary’s Hospital, 
Manchester. There were a reduced number of 1/1 genotypes (7.2%) for the PARK7 
SVA in the breast cancer patients compared to the control group (Table 6.3).  
However there was not a significant difference between the breast cancer patients 
and the control group for the genotype of the PARK7 SVA when analysed using 
CLUMP (Sham and Curtis 1995). A greater in depth analysis of the PARK7 SVA 
variants and their association with particular characteristics of the tumour of the 
patients would be valuable especially in light of the up regulation of PARK7 gene in 
response to cellular stimulation with oestrogen. The frequency of the genotypes of 
the PARK7 SVA in the breast cancer and control group were noted to be different to 
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the frequency of the genotypes in the King’s control group from the ALS cohort used 
in chapter 3 for the FUS SVA analysis. The King’s control group consisted of male 
and females whereas the breast cancer cohort was all female, therefore the King’s 
control group were broken down by sex. The frequency of the genotypes in the 
females of King’s control group was more similar to those of the breast cancer 
control group than the males (Table 6.3) with fewer 1/3 genotypes in the males and 
allele 5 only present in the males. These cohorts are still small so this may be a factor 
of not a high enough N number and the reason for these sex differences is unclear.  
 In a similar process as for the FUS SVA tagging SNPs were identified for the 
PARK7 SVA. This was a more complicated process due the increased number 
alleles of the PARK7 SVA. Two tagging SNPs were identified that could be used to 
determine the most common alleles 1, 2 and 3: rs2493215 a G corresponds to allele 1 
and a A corresponds to allele 3 and at rs226476 a T corresponds to allele 2 (section 
6.4.6). Unfortunately a tagging SNP for the rarer allele 4 and allele 5 as not present 
in the HapMap cohort could not be identified. These tagging SNPs could be used, 
similar for the FUS SVA, to analyse the genetic variation of the PARK7 SVA in 
larger cohorts as analysis of the SVA variants is time consuming and labour 
intensive. This model is being continued by others in our group. 
 The analysis of the presence of SVAs in causative genes for PD identified 5 
of these genes, including PARK7, with a SVA within the gene or its 10kb flank 
(Table 6.5) which was an overrepresentation when compared to the percentage of 
genes across the whole genomes with SVAs in those relative regions. The potential 
of these SVAs to be polymorphic was tested in two elements in addition to the 
already characterised genetic variation of the PARK7 SVA. In a small sample of 
individuals from the CEU HapMap cohort the SVAs within introns of the PARK2 
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and LRRK2 genes were identified to contain two alleles each (Figure 6.8). This 
initial analysis shows that there are at least two other polymorphic SVAs in known 
PD causing genes providing further genetic variation to be considered in disease 
association studies. If the numbers of HapMap samples genotyped were to be 
expanded a tagging SNP may be identified for the alleles of the SVAs within 
LRRK2 and PARK2, as had been completed for the FUS and PARK7 SVAs. This 
could make the studies of potential genetic association with disease simpler.  
 The intron 32 of the TAF1 gene was analysed further due to the disease 
causing insertion of an SVA associated with X-linked dystonia-parkinsonism. The 
disease causing insertion was identified to have inserted less than 11kb upstream of a 
SVA already present in the intron 32 when I analysed the sequence online provided 
by the authors of the manuscript. There was also a SVA identified in the UCSC 
genome browser at the same locus (Figure 6.9) and the presence of this SVA in 
Caucasian individuals was confirmed (Figure 6.11). The size of the VNTR of this 
SVA varied between the sequence from the Philippine individual and the sequence 
from UCSC (Figure 6.10) but did not show variation across the Caucasian 
individuals tested. This difference in VNTR size may be due to the ethnic 
differences. It is the second SVA insertion in this intron that is associated with 
disease but the presence of one SVA is not sufficient to be pathogenic. This could 
mean that the impact of SVAs on the genomic locus is amplified when more than 
one element in present in a relatively small region. Therefore the frequency of these 
close proximity insertions was analysed using UCSC and identified 110 SVAs 
within 10kb of another SVA and 863 had inserted within 100kb of another SVA. The 
preference of SVA insertions had been shown to be in genic regions over gene 
deserts (chapter 4) but this data indicates there may be regions that are particularly 
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susceptible to SVA insertions over others. The hypothesis that there are regions of 
the genome that are particularly vulnerable to retrotransposon insertions has been 
suggested previously due to the insertion of a SVA and an AluY in two different 
individuals at the exact same nucleotide of exon 9 of the BTK gene resulting in X-
linked agammaglobulinemia (Conley et al. 2005). There have been other 
documented independent retrotransposon insertions occurring at the same genomic 
loci of Factor IX and APC of different individuals (Miki et al. 1992; Vidaud et al. 
1993; Halling et al. 1999; Wulff et al. 2000) and Conley et al suggest due to the lack 
of similarities of the DNA sequence across these insertion sites it is the surrounding 
DNA and chromatin structure that make them vulnerable to retrotransposon 
insertions. Although a full analysis of whether these regions acted as hot spots for 
insertions for all classes of retrotransposons was outside the scope of this thesis. 
Alternatively the close proximity of multiple SVA insertions described in this 
chapter such as at chr19p12 (ZNF90 and ZNF486) and at chrXp11.22 (HUWE1, 
Mir98 and PHF8)  may be due to the initial SVA insertion increasing the 
susceptibility of the genomic locus to further SVA insertions perhaps through 
altering the structure of the locus.  
 The chapter has highlighted important preliminary data including the 
regulation of the PARK7 gene, identification of additional polymorphic SVAs in 
disease associated genes and indicated the potential greater complexity to the site of 
SVA insertions and that their influence on the genome may be amplified when two 
elements are in close proximity to one another.  
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 Over 98% of the human genome is non-coding containing domains of various 
regulatory functions, including controlling the specific genes expressed and the 
levels of their expression that is crucial to direct and maintain the function and 
phenotype of the cell. The regulation of gene expression can occur in many forms 
from the proximal promoter, enhancers and repressors to the packaging of the DNA 
into chromatin and its state of methylation, the latter parameters representing 
epigenetic regulation. To identify potential regulatory domains within the non-
coding DNA, genome browsers have proved a useful tool for bioinformatic analysis 
of the plethora of data now available. This has dramatically increased in recent years 
with the publication of data from the ENCODE consortium (Kavanagh et al. 2013b). 
For example genome browsers have provided an easy method to identify regions that 
are highly conserved between species indicating potential function which from 
further analysis proved to be regulators of gene expression in vitro and in vivo  
(Davidson et al. 2006; Shanley et al. 2010; Paredes et al. 2011). There is also a 
wealth of data available within these browsers, in particular UCSC, not just on the 
sequence of the genome but the chromatin state (inactive and active histone marks), 
transcription factor (TF) binding and DNase clusters across cell lines that can be 
used to predict transcriptionally active regions. One of the areas of expertise of the 
laboratory in which I did my study lay in the analysis of VNTR domains and their 
ability to affect gene expression in a tissue specific and stimulus inducible manner 
and their association to disease which was correlated with specific copy number of 
the VNTR (Guindalini et al. 2006; Breen et al. 2008; Haddley et al. 2008; Ali et al. 
2010; Vasiliou et al. 2012). Such variation in an individual’s genetics to another can 
influence the levels of gene expression and the response to their environment not 
only in the short term but in the long term by altering epigenetic factors. This gene-
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environment interaction can play an important role in phenotypic differences and 
disease susceptibility. Therefore the analysis of specific genomic regions 
encompassing genes of interest was undertaken to identify potential novel regulatory 
and polymorphic domains.  
 The analysis of the 10kb upstream of the FUS gene for regions of DNA that 
may be functional and polymorphic identified a large repetitive region which was 
part of a composite element called a SVA (Figure 4.1). SVAs are a non-autonomous 
hominid specific member of the non-LTR retrotransposons. 2676 SVAs were 
identified across the human genome using the UCSC genome browser and therefore 
have the potential to affect gene expression at multiple loci. The repetitive nature of 
the domains within their structure, the central VNTR and 5’ CCCTCT repeat, 
provide sources of genetic variation that may result in differential regulation between 
individuals. There is also growing interest in the ability of retrotransposon insertions 
to create intra-individual genetic variation through somatic retrotransposition events, 
generating genetically distinct cells and providing the cell with additional 
mechanisms of transcriptional control (Faulkner 2011). Somatic retrotransposition 
has been shown to occur in the human brain altering the genetic landscape of the 
individual (Baillie et al. 2011). The functional properties of the SVAs therefore may 
differentially affect populations of cells within an individual due to somatic 
insertions.  
 The sequence of the SVAs indicated their role in the regulation of gene 
expression through several mechanisms including the provision of multiple TF 
binding sites, G4 structural formation and sites of methylation (Hancks and Kazazian 
2010). In chapter 4 a global analysis of the distribution of SVAs across the human 
reference genome 19 was undertaken to determine if the sites of their insertions 
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correlated with any particular features of the genome. The insertion of the SVAs 
showed a preference for genic regions as opposed to gene deserts and their density 
was correlated with gene density across chromosomes (Figure 4.2 and 4.3). This is 
an indicator that their site of insertion is linked to active chromatin as the more open 
nature of the chromatin would make it more accessible to retrotransposon insertions. 
Once inserted into these transcriptionally active regions retrotransposons may be 
under negative selection if they are imposing detrimental affects to the host genome. 
LINE and LTR elements are depleted in introns and flanking regions of genes in 
particular when in the same orientation as the gene, however Alus are enriched in 
genes and their flanking regions suggesting LINEs and LTRs are selected against in 
these regions whereas Alus are not (Medstrand et al. 2002). SVAs show similar 
distribution to Alus due to their enriched presence in the flanking regions of genes 
(Figure 4.4) but show similarities to LINEs as appear to be selected against when 
inserting intronically in the same orientation as the gene (Table 4.1). Only 26.1% of 
intronic SVA insertions are in the same orientation as the gene whereas this is near 
to 50% when they have inserted in within the 10kb flank of the gene. The negative 
impact of SVAs inserted into an intron in the same orientation of the gene may be 
related to the introduction of alternative splice sites as exemplified by disease 
causing insertions (Kaer and Speek 2013) or the presence of polyadenylation signals 
within the SVA sequence affecting the transcriptional machinery.  
 The retrotransposition of the SVAs, along with other retrotransposons, is 
inhibited by the cell to prevent potential de novo insertions that may have a negative 
impact through heterochromatin formation and methylation. SVAs have a high GC 
content (~60%) and were hypothesised to act as mobile CpG islands (Wang et al. 
2005). Therefore a handful of SVAs from each subtype were analysed for their 
234 
 
ability to meet a set of three criteria used to predict CpG islands by the UCSC 
genome browser taken from the literature (Gardiner-Garden and Frommer 1987). 
The SVAs in this analysis met two of the criteria but not the third as they had an 
average ratio of the observed number of CG dinucleotides to the expected of 0.53 
which was below the 0.6 threshold. However there are still many sites for 
methylation within the sequence of the SVAs and may interfere with regulatory 
domains in their proximity, for example hypermethylation of the disease causing 
SVA insertion into intron 32 of the TAF1 gene is associated with a reduction of 
TAF1 mRNA in the caudate nucleus (Makino et al. 2007). 
 There is growing evidence for the loss of silencing of retrotransposons, 
including SVAs, in specific conditions such as cancer, the aging brain and 
replicatively senescent cells (Szpakowski et al. 2009; Baillie et al. 2011; De Cecco et 
al. 2013), which could lead to the activation of regulatory properties within the 
SVAs sequence. Analysis within this project of a specific SVA, upstream of the 
PARK7 gene, demonstrated the locus of this element and the adjacent sequence is 
the site of active chromatin and transcription in the SK-N-AS (human 
neuroblastoma) cell line. The majority of the transcripts of the human PARK7 gene 
originate at the already characterised promoter (Taira et al. 2001) which is 8kb 
downstream of the PARK7 SVA and their expression was confirmed in the SK-N-
AS and MCF-7 (human breast adenocarcinoma) cell line (Figure 5.2). There was 
also evidence of another TSS of the PARK7 gene which included a CpG island, 
ENCODE data of active histone marks and DNase hypersensitivity clusters and a 
transcript predicted by Archive Ensembl within less than 1kb of the PARK7 SVA 
(Figure 5.1). The expression of this transcript was confirmed in the SK-N-AS cell 
line but not in the MCF-7s (Figure 5.2). There are 243 Archive Ensembl predicted 
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transcripts that contain a SVA within 1kb upstream compared to the 58 UCSC genes 
which indicates there could be more TSSs within 1kb of a SVA than indicated by the 
number of known transcripts if these were confirmed as in the PARK7 example. 
ChIP analysis of the minor and major TSSs of the PARK7 gene and 5’ of the SVA in 
the SK-N-AS cell line identified active histone marks, RNA polymerase II and Sp1 
present at these loci showing this region is transcriptionally active and the SVA is 
not epigenetically silenced (Figure 5.4). Both of the PARK7 TSSs were shown to be 
transcriptionally active in several regions of the human brain using Affymetrix 
human exon array probes which provides further evidence that the region adjacent to 
the SVA is active (Table 5.1 and 5.2). The Affymetrix human exon array probes 
could provide a tool for analysing the prevalence of transcription occurring close to 
SVAs on a global scale as there are 1248 extended probe sets located within 1kb up 
or downstream of 729 different SVAs.  
 The evidence suggesting that all SVAs are not always silenced suggest they 
could support regulatory properties within their sequence and influence the 
expression of gene near to their site of insertion (we are not ruling out their 
regulation of more distant genes but this is the most straightforward hypothesis to 
test currently). The ability of two SVAs, one located upstream of the PARK7 gene 
and the other upstream of the FUS gene, to affect gene expression were tested in 
reporter gene models. Both of these SVA are members of the subtype D, however 
the PARK7 is human specific and contains all the domains of a canonical SVA 
whereas the FUS SVA is found in both the human and chimpanzee genomes and is 
missing the CCCTCT repeat located at its 5’ end. I demonstrated both FUS and 
PARK7 SVAs to be polymorphic in terms of the number of repeats in their VNTR 
domains, which is discussed in further detail later. VNTRs have previously been 
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shown to affect gene expression in a tissue specific manner and their function 
dependant on the allele present in vitro and in vivo (MacKenzie and Quinn 1999b; 
Haddley et al. 2008; Ali et al. 2010; Haddley et al. 2012) and it was therefore 
hypothesised that the SVAs or at least their VNTR domains may function in a 
similar manner. 
 Both alleles (long and short) of the intact FUS SVA and its TR/VNTR 
domain (due to adjacent TR the VNTR could not be cloned alone) were tested in a 
reporter gene vector with a minimal promoter in the SK-N-AS cell line (Figure 3.4B) 
(completed by Thomas Wilm). The long and short complete SVAs showed 
repressive function whereas the long and short of the TR/VNTR increased 
transcription of the reporter gene. This suggested the addition of the SINE element in 
the complete SVA compared to the TR/VNTR was acting as a dominant repressor 
within the SK-N-AS cell line. There was a small but statistically significant 
difference between the long and short alleles when tested in the complete SVA 
however this difference was not seen when the alleles were tested in the TR/VNTR. 
The ability of the long allele of the FUS SVA and TR/VNTR to affect gene 
expression was tested in an in vivo chick embryo model (Figure 3.4A) (completed by 
Kejhal Khursheed). Both the complete SVA and TR/VNTR supported expression of 
the reporter gene in the neural tube of the chick embryo which was not seen when 
the minimal promoter alone was transfected. The intact FUS SVA in the SK-N-AS 
cell line showed repressive properties and in the chick embryo enhancer properties 
therefore it affects gene expression in a tissue specific manner.  
 The ability of the different domains of the PARK7 SVA and four of its 
alleles to affect reporter gene expression was tested in the SK-N-AS and MCF-7 cell 
lines. The domains of the PARK7 SVA demonstrated differential function and the 
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TR/VNTR domain demonstrated tissue specific regulatory properties (Figure 5.9). 
The construct containing the fragment of the PARK7 SVA without the SINE domain 
showed increased expression levels over the intact SVA suggesting it is a repressor 
which was also noted for the SINE of the FUS SVA. The PARK7 SVA fragments 
showed different regulatory functions depending on whether they were in the 
forwards or reverse orientation within the reporter gene therefore the relative 
orientation of a SVA to a gene could influence its affect on gene expression. The 
complete SVA was also tested in a promoter less reporter gene but did not display 
the ability to initiate transcription itself. The ability of the four alleles of the PARK7 
SVA identified and cloned from individuals from the CEU HapMap cohort to 
differentially affect reporter gene expression were tested as part of the complete 
SVA sequence. All four alleles showed similar levels of reporter gene expression in 
the SK-N-AS cell line as did alleles 1, 3 and 4 in the MCF-7, however allele 2 
showed increased levels of reporter gene expression that were significantly different 
to the other three alleles (Figure 5.11). The full potential of the alleles to 
differentially affect transcription may only be seen in response to a stimulus.  
 The primary sequence of DNA determines the TFs that may bind and in turn 
regulate gene expression. SVAs at multiple loci of the human genome may respond 
to similar factors and stimuli due to the similarities in sequence they share. The 
primary sequence of specific repeats from the PARK7 central TR and VNTR was 
used to define a subset of SVAs and the closest genes to their insertion. MetaCore 
software was used to determine the factors that regulate these genes and PROMO 
software was used to define potential factors that may bind to the sequence of the 
PARK7 SVA. ESR1 was shown to regulate a number of the genes containing a SVA 
and there were binding sites present in the sequence of the SVA (Table 6.2 and 
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Figure 6.3B) therefore the response of the endogenous expression of a small number 
of genes on the list and the PARK7 SVA to oestrogen in the MCF-7 cell line was 
tested. The expression of the endogenous PARK7 gene responded to signalling 
pathways stimulated by the exposure of the cell to oestrogen (Figure 6.4), however 
the regulatory properties of the PARK7 SVA were not altered by the same stimulus 
(Figure 6.6). It might be that the full complexity of SVA transcriptional regulation 
will be required to be addressed in reporter gene analysis from a chromosomal or 
nucleosomal construct to address the structural importance that might reside in such 
retrotransposons. 
 The sequence of several of the SVAs domains also provides the potential for 
formation of G-quadruplex (G4) DNA (runs of guanine nucleotides) which is 
involved in the repression of gene expression (Gonzalez and Hurley 2010). All of the 
SVA subtypes contained G4 potential however the amount of G4 potential in general 
increased as the age of the subtype decreased with the human specific subtypes E-F1 
showing the greatest G4 potential in particularly in the emerging second central 
VNTR domain within their structure (Figure 4.6). There is evidence in the literature 
for the binding of nucleolin to G4 structures and has been shown through ChIP to be 
bound to the c-MYC NHE IIII domain in HeLa cells (Gonzalez et al. 2009). 
Therefore the binding of nucleolin in the region of the PARK7 SVA was analysed in 
SK-N-AS cell line to potentially validate the presence of G4 DNA at this locus. 
There was no binding of nucleolin under the conditions the ChIP was performed 
(Figure 5.4), however this PARK7 locus was associated with active transcription 
(presence of active histone marks and RNA Pol II) which would be consistent with 
the lack G4 formation as this would linked to repression of gene expression.  
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 Both the FUS and PARK7 SVAs were shown to be polymorphic with two 
alleles and five alleles respectively. In both cases the central repetitive region 
consisted of a TR and a VNTR, however in addition the alleles of the PARK7 SVA 
showed differences in the number of repeats of the CCCTCT domain which was not 
present in the FUS SVA (Figure 3.2 and 5.7). The number of repeats of the long and 
short alleles of the FUS SVAs and alleles 1-4 of the PARK7 SVAs were confirmed 
by sequence analysis. The fifth allele of the PARK7 SVA was identified at a later 
stage in a separate control cohort and was not part of the initial analysis of the 
variants of this SVA carried out in the CEU HapMap cohort and therefore has not 
been sequenced at this time. Many multifactorial diseases are caused by both a 
genetic and an environmental component and a specific allele of a common variant 
within the population can provide a genetic predisposition to a specific disease. For 
example VNTRs of the SLC6A4 and SLC6A3 gene have demonstrated ‘risk’ alleles 
for a variety of disorders including depression, addiction and PD (reviewed in 
Haddley et al. 2008; Haddley et al. 2012). It was therefore hypothesised that the 
VNTRs within the FUS and PARK7 SVAs may also be involved in genetic 
predisposition to disease.  
 In 3-5% of FALS and ~1% of SALS cases mutations in the FUS gene have 
been identified as causative for the disease (Kwiatkowski et al. 2009; Vance et al. 
2009; Corrado et al. 2010). Genes known to be involved in the familial form of a 
disease can indicate loci of common variants that may contribute a predisposition to 
the sporadic form which may be involved in differential gene expression in response 
to the environment. Therefore the FUS SVA, shown to be a regulatory of gene 
expression in vitro and in vivo, was genotyped in a SALS and matched control 
cohort provided by collaborators at King’s College London. There was a small 
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difference of 4.4% between the SS genotype frequency of the SALS and control 
cohorts (15.4% vs 11%) (Figure 3.5) which was not significant when analysed using 
CLUMP (T1 P=0.36 and T4 P=0.33) (Sham and Curtis 1995).  
 The protein levels of PARK7 within breast tumours has been linked to the 
prognosis of the patient and the response to neoadjuvent chemotherapy and has been 
considered as a useful biomarker for breast cancer due to elevated levels identified in 
the sera and nipple fluid of breast cancer patients (Le Naour et al. 2001; Oda et al. 
2012; Tsuchiya et al. 2012; Kawate et al. 2013). Expression of PARK7 and its 
presence within cancer cells could be an important factor in the cancer cells’ 
survival. The frequency of the PARK7 SVA genotypes were analysed in a cohort of 
breast cancer patients without mutations in their BRCA genes and matched controls 
to determine if the variation of the SVA may contribute a risk factor for the disease. 
There was no significant difference between the patients and controls when analysed 
using CLUMP (T1 P=0.65 and T4 P=0.65). 
 The genotyping analysis of SVAs is time consuming and labour intensive and 
would be an impractical method, although feasible, for analysing large cohorts. 
Therefore using the genotype data for the CEU HapMap cohort generated for the 
FUS and PARK7 SVAs in conjunction with SNP data available for these individuals 
on the International HapMap website tagging SNPs could be identified for the alleles 
of the SVAs. A tagging SNP for both alleles of the FUS SVA and alleles 1, 2 and 3 
(the most common) for the PARK7 SVA were successfully identified (section 3.4.5 
and 6.4.6). This could provide a more practical method for analysing large disease 
cohorts for variants of the SVAs. This could also be employed for other polymorphic 
SVAs of interest. For example a list of known PD associated genes were analysed 
for the presence of a SVA and 5 out of 13 contained a SVA within their intron or 
241 
 
their 10kb flank (Table 6.5). Two of these SVAs, within an intron of PARK2 and 
LRRK2, were analysed further and shown to be polymorphic (Figure 6.8) and a 
tagging SNP for these SVAs may prove a useful tool in disease association studies. 
The study of SVAs as regulatory and polymorphic domains using data generated in 
this thesis as a starting point is continuing within the research group.   
 The work carried out in this project has contributed to the field adding to the 
understanding of the functional properties of the SVAs along with identification of 
novel genetic variation within these elements. Data presented here in this thesis has 
been published (Savage et al. 2013) and further publications are within the 
submission process. The analysis of this family of hominid specific retrotransposons 
has demonstrated their ability to modulate gene expression in vitro and in vivo and in 
a tissue specific and allelic dependant manner. SVAs located in many functional 
regions are a source of genetic variation throughout the human genome contributing 
to the genetic differences between individuals and potentially to the phenotypic 
differences and disease susceptibility. The functional properties of the SVAs may be 
activated in specific conditions such as cancer or even the aging brain due to the loss 
of silencing across retrotransposons. The emerging field of somatic 
retrotransposition may provide further roles for the differential regulation of gene 
expression by SVAs within an individual and SVAs should be considered important 
sources of genetic variation and function when analysing genomic loci.  
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A.1 The sequence, target region and cycling conditions used for each primer set 
Primers 
Application for 
Primer Use 
Target Region 
Expected 
Product Size 
PCR Conditions 
For 5’cagttttccctcagacccagcac 3’ 
Rev 5’gagctgttgggtacacctcccagac 3’ 
 
Genotyping 
VNTR of FUS SVA 
chr16:31180471-31181135 
615/665bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 60.3
o
C for 30s and 72
o
C 
for 1min, 1 cycle of 72
o
C for 5mins 
For 5’ ttcattttcagcctggtgtg 3’ 
Rev 5’ cgtctccatttcctctgctc 3’ 
mRNA 
expression 
levels 
Exon 1 and 2 of transcripts 
of PARK7 gene originating 
from major TSS 
102bp and 
159bp 
(cDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 60
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’ catcctggctaaaggagcag 3’ 
Rev 5’ ttcatgagccaacagagcag 3’ 
mRNA 
expression 
levels 
Exon 2 and 6 of transcripts 
PARK7 gene 
325bp 
(cDNA) 
1 cycle of 95
o
C for 2mins, 28 cycles of 
95
o
C for 30s, 62
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’ agtggacctacgtcatgcag 3’ 
Rev 5’ cgtctccatttcctctgctc 3’ 
mRNA 
expression 
levels 
Exon 1 and 2 of predicted 
transcript of PARK7 gene 
108bp 
(cDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 57
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’ caccttctacaatgagctgcgtgtg 3’ 
Rev 5’atagcacagcctggatagcaacgtac3’ 
mRNA 
expression 
levels 
Exon 3 and 4 of the β-Actin 
gene 
158bp 
(cDNA) 
1 cycle of 95
o
C for 2mins, 25 cycles of 
95
o
C for 30s, 60
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’ ttgtggttttcctggtgtca 3’ 
Rev 5’ ccgagctctgggactaatca 3’ 
mRNA 
expression 
levels 
Exon 2 and 3 of the Trefoil 
factor 1 (TFF1) gene 
209bp 
(cDNA) 
1 cycle of 95
o
C for 2mins, 28 cycles of 
95
o
C for 30s, 62
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’  ttccgaataaaggccatcag 3’ 
Rev 5’  caagtgcagggatccaaact 3’ 
mRNA 
expression 
levels 
Exon 5 and 6 of the 
Mannosidase α class 1C 
member 1 (MAN1C1) 
159bp 
(cDNA) 
1 cycle of 95
o
C for 2mins, 30 cycles of 
95
o
C for 30s, 60
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
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Primers 
Application for 
Primer Use 
Target Region 
Expected 
Product Size 
PCR Conditions 
For 5’ gcctgggcaatatgaacaat 3’ 
Rev 5’ ctcattggcacgacacaatc 3’ 
mRNA 
expression 
levels 
Exon 5 and 7 of the Tissue 
factor pathway inhibitor 
(TFPI) gene 
218bp 
(cDNA) 
1 cycle of 95
o
C for 2mins, 30 cycles of 
95
o
C for 30s, 60
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’ agttgtgcaggttggctagg 3’ 
Rev 5’  ccttgaaaagtctgccctga 3’ 
Analysis of 
genomic DNA 
5kb upstream of major 
PARK7 promoter 
chr1:8016444-8016598 
155bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 63.1
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’ aggaagggtagccaggagaa 3’ 
Rev 5’ cttgctgaggctgcactctt 3’ 
Analysis of 
genomic DNA 
1kb upstream of major 
PARK7 promoter 
chr1:8020452-8020653 
202bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 63.1
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’tcgaactcctggcttcaagt 3’ 
Rev 5’ggaaggaagaaggggcatag 3’ 
Analysis of 
genomic DNA 
2kb downstream of major 
PARK7 promoter 
chr1:8023653-8023829 
177bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 63.1
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’ ctgagcccaggagttttgag 3’ 
rev 5’  gagtgcagtgatgcaatcgt 3’ 
Analysis of 
genomic DNA 
6kb downstream of major 
PARK7 promoter 
chr1:8027761-8027948 
188bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 63.1
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’ aggcctggaccagagtccta 3’ 
Rev 5’ cggtcagtcaaatccaacg 3’ 
Analysis of 
genomic DNA 
Major PARK7 promoter 
chr1:8021368-8022040 
 
673bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 60.6
o
C for 30s and 72
o
C 
for 1min, 1 cycle of 72
o
C for 5mins 
For 5’ggctttttgataacccctga 3’         
Rev 5’tttcggatcacaggcatgagc 3’ 
Cloning 
Whole PARK7 SVA 
chr1:8012044-8013681 
1638bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 20s, 61
o
C for 10s and 70
o
C 
for 1min, 1 cycle of 70
o
C for 2mins 
For 5’ggctttttgataacccctga 3’ 
Rev 5’ ccgcctttctattccacaaa 3’ 
Cloning 
SVA Δ SINE PARK7 SVA 
chr1:8012044-8013503 
1460bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 20s, 59.6
o
C for 10s and 70
o
C 
for 1min, 1 cycle of 70
o
C for 2mins 
For 5’ctcagtgctcaatggtgcc 3’ 
Rev 5’ ccgcctttctattccacaaa 3’ 
Cloning 
VNTRs of PARK7 SVA 
chr1:8012424-8013503 
1080bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 20s, 60
o
C for 10s and 70
o
C 
for , 1 cycle of 70
o
C for 2mins 
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Primers 
Application for 
Primer Use 
Target Region 
Expected 
Product Size 
PCR Conditions 
For 5’tgtaggtaccggctttttgataaccc 3’ 
Rev 5’gtaactcgagtttcggatcacaggc 3’ 
Cloning 
Alleles of PARK7 SVA with 
restriction sites 
chr1:8012034-8013691 
1658bp 
(+VNTR 
variation) 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 20s, 60
o
C for 10s and 70
o
C 
for 1min, 1 cycle of 70
o
C for 2mins 
For 5’ggctttttgataacccctga 3’ 
Rev 5’gcaaggcttagcttggacag 3’ 
Genotyping 
PARK7 SVA 
chr1:8012044-8013878 
1835bp 
(+VNTR 
variation) 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 20s, 63.9
o
C for 10s and 70
o
C 
for 1min, 1 cycle of 70
o
C for 2mins 
For 5’ gcatttgctcctgacttcaa 3’ 
Rev 5’ tctgattttcttggttctcacg 3’ 
Genotyping 
PARK2 SVA 
chr6:162759153-162761242 
 
2090bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 59.3
o
C for 30s and 72
o
C 
for 3min, 1 cycle of 72
o
C for 5mins 
For 5’ tggcagacaagttttgccta 3’ 
Rev 5’gagatctggacatggctcct 3’ 
Genotyping 
LRRK2 SVA 
chr12:40746123-40747934 
 
1812bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 30 cycles of 
95
o
C for 20s, 64.9
o
C for 10s and 70
o
C 
for 1min, 1 cycle of 70
o
C for 2mins 
For 5’ccaactggtctggagtaagaca 3’  
Rev 5’aactacaagccaccagtttgc 3’ 
 
Genotyping 
TAF1 SVA D2 
chrX:70671054-70673009 
 
1956bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 20s, 64.9
o
C for 10s and 70
o
C 
for 1min, 1 cycle of 70
o
C for 2mins 
For 5’agccactgcttaccaacctc 3’ 
Rev 5’atttctgtcaatgggcaagg 3’ 
ChIP analysis 
5’ of PARK7 SVA 
chr1:8011671-8011836 
166bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 64
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’cggaagtggacctacgtcat 3’ 
Rev 5’ tgacaccgagttctgtgagg 3’ 
ChIP analysis 
Minor Promoter of PARK7 
gene 
chr1:8014352-8014509 
158bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 64
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
For 5’ agggtggcggtagagactgt 3’ 
Rev 5’ cacaccaggctgaaaatgaa 3’ 
ChIP analysis 
Major Promoter of PARK7 
gene 
chr1:8021524-8021793 
270bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 35 cycles of 
95
o
C for 30s, 64
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
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Primers 
Application for 
Primer Use 
Target Region 
Expected 
Product Size 
PCR Conditions 
For 5’ agggtggcggtagagactgt 3’ 
Rev 5’ cacaccaggctgaaaatgaa 3’ 
ChIP analysis 
Region within a gene desert 
chr8:127755406-127755513 
108bp 
(gDNA) 
1 cycle of 95
o
C for 2mins, 30 cycles of 
95
o
C for 30s, 60
o
C for 30s and 72
o
C 
for 30s, 1 cycle of 72
o
C for 5mins 
 
 
Table A1: Details of the primers used in amplification of target regions using PCR. The sequence of the forward and reverse primers, the 
application for their use, the target for amplification, product size and cycling conditions are listed for all primers used.  
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A.2 Information regarding the antibodies used in the ChIP protocol 
 
Table A2: Details of the antibodies used in chromatin immunoprecipitation protocol. The target of the antibody, host species, company the 
antibody was obtained from and the amount used in the ChIP protocol are listed in the table. 
Antibody Host Species Immunogen Company and 
Cat No. 
Amount used per IP with 
10µg of sheared chromatin 
Anti - H3 Rabbit 
(Polyclonal) 
Synthetic peptide conjugated to KLH derived from 
within residues 100 to the C-terminus of Human 
Histone H3. 
Abcam 1791 5µg 
Anti - H3K9M3 Rabbit  
(Polyclonal) 
Synthetic peptide conjugated to KLH derived from 
within residues 1-100 of Human H3, trimethylated at 
lysine 9. 
Abcam, 8898 3.5µg 
Anti - H3K4M2 Rabbit 
(Monoclonal) 
A synthetic (Dimethyl K) peptide corresponding to 
residues surrounding Lys4 of Histone H3. 
Abcam 32356 3µg 
Anti - RNA PolII 
CTD phospho Ser5 
Rat 
(Monoclonal) 
This RNA pol II CTD phospho Ser5 antibody was 
raised against a peptide containing the RNA pol II 
CTD sequence phosphorylated at serine 5. 
Active Motif 
61085 
5µg 
Anti - Nucleolin Mouse 
(Monoclonal) 
Human nucleolin protein from Raji cell extract. 
Abcam 13541 4µg 
Anti - Sp1 Rabbit 
(Polyclonal) 
Full length human Sp1 protein. Millipore  
17-601 
4µg 
Anti - hnRNPK Rabbit 
(Polyclonal) 
Synthetic peptide corresponding to a sequence from 
the C-terminus of isoform a of human hnRNP K. 
Abcam 70492 2µg 
Anti - CTCF Mouse 
(Monoclonal) 
His-tagged recombinant protein corresponding to 
human CTCF. 
Millipore 
17-10044 
2µg 
248 
 
A.3 Screen shot of the PARK7 gene locus in UCSC genome browser 
 
 
 
Figure A1: UCSC genome browser displaying data suggesting there are two 
PARK7 TSSs. The two orange boxes highlight the two PARK7 TSSs which are 
both demonstrating features such as a CpG island, DNase clusters, transcription 
factor binding and histone marks associated with active regulatory elements. The 
region boxed in orange on the right is the characterised promoter with the PARK7 
gene transcripts originating here and is termed the major promoter. The orange box 
on the left of the image was predicted to be another TSS and was termed the minor 
promoter. There was a transcript predicted to originate from this minor promoter by 
the Archive Ensembl database and the transcripts from this browser are shown in 
red. There are Affymetrix Human Exon Array extended probe sets in the region of 
the minor TSS boxed in black and human ESTs also present. There is a SVA D 
located less than 1kb upstream of the minor TSS and 8kb upstream of the major TSS 
which is boxed in blue.  
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